Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Previous issues

Page Path
HOME > Browse articles > Previous issues
30 Previous issues
Filter
Filter
Article category
Keywords
More +
Authors
More +
Funded articles
More +
Volume 49(1); January 2017
Prev issue Next issue
Special Article
How Can We Treat Cancer Disease Not Cancer Cells?
Kyu-Won Kim, Su-Jae Lee, Woo-Young Kim, Ji Hae Seo, Ho-Young Lee
Cancer Res Treat. 2017;49(1):1-9.   Published online December 26, 2016
DOI: https://doi.org/10.4143/crt.2016.606
AbstractAbstract PDFPubReaderePub
Since molecular biology studies began, researches in biological science have centered on proteins and genes at molecular level of a single cell. Cancer research has also focused on various functions of proteins and genes that distinguish cancer cells from normal cells. Accordingly, most contemporary anticancer drugs have been developed to target abnormal characteristics of cancer cells. Despite the great advances in the development of anticancer drugs, vast majority of patients with advanced cancer have shown grim prognosis and high rate of relapse. To resolve this problem, we must reevaluate our focuses in current cancer research. Cancer should be considered as a systemic disease because cancer cells undergo a complex interaction with various surrounding cells in cancer tissue and spread to whole body through metastasis under the control of the systemic modulation. Human body relies on the cooperative interaction between various tissues and organs, and each organ performs its specialized function through tissue-specific cell networks. Therefore, investigation of the tumor-specific cell networks can provide novel strategy to overcome the limitation of current cancer research. This review presents the limitations of the current cancer research, emphasizing the necessity of studying tissue-specific cell network which could be a new perspective on treating cancer disease, not cancer cells.

Citations

Citations to this article as recorded by  
  • New Breakthroughs in the Diagnosis of Leptomeningeal Carcinomatosis: A Review of Liquid Biopsies of Cerebrospinal Fluid
    Maria Goldberg, Michel G Mondragon-Soto, Ghaith Altawalbeh, Bernhard Meyer, Amir Kaywan Aftahy
    Cureus.2024;[Epub]     CrossRef
  • Equine Melanocytic Tumors: A Narrative Review
    José Pimenta, Justina Prada, Mário Cotovio
    Animals.2023; 13(2): 247.     CrossRef
  • Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation
    Ion G. Motofei
    Seminars in Cancer Biology.2022; 86: 600.     CrossRef
  • Mechanisms of resistance to chemotherapy in non-small cell lung cancer
    Hye-Young Min, Ho-Young Lee
    Archives of Pharmacal Research.2021; 44(2): 146.     CrossRef
  • The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients
    Giovanni Paolino, Veronica Huber, Serena Camerini, Marialuisa Casella, Alberto Macone, Lucia Bertuccini, Francesca Iosi, Elisa Moliterni, Serena Cecchetti, Irene Ruspantini, Flavia Chiarotti, Elisabetta Vergani, Luca Lalli, Carla Raggi, Antonella Di Biase
    Cancers.2021; 13(16): 4157.     CrossRef
  • Bone-marrow-derived cell-released extracellular vesicle miR-92a regulates hepatic pre-metastatic niche in lung cancer
    Ya-Ling Hsu, Ming-Shyan Huang, Jen-Yu Hung, Wei-An Chang, Ying-Ming Tsai, Yi-Chung Pan, Yi-Shiuan Lin, Hung-Pei Tsai, Po-Lin Kuo
    Oncogene.2020; 39(4): 739.     CrossRef
  • 18,688 View
  • 336 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Original Articles
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
Ji-Youn Han, Ki Hyeong Lee, Sang-We Kim, Young Joo Min, Eunkyung Cho, Youngjoo Lee, Soo-Hyun Lee, Hyae Young Kim, Geon Kook Lee, Byung Ho Nam, Hyesun Han, Jina Jung, Jin Soo Lee
Cancer Res Treat. 2017;49(1):10-19.   Published online May 3, 2016
DOI: https://doi.org/10.4143/crt.2016.058
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We examined the efficacy of poziotinib, a second-generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) in patients with lung adenocarcinoma with activating EGFR mutations, who developed acquired resistance (AR) to EGFR-TKIs.
Materials and Methods
This single-arm phase II study included EGFR-mutant lung adenocarcinoma with AR to erlotinib or gefitinib based on the Jackman criteria. Patients received poziotinib 16 mg orally once daily in a 28-day cycle. The primary endpoint was progression-free survival (PFS). Prestudy tumor biopsies and blood samples were obtained to determine resistance mechanisms.
Results
Thirty-nine patients were treated. Tumor genotyping was determined in 37 patients; 19 EGFR T790M mutations and two PIK3CAmutations were detected in the prestudy tumors, and seven T790M mutations were detected in the plasma assay. Three (8%; 95% confidence interval [CI], 2 to 21) and 17 (44%; 95% CI, 28 to 60) patients had partial response and stable disease, respectively. The median PFS and overall survival were 2.7 months (95% CI, 1.8 to 3.7) and 15.0 months (95% CI, 9.5 to not estimable), respectively. A longer PFS was observed for patients without T790M or PIK3CA mutations in tumor or plasma compared to those with these mutations (5.5 months vs. 1.8 months, p=0.003). The most frequent grade 3 adverse events were rash (59%), mucosal inflammation (26%), and stomatitis (18%). Most patients required one (n=15) or two (n=15) dose reductions.
Conclusion
Low activity of poziotinib was detected in patients with EGFR-mutant non-small cell lung cancer who developed AR to gefitinib or erlotinib, potentially because of severe-toxicityimposed dose limitation.

Citations

Citations to this article as recorded by  
  • Repeat biopsy versus initial biopsy in terms of complication risk factors and clinical outcomes for patients with non-small cell lung cancer: a comparative study of 113 CT-guided needle biopsy of lung lesions
    Yangyang Wang, Yongyuan Zhang, Nana Ren, Fangting Li, Lin Lu, Xin Zhao, Zhigang Zhou, Mengyu Gao, Meng Wang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
    Isabella Michelon, Maysa Vilbert, Caio Ernesto do Rego Castro, Carlos Stecca, Maria Inez Dacoregio, Manglio Rizzo, Vladmir Cláudio Cordeiro de Lima, Ludimila Cavalcante
    Journal of Personalized Medicine.2024; 14(7): 752.     CrossRef
  • 3D bioprinted vascularized lung cancer organoid models with underlying disease capable of more precise drug evaluation
    Yoo-mi Choi, Haram Lee, Minjun Ann, Minyeong Song, Jinguen Rheey, Jinah Jang
    Biofabrication.2023; 15(3): 034104.     CrossRef
  • Association of Hypokalemia Incidence and Better Treatment Response in NSCLC Patients: A Meta-Analysis and Systematic Review on Anti-EGFR Targeted Therapy Clinical Trials
    Jiawei Zhou, Jianling Bai, Yuanping Yue, Xin Chen, Theis Lange, Dongfang You, Yang Zhao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Anlotinib plus chemotherapy for T790M‐negative EGFR‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial
    Juan Li, Yuke Tian, Min Zheng, Jun Ge, Jiliang Zhang, Dejun Kong, Mei Chen, Ping Yu
    Thoracic Cancer.2022; 13(24): 3496.     CrossRef
  • Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers
    Vidhi Malik, Vipul Kumar, Sunil C. Kaul, Renu Wadhwa, Durai Sundar
    Biomolecules.2021; 11(2): 160.     CrossRef
  • Validation of a multicellular tumor microenvironment system for modeling patient tumor biology and drug response
    Devin G. Roller, Stephen A. Hoang, Kristopher D. Rawls, Katherine A. Owen, Michael B. Simmers, Robert A. Figler, Julia D. Wulfkuhle, Emanuel F. Petricoin, Brian R. Wamhoff, Daniel Gioeli
    Scientific Reports.2021;[Epub]     CrossRef
  • Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management
    Gabriel Tao, Pavan Kumar Chityala
    Toxicology Research.2021; 10(3): 476.     CrossRef
  • Geriatric Nutritional Risk Index as a Prognostic Factor for Mortality in Elderly Patients with Moderate to Severe Traumatic Brain Injuries
    Wei-Ti Su, Ching-Hua Tsai, Chun-Ying Huang, Sheng-En Chou, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
    Risk Management and Healthcare Policy.2021; Volume 14: 2465.     CrossRef
  • Geriatric nutritional risk index in screening malnutrition among young adult and elderly trauma patients
    Yueh-Wei Liu, Ching-Hua Tsai, Sheng-En Chou, Wei-Ti Su, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
    Formosan Journal of Surgery.2021; 54(5): 183.     CrossRef
  • In silico studies on p21-activated kinase 4 inhibitors: comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation
    Yinli Gao, Hanxun Wang, Jian Wang, Maosheng Cheng
    Journal of Biomolecular Structure and Dynamics.2020; 38(14): 4119.     CrossRef
  • Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
    Iosune Baraibar, Laura Mezquita, Ignacio Gil-Bazo, David Planchard
    Critical Reviews in Oncology/Hematology.2020; 148: 102906.     CrossRef
  • Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
    Afshin Derakhshani, Zohreh Rezaei, Hossein Safarpour, Morteza Sabri, Atefeh Mir, Mohammad Amin Sanati, Fatemeh Vahidian, Ali Gholamiyan Moghadam, Ali Aghadoukht, Khalil Hajiasgharzadeh, Behzad Baradaran
    Journal of Cellular Physiology.2020; 235(4): 3142.     CrossRef
  • Toward a More Precise Future for Oncology
    Yonina R. Murciano-Goroff, Barry S. Taylor, David M. Hyman, Alison M. Schram
    Cancer Cell.2020; 37(4): 431.     CrossRef
  • Nanocarrier centered therapeutic approaches: Recent developments with insight towards the future in the management of lung cancer
    Jigar D. Vanza, Rashmin B. Patel, Mrunali R. Patel
    Journal of Drug Delivery Science and Technology.2020; 60: 102070.     CrossRef
  • Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
    Yongchao Zhang, Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Jun Li, Zoey Sun, Qiu-Xu Teng, Charles R. Ashby, Dong-Hua Yang
    Cancers.2020; 12(11): 3249.     CrossRef
  • Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib
    Nishan Tchekmedyian, Bill Paxton, Francois Lebel, Lena Keossayan, John V. Heymach
    JTO Clinical and Research Reports.2020; 1(4): 100081.     CrossRef
  • Geriatric Nutritional Risk Index as a Screening Tool to Identify Patients with Malnutrition at a High Risk of In-Hospital Mortality among Elderly Patients with Femoral Fractures—A Retrospective Study in a Level I Trauma Center
    Wei-Ti Su, Shao-Chun Wu, Chun-Ying Huang, Sheng-En Chou, Ching-Hua Tsai, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
    International Journal of Environmental Research and Public Health.2020; 17(23): 8920.     CrossRef
  • Geriatric Nutritional Risk Index as a Tool to Evaluate Impact of Malnutrition Risk on Mortality in Adult Patients with Polytrauma
    Cheng-Hsi Yeh, Shao-Chun Wu, Sheng-En Chou, Wei-Ti Su, Ching-Hua Tsai, Chi Li, Shiun-Yuan Hsu, Ching-Hua Hsieh
    International Journal of Environmental Research and Public Health.2020; 17(24): 9233.     CrossRef
  • Association between Geriatric Nutritional Risk Index and Mortality in Older Trauma Patients in the Intensive Care Unit
    Hang-Tsung Liu, Shao-Chun Wu, Ching-Hua Tsai, Chi Li, Sheng-En Chou, Wei-Ti Su, Shiun-Yuan Hsu, Ching-Hua Hsieh
    Nutrients.2020; 12(12): 3861.     CrossRef
  • Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology
    Rashmi R. Shah, Devron R. Shah
    Drug Safety.2019; 42(2): 181.     CrossRef
  • Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
    Wei Jiang, Meiju Ji
    Seminars in Cancer Biology.2019; 59: 3.     CrossRef
  • Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non–Small-Cell Lung Cancer
    Juliane Martin, Annika Lehmann, Frederick Klauschen, Michael Hummel, Dido Lenze, Christian Grohé, Antje Tessmer, Joachim Gottschalk, Berndt Schmidt, Hans-Wilhelm Pau, Christian Witt, Stefan Moegling, Robert Kromminga, Korinna Jöhrens
    Clinical Lung Cancer.2019; 20(5): 350.     CrossRef
  • Metastasiertes Lungenkarzinom – therapierbare molekulare Alterationen
    W. M. Brückl, J. H. Ficker
    Der Pneumologe.2019; 16(6): 343.     CrossRef
  • Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib
    Juyin Yang, Jian Yang, Shao Ban, Xinmin Li, Xingde Chen, Jihua Yang, Jun Qian
    Journal of Thoracic Oncology.2019; 14(9): e198.     CrossRef
  • Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective
    Shui-Ming Bao, Qing-Hui Hu, Wen-Ting Yang, Yao Wang, Yin-Ping Tong, Wen-Dai Bao
    Anti-Cancer Agents in Medicinal Chemistry.2019; 19(8): 984.     CrossRef
  • Maximum allele frequency observed in plasma: A potential indicator of liquid biopsy sensitivity
    Yong Tang, Xianling Liu, Zhu'an Ou, Zhe He, Qihang Zhu, Ye Wang, Mei Yang, Junyi Ye, Han Han‑Zhang, Guibin Qiao
    Oncology Letters.2019;[Epub]     CrossRef
  • TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
    Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Rumi Fujioka, Yumi Hakozaki, Mikiko Shibuya, Naomi Abe, Toshiharu Komori, Tomonori Haruma, Miki Terasaka, Ryoto Fujita, Akihiro Hashimoto, Kaoru Funabashi, Hiroyuki Yasuda, Kazutaka Miyadera, Koichi Goto, D
    Molecular Cancer Research.2019; 17(11): 2233.     CrossRef
  • Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor
    Chengying Xie, Xiaozhe Wan, Haitian Quan, Mingyue Zheng, Li Fu, Yun Li, Liguang Lou
    Cancer Science.2018; 109(4): 1207.     CrossRef
  • Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
    Jacqulyne P. Robichaux, Yasir Y. Elamin, Zhi Tan, Brett W. Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal, Anh T. Le, Anna Truini, Monique B. Nilsson, Huiying Sun, Emily Roarty, Sarah B. Goldberg, Julie R.
    Nature Medicine.2018; 24(5): 638.     CrossRef
  • Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma
    In-Jae Oh, Jae Young Hur, Cheol-Kyu Park, Young-Chul Kim, Seung Joon Kim, Min Ki Lee, Hee Joung Kim, Kye Young Lee, Jae Cheol Lee, Chang-Min Choi
    Clinical Lung Cancer.2018; 19(5): e775.     CrossRef
  • Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors
    Yanmei Peng, Qiang Li, Jingyi Zhang, Wen Shen, Xu Zhang, Chenyao Sun, Huijuan Cui
    BioScience Trends.2018; 12(6): 537.     CrossRef
  • EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
    Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, Daniel B. Costa
    Clinical Cancer Research.2018; 24(24): 6548.     CrossRef
  • EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs
    Zhiyong Liang, Ying Cheng, Yuan Chen, Yanping Hu, Wei-Ping Liu, You Lu, Jie Wang, Ye Wang, Gang Wu, Jian-Ming Ying, He-Long Zhang, Xu-Chao Zhang, Yi-Long Wu
    Cancer Letters.2017; 403: 186.     CrossRef
  • Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer
    Xuefei Li, Caicun Zhou
    Oncotarget.2017; 8(59): 100801.     CrossRef
  • 14,422 View
  • 563 Download
  • 37 Web of Science
  • 35 Crossref
Close layer
Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery
Ciro Franzese, Davide Franceschini, Luca Cozzi, Giuseppe D’Agostino, Tiziana Comito, Fiorenza De Rose, Pierina Navarria, Pietro Mancosu, Stefano Tomatis, Antonella Fogliata, Marta Scorsetti
Cancer Res Treat. 2017;49(1):20-28.   Published online April 27, 2016
DOI: https://doi.org/10.4143/crt.2016.057
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to study the clinical outcome for patients with metastases of the adrenal gland treated with stereotactic body radiation therapy.
Materials and Methods
Forty-six patients were studied retrospectively. The dose prescription was 40 Gy in four fractions. Dosimetric analysis was performed using the dose volume histograms while clinical outcome was assessed using actuarial analysis with determination of the overall survival (OS) and local control (LC) rates.
Results
The planning objectives were met for all patients. With a median follow-up period of 7.6 months, at the last follow-up 42 patients (91.3%) were alive and four had died because of distant progression. The actuarial mean OS was 28.5±1.6 months, the median was not reached. One-year and 2-year OS were 87.6±6.1%. None of the risk factors was significant in univariate analysis. Actuarial mean LC was 14.6±1.8 months (95% confidence interval [CI], 11.0 to 18.2) and median LC was 14.5±2.0 months (95% CI, 10.5 to 18.5). One-year and 2-year LC were 65.5±11.9% and 40.7±15.8%, respectively. A mild profile of toxicity was observed in the cohort of patients. Forty patients (86.9%) showed no complication (grade 0); two patients reported asthenia, six patients (13.1%) reported either pain, nausea, or vomiting. Of these six patients, five patients (10.9%) were scored as grade 1 toxicity while one patient (2.2%) was scored as grade 2.
Conclusion
Stereotactic body radiation therapy treatment provided an adequate clinical response in the management of adrenal gland metastases.

Citations

Citations to this article as recorded by  
  • Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer
    Bichun Xu, Xianzhi Zhao, Di Chen, Wenjuan Zhao, Xiaoyan Wang, Changhua Ding, Zhiyong Yuan, Huojun Zhang
    BMC Cancer.2023;[Epub]     CrossRef
  • Radiation Therapy in the Management of Adrenal Metastases
    Ciro Franzese, Sara Stefanini, Marta Scorsetti
    Seminars in Radiation Oncology.2023; 33(2): 193.     CrossRef
  • The efficacy and outcomes of stereotactic body radiotherapy in adrenal gland metastases
    Esra Kekilli, Taciser Demirkasımoğlu
    Journal of Cancer Research and Therapeutics.2023; 19(Suppl 1): S47.     CrossRef
  • Twenty Years of Advancements in a Radiotherapy Facility: Clinical Protocols, Technology, and Management
    Stefano Tomatis, Pietro Mancosu, Giacomo Reggiori, Francesca Lobefalo, Pasqualina Gallo, Nicola Lambri, Lucia Paganini, Francesco La Fauci, Andrea Bresolin, Sara Parabicoli, Marco Pelizzoli, Pierina Navarria, Ciro Franzese, Domenico Lenoci, Marta Scorsett
    Current Oncology.2023; 30(7): 7031.     CrossRef
  • Risk factors of local control in adrenal metastases treated by stereotactic body radiation therapy - a systematic review and meta-analysis
    Xuehong Liao, Kazushi Kishi, Kaixin Du, Ritsuko Komaki, Junetsu Mizoe, Gosuke Aikawa, Wei Zheng, Chao Pan
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Management of an Unusual Metastasis of Cervical Cancer in the Adrenal Bed With Stereotactic Ablative Body Radiation Therapy
    Raul Puente-Vallejo, Pamela Ochoa, Cristina Núñez, Luis De Los Reyes
    Cureus.2022;[Epub]     CrossRef
  • Stereotactic body radiotherapy of adrenal metastases—A dose‐finding study
    Daniel Buergy, Florian Würschmidt, Eleni Gkika, Juliane Hörner‐Rieber, Stefan Knippen, Sabine Gerum, Panagiotis Balermpas, Christoph Henkenberens, Theresa Voglhuber, Christine Kornhuber, Steffen Barczyk, Barbara Röper, Ali Rashid, Oliver Blanck, Andrea Wi
    International Journal of Cancer.2022; 151(3): 412.     CrossRef
  • Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results
    Morgan Michalet, Ons Bettaïeb, Samia Khalfi, Asma Ghorbel, Simon Valdenaire, Pierre Debuire, Norbert Aillères, Roxana Draghici, Mailys De Méric De Bellefon, Marie Charissoux, Pierre Boisselier, Sylvain Demontoy, Alexis Marguerit, Morgane Cabaillé, Marie C
    Journal of Clinical Medicine.2022; 12(1): 291.     CrossRef
  • Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis
    Daniel Buergy, Florian Würschmidt, Eleni Gkika, Juliane Hörner‐Rieber, Stefan Knippen, Sabine Gerum, Panagiotis Balermpas, Christoph Henkenberens, Theresa Voglhuber, Christine Kornhuber, Steffen Barczyk, Barbara Röper, Ali Rashid, Oliver Blanck, Andrea Wi
    International Journal of Cancer.2021; 149(2): 358.     CrossRef
  • Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors
    Priscilla K. Stumpf, Ellen D. Yorke, Issam El Naqa, Kyle C. Cuneo, Jimm Grimm, Karyn A. Goodman
    International Journal of Radiation Oncology*Biology*Physics.2021; 110(1): 217.     CrossRef
  • Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production
    Ciro Franzese, Sara Stefanini, Maria Massaro, Tiziana Comito, Pierina Navarria, Elena Clerici, Ausilia Teriaca, Davide Franceschini, Giacomo Reggiori, Stefano Tomatis, Andrea Lania, Marta Scorsetti
    Journal of Cancer Research and Clinical Oncology.2021; 147(12): 3619.     CrossRef
  • Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis
    Ciro Franzese, Luca Nicosia, Giuseppe Facondo, Lorenzo Lo Faro, Francesco Cuccia, Gianluca Vullo, Mattia Falchetto Osti, Filippo Alongi, Marta Scorsetti
    Clinical & Experimental Metastasis.2021; 38(6): 511.     CrossRef
  • Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients
    William C. Chen, Joe D. Baal, Ulysis Baal, Jonathan Pai, Alexander Gottschalk, Lauren Boreta, Steve E. Braunstein, David R. Raleigh
    International Journal of Radiation Oncology*Biology*Physics.2020; 107(1): 48.     CrossRef
  • Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
    Laila König, Matthias F. Häfner, Sonja Katayama, Stefan A. Koerber, Eric Tonndorf-Martini, Denise Bernhardt, Bastian von Nettelbladt, Fabian Weykamp, Philipp Hoegen, Sebastian Klüter, Matthew S. Susko, Jürgen Debus, Juliane Hörner-Rieber
    Radiation Oncology.2020;[Epub]     CrossRef
  • Clinical efficacy of Stereotactic Body Radiation Therapy (SBRT) for adrenal gland metastases: A multi-center retrospective study from China
    Xianzhi Zhao, Xiaofei Zhu, Hongqing Zhuang, Xueling Guo, Yongchun Song, Xiaoping Ju, Ping Wang, Zhiyong Yuan, Huojun Zhang
    Scientific Reports.2020;[Epub]     CrossRef
  • Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases
    Theresa Voglhuber, Kerstin A. Kessel, Markus Oechsner, Marco M. E. Vogel, Jürgen E. Gschwend, Stephanie E. Combs
    BMC Cancer.2020;[Epub]     CrossRef
  • Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity
    Ciro Franzese, Marco Lorenzo Bonu, Tiziana Comito, Elena Clerici, Mauro Loi, Pierina Navarria, Davide Franceschini, Tiziana Pressiani, Lorenza Rimassa, Marta Scorsetti
    Journal of Cancer Research and Clinical Oncology.2020; 146(9): 2289.     CrossRef
  • Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment’s intensification?
    Ciro Franzese, Marco Badalamenti, Tiziana Comito, Davide Franceschini, Elena Clerici, Pierina Navarria, Mauro Loi, Giuseppe D'agostino, Davide Baldaccini, Ilaria Chiola, Giacomo Reggiori, Pietro Mancosu, Stefano Tomatis, Marta Scorsetti
    Radiotherapy and Oncology.2020; 150: 184.     CrossRef
  • Adrenal SBRT: a multi-institutional review of treatment outcomes and toxicity
    Corbin A. Helis, Ryan T. Hughes, Karina Nieto, Adannia Ufondu, Emily C. Daugherty, Michael K. Farris
    Clinical & Experimental Metastasis.2020; 37(5): 585.     CrossRef
  • Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients
    Fabio Arcidiacono, Cynthia Aristei, Alessandro Marchionni, Marco Italiani, Cristian Paolo Luca Fulcheri, Simonetta Saldi, Michelina Casale, Gianluca Ingrosso, Paola Anselmo, Ernesto Maranzano
    The British Journal of Radiology.2020; 93(1115): 20200645.     CrossRef

  • Hypofractionated Radiotherapy for 35 Patients with Adrenal Metastases: A Single-Institution Experience


    Ruizhi Zhao, Yuchao Ma, Siran Yang, Qingfeng Liu, Yuan Tang, Kai Wang, Ye Zhang, Nan Bi, Hongmei Zhang, Junlin Yi, Yexiong Li, Jingwei Luo, Jianping Xiao
    Cancer Management and Research.2020; Volume 12: 11563.     CrossRef
  • Usefulness of Stereotactic Body Radiation Therapy for Treatment of Adrenal Gland Metastases
    Cyrielle Scouarnec, David Pasquier, Joel Luu, Florence le Tinier, Loïc Lebellec, Erwann Rault, Eric Lartigau, Xavier Mirabel
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity
    Diego A.S. Toesca, Amanda J. Koong, Rie von Eyben, Albert C. Koong, Daniel T. Chang
    Advances in Radiation Oncology.2018; 3(4): 621.     CrossRef
  • Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal Metastases
    Miguel A. Palacios, Omar Bohoudi, Anna M.E. Bruynzeel, John R. van Sörsen de Koste, Paul Cobussen, Ben J. Slotman, Frank J. Lagerwaard, Suresh Senan
    International Journal of Radiation Oncology*Biology*Physics.2018; 102(2): 426.     CrossRef
  • Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer
    Xianzhi Zhao, Xiaofei Zhu, Jianfeng Fei, Haipeng Ren, Yangsen Cao, Xiaoping Ju, Zhiyong Yuan, Huojun Zhang
    Radiation Oncology.2018;[Epub]     CrossRef
  • Real-Time Tumor-Tracking Radiotherapy and General Stereotactic Body Radiotherapy for Adrenal Metastasis in Patients With Oligometastasis
    Norio Katoh, Hiroshi Onishi, Yusuke Uchinami, Tetsuya Inoue, Kengo Kuriyama, Kentaro Nishioka, Shinichi Shimizu, Takafumi Komiyama, Naoki Miyamoto, Hiroki Shirato
    Technology in Cancer Research & Treatment.2018;[Epub]     CrossRef
  • Adrenal insufficiency in Bilateral Adrenal Metastasis implemented SBRT
    Cihan YB
    Journal of Radiology and Oncology.2018; : 009.     CrossRef
  • Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis
    Ciro Franzese, Antonella Fogliata, Tiziana Comito, Angelo Tozzi, Cristina Iftode, Elena Clerici, Davide Franceschini, Pierina Navarria, Anna Maria Ascolese, Lucia Di Brina, Fiorenza De Rose, Giuseppe R D'Agostino, Luca Cozzi, Marta Scorsetti
    The British Journal of Radiology.2017;[Epub]     CrossRef
  • SBRT to adrenal metastases provides high local control with minimal toxicity
    Kristin Plichta, Nathan Camden, Muhammed Furqan, Taher Abu Hejleh, Gerald H. Clamon, Jun Zhang, Ryan T. Flynn, Sudershan K. Bhatia, Mark C. Smith, John M. Buatti, Bryan G. Allen
    Advances in Radiation Oncology.2017; 2(4): 581.     CrossRef
  • 10,256 View
  • 201 Download
  • 35 Web of Science
  • 29 Crossref
Close layer
Association between Metformin Use and Survival in Nonmetastatic Rectal Cancer Treated with a Curative Resection: A Nationwide Population Study
Young-Jun Ki, Hyo Jeong Kim, Mi-Sook Kim, Chan Mi Park, Min Jung Ko, Young Seok Seo, Sun Mi Moon, Jin A Choi
Cancer Res Treat. 2017;49(1):29-36.   Published online July 4, 2016
DOI: https://doi.org/10.4143/crt.2016.128
AbstractAbstract PDFPubReaderePub
Purpose
Metformin is associated with an anticancer effect. However, the effects of metformin in rectal cancer are controversial. This study investigated the impact of metformin on the survival of patients with diabetes mellitus and nonmetastatic rectal cancer who underwent curative surgery.
Materials and Methods
The database was provided by the Korea Center Cancer Registry and National Health Insurance Service of the Republic of Korea. A cohort of patients with newly diagnosed rectal cancer between 2005 and 2011 was identified. Drug exposure was defined as receiving the oral hypoglycemic agent for at least 90 days over the period from 6 months before the initial diagnosis of rectal cancer to the last follow-up.
Results
A total of 4,503 patients were prescribed oral hypoglycemic agents and classified as the diabetic group, of which 3,694 patients received metformin for at least 90 days. Unadjusted analyses showed a significantly higher overall survival (hazard ratio, 0.596; 95% confidence interval, 0.506 to 0.702) and rectal cancer-specific survival (hazard ratio, 0.621; 95% confidence interval, 0.507 to 0.760) in the metformin group than in the nonmetformin group. The adjusted overall survival (hazard ratio, 0.631; 95% confidence interval, 0.527 to 0.755) and cancer-specific survival (hazard ratio, 0.598; 95% confidence interval, 0.479 to 0.746) in the group with a medication possession ratio of 80% or greater was significantly higher than in the group with a medication possession ratio of less than 80%.
Conclusion
Metformin use is associated with overall and cancer-specific survival in diabetic patients with a nonmetastatic rectal cancer treated with a curative resection.

Citations

Citations to this article as recorded by  
  • Metformin Does not Affect Outcomes in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Therapy and Resection
    Swati Sonal, Chloe Boudreau, Hiroko Kunitake, Robert N. Goldstone, Grace C. Lee, Christy E. Cauley, Liliana G. Bordeianou, Todd D. Francone, Rocco Ricciardi, David L. Berger
    The American Surgeon™.2024; 90(4): 858.     CrossRef
  • View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences
    Guglielmina Froldi
    Pharmaceuticals.2024; 17(4): 478.     CrossRef
  • Type II diabetes and metformin use does not affect colorectal cancer prognosis
    Mehrnoosh Shahrivar, Caroline E. Dietrich, Bengt Glimelius, Deborah Saraste, Anna Martling, Christian Buchli, Caroline Nordenvall
    International Journal of Cancer.2024;[Epub]     CrossRef
  • Survival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndrome
    Ji Soo Park, Soo Jin Moon, Hyung Seok Park, Sang-Hoon Cho
    Preventive Medicine Reports.2024; 48: 102928.     CrossRef
  • Metformin combined with local irradiation provokes abscopal effects in a murine rectal cancer model
    Mineyuki Tojo, Hideyo Miyato, Koji Koinuma, Hisanaga Horie, Hidenori Tsukui, Yuki Kimura, Yuki Kaneko, Hideyuki Ohzawa, Hironori Yamaguchi, Kotaro Yoshimura, Alan Kawarai Lefor, Naohiro Sata, Joji Kitayama
    Scientific Reports.2022;[Epub]     CrossRef
  • Clinicopathological Characteristics and Overall 5-Year Survival of Colorectal Cancer: A Retrospective Study
    Rahaf Almuhanna, Fatma Al-Thoubaity, Khadijah Almalki, Nada Algarni, Renad Hamad, Toleen Makhtoum
    Medical Sciences.2022; 10(3): 42.     CrossRef
  • Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies
    Jing Yang, Hang Yang, Ling Cao, Yuzhen Yin, Ying Shen, Wei Zhu
    Medicine.2022; 101(49): e31799.     CrossRef
  • Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study
    Byoung Hyuck Kim, Moon-June Cho, Jeanny Kwon
    International Journal of Clinical Oncology.2021; 26(11): 2004.     CrossRef
  • Suppressive effects of metformin on colorectal adenoma incidence and malignant progression
    Min Deng, Siqin Lei, Dongdong Huang, Hui Wang, Shuli Xia, Enping Xu, Yihua Wu, Honghe Zhang
    Pathology - Research and Practice.2020; 216(2): 152775.     CrossRef
  • Effect of metformin on the mortality of colorectal cancer patients with T2DM: meta-analysis of sex differences
    Yunzi Wang, Jingping Xiao, Yuanyu Zhao, Shijuan Du, Jiang Du
    International Journal of Colorectal Disease.2020; 35(5): 827.     CrossRef
  • Postdiagnostic metformin use and survival of patients with colorectal cancer: A Nationwide cohort study
    Wen‐Kuan Huang, Shu‐Hao Chang, Hung‐Chih Hsu, Wen‐Chi Chou, Tsai‐Sheng Yang, Jen‐Shi Chen, John Wen‐Cheng Chang, Yung‐Chang Lin, Chang‐Fu Kuo, Lai‐Chu See
    International Journal of Cancer.2020; 147(7): 1904.     CrossRef
  • Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression
    Cheng-Ann Winston Ng, Amy Aimei Jiang, Emma Min Shuen Toh, Cheng Han Ng, Zhi Hao Ong, Siyu Peng, Hui Yu Tham, Raghav Sundar, Choon Seng Chong, Chin Meng Khoo
    International Journal of Colorectal Disease.2020; 35(8): 1501.     CrossRef
  • Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus
    Akira Saito, Joji Kitayama, Hisanaga Horie, Koji Koinuma, Hideyuki Ohzawa, Hironori Yamaguchi, Hiroshi Kawahira, Toshiki Mimura, Alan Kawarai Lefor, Naohiro Sata
    Cancer Science.2020; 111(11): 4012.     CrossRef
  • Patterns of Rectal Cancer Radiotherapy Adopting Evidence-Based Medicine: An Analysis of the National Database from 2005 to 2016
    Hae Jin Park, Sanghyun Cho, Yoon Kim
    Cancer Research and Treatment.2018; 50(3): 975.     CrossRef
  • UEG Week 2018 Poster Presentations

    United European Gastroenterology Journal.2018;[Epub]     CrossRef
  • 11,713 View
  • 307 Download
  • 17 Web of Science
  • 15 Crossref
Close layer
Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer
Dalyong Kim, Yong Sang Hong, Jeong Eun Kim, Kyu-pyo Kim, Jae-Lyun Lee, Sung-Min Chun, Jihun Kim, Se Jin Jang, Tae Won Kim
Cancer Res Treat. 2017;49(1):37-43.   Published online April 27, 2016
DOI: https://doi.org/10.4143/crt.2016.069
AbstractAbstract PDFPubReaderePub
Purpose
Cetuximab demonstrates improved efficacy outcomes in patients with metastatic colorectal cancer (mCRC) harboring wild-type KRAS exon 2. Resistance to cetuximab is mediated by activating less frequent mutations in the RAS genes beyond KRAS exon 2. We performed extended RASmutational analysis using a high -throughput genotyping platform (OncoMap) and evaluated extended RAS analysis for predicting cetuximab efficacy in patients harboring wild-type KRAS exon 2 tumors following Sanger sequencing.
Materials and Methods
Extended RAS analysis was performed on 227 wild-type KRAS exon 2 mCRC patients who received cetuximab as salvage treatment using OncoMap ver. 4.0. Targeted genes included exon 2, exon 3, and exon 4, both in KRAS and NRAS, and included BRAF exon 15. We assessed efficacy by the new RAS mutation status.
Results
The OncoMap detected 57 additional mutations (25.1%): 25 (11%) in KRAS exon 2 and 32 (14.1%) beyond KRAS exon 2. Survival differences were observed after dividing patients into the wild-type RAS group (n=170) and mutant RAS group (n=57) using OncoMap. Progression-free survival was 4.8 months versus 1.8 months (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.32 to 0.61), and overall survival was 11.9 months versus 8.4 months (HR, 0.65; 95% CI, 0.47 to 0.88).
Conclusion
Sanger sequencing is not sufficient for selecting candidates for cetuximab treatment. High-throughput extended RAS genotyping is a feasible approach for this purpose and identifies patients who might benefit from cetuximab treatment.

Citations

Citations to this article as recorded by  
  • Metastatik Kolorektal Kanserli Hastaların RAS Mutasyon Durumuna Göre Klinik ve Patolojik Özellikleri
    Mehmet SEZEN, Murat ARAZ
    Uludağ Üniversitesi Tıp Fakültesi Dergisi.2019; 45(2): 131.     CrossRef
  • Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
    T. Yoshino, D. Arnold, H. Taniguchi, G. Pentheroudakis, K. Yamazaki, R.-H. Xu, T.W. Kim, F. Ismail, I.B. Tan, K.-H. Yeh, A. Grothey, S. Zhang, J.B. Ahn, M.Y. Mastura, D. Chong, L.-T. Chen, S. Kopetz, T. Eguchi-Nakajima, H. Ebi, A. Ohtsu, A. Cervantes, K.
    Annals of Oncology.2018; 29(1): 44.     CrossRef
  • Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer
    Sumi Yun, Yoonjin Kwak, Soo Kyung Nam, An Na Seo, Heung-Kwon Oh, Duck-Woo Kim, Sung-Bum Kang, Hye Seung Lee
    Cancer Research and Treatment.2018; 50(4): 1351.     CrossRef
  • Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
    Dalyong Kim, Sun Young Kim, Ji Sung Lee, Yong Sang Hong, Jeong Eun Kim, Kyu-pyo Kim, Jihun Kim, Se Jin Jang, Young-Kwang Yoon, Tae Won Kim
    BMC Gastroenterology.2017;[Epub]     CrossRef
  • 10,418 View
  • 196 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort
Minkyu Jung, Jeeyun Lee, Tae Min Kim, Dae Ho Lee, Jin Hyung Kang, Sung Young Oh, Soo Jung Lee, Sang Joon Shin
Cancer Res Treat. 2017;49(1):44-53.   Published online April 27, 2016
DOI: https://doi.org/10.4143/crt.2016.024
AbstractAbstract PDFPubReaderePub
Purpose
Ipilimumab improves survival in advanced melanoma patients. However, the efficacy and safety of ipilimumab has not been evaluated in Asian melanoma patients with a high frequency of mucosal and acral melanoma subtypes.
Materials and Methods
Advanced melanoma patients treated with 3 mg/kg ipilimumab in a Korean multicenter named-patient program (NPP) were evaluated between September 2014 and July 2015. Baseline characteristics and blood parameters including neutrophil to lymphocyte ratio (NLR) were assessed, and outcome and adverse events were evaluated according to subtypes.
Results
A total of 104 advanced melanoma patients were treated. The primary sites were acral (31.7%), mucosal (26%), cutaneous (26%), uveal (9.6%), and unknown (6.7%). Sixty-eight patients (65.4%) experienced adverse events, and the most common toxicity was skin rash (22.1%), 10 patients (9.6%) experienced adverse events of grade 3 or higher. The median progression-free survival (PFS) was 2.73 months (95% confidence interval, 2.67 to 2.85), and there was no difference in PFS according to subtypes. Poor performance status, liver metastasis, and NLR (≥5) were independent poor prognostic factors by multivariate analysis.
Conclusion
In the Korean NPP cohort, ipilimumab showed similar efficacy and tolerability compared to Western patients, regardless of subtypes. All subtypes should benefit from ipilimumab with consideration of performance status, liver metastasis, and NLR.

Citations

Citations to this article as recorded by  
  • Baseline neutrophil-to- ratio combined with the change during treatment provides risk stratification for metastatic malignant melanoma patients treated with PD-1 inhibitors in a Chinese population
    Chen Wang, Shengyan Liu, Xin Li, Kang Cui, Weijie Zhang, Yabing Du
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis
    Bao-Wen Tian, Cheng-Long Han, Han-Chao Wang, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Xin-Cheng Mao, Jin-Cheng Tian, Jun-Shuai Xue, Long-Shan Yang, Si-Yu Tan, Zhao-Ru Dong, Yu-Chuan Yan, Dong-Xu Wang, Tao Li
    Clinical & Experimental Metastasis.2023; 40(4): 255.     CrossRef
  • MelRisk: Using neutrophil-to-lymphocyte ratio to improve risk prediction models for metastatic cutaneous melanoma in the sentinel lymph node
    Ryckie G. Wade, Samuel Bailey, Alyss V. Robinson, Michelle C.I. Lo, Howard Peach, Marc D.S. Moncrieff, James Martin
    Journal of Plastic, Reconstructive & Aesthetic Surgery.2022; 75(5): 1653.     CrossRef
  • The Prognostic Significance of Baseline Neutrophil-to-Lymphocyte Ratio in Melanoma Patients Receiving Immunotherapy
    Yayun Li, Yu Meng, Huiyan Sun, Lin Ye, Furong Zeng, Xiang Chen, Guangtong Deng
    Journal of Immunotherapy.2022; 45(1): 43.     CrossRef
  • The pharmacotherapeutic management of nail unit and acral melanomas
    Julianne M. Falotico, Shari R. Lipner
    Expert Opinion on Pharmacotherapy.2022; 23(11): 1273.     CrossRef
  • Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
    Yongchao Zhang, Bozhi Liu, Sergei Kotenko, Wei Li
    Medicine.2022; 101(32): e29536.     CrossRef
  • Real‐world, population‐based cohort study of toxicity and resource utilization of second‐line ipilimumab for metastatic melanoma in Ontario, Canada
    Wei Fang Dai, Jaclyn Beca, Ruth Croxford, Wanrudee Isaranuwatchai, Ines B. Menjak, Teresa M. Petrella, Nicole Mittmann, Craig C. Earle, Scott Gavura, Rebecca E. Mercer, Timothy P. Hanna, Kelvin K. W. Chan
    International Journal of Cancer.2021; 148(8): 1910.     CrossRef
  • Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis
    Náthali Felícia Mineiro dos Santos Garrett, Ana Cristina Carvalho da Costa, Elaine Barros Ferreira, Giovanni Damiani, Paula Elaine Diniz dos Reis, Christiane Inocêncio Vasques, Gayle E. Woloschak
    PLOS ONE.2021; 16(8): e0255716.     CrossRef
  • Novel Prognostic Immunohistochemical Markers in Uveal Melanoma-Literature Review
    Malgorzata Gajdzis, Radoslaw Kaczmarek, Pawel Gajdzis
    Cancers.2021; 13(16): 4031.     CrossRef
  • The Role of Immune Checkpoint Blockade in Uveal Melanoma
    Anja Wessely, Theresa Steeb, Michael Erdmann, Lucie Heinzerling, Julio Vera, Max Schlaak, Carola Berking, Markus Vincent Heppt
    International Journal of Molecular Sciences.2020; 21(3): 879.     CrossRef
  • Neutrophil diversity and plasticity in tumour progression and therapy
    Sebastien Jaillon, Andrea Ponzetta, Diletta Di Mitri, Angela Santoni, Raffaella Bonecchi, Alberto Mantovani
    Nature Reviews Cancer.2020; 20(9): 485.     CrossRef
  • Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis
    Kelcie Witges, Leigh Anne Shafer, Ryan Zarychanski, Ahmed M. Abou-Setta, Rasheda Rabbani, Orvie Dingwall, Charles N. Bernstein
    Drug Safety.2020; 43(12): 1255.     CrossRef
  • Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis
    Fausto Petrelli, Raffaele Ardito, Barbara Merelli, Veronica Lonati, Mary Cabiddu, Silvia Seghezzi, Sandro Barni, Antonio Ghidini
    Melanoma Research.2019; 29(1): 1.     CrossRef
  • Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for Non–Small-Cell Lung Cancer
    Wungki Park, Gilberto Lopes
    Clinical Lung Cancer.2019; 20(3): 143.     CrossRef
  • Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors
    Xianhe Xie, Junjin Liu, Haitao Yang, Huijuan Chen, Sijing Zhou, Heng Lin, Ziyuan Liao, Yin Ding, Liting Ling, Xuewen Wang
    Cancer Investigation.2019; 37(6): 265.     CrossRef
  • Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
    Ernesto Rossi, Giovanni Schinzari, Ilaria Grazia Zizzari, Brigida Anna Maiorano, Monica Maria Pagliara, Maria Grazia Sammarco, Vincenzo Fiorentino, Gianluigi Petrone, Alessandra Cassano, Guido Rindi, Emilio Bria, Maria Antonietta Blasi, Marianna Nuti, Gia
    Cancers.2019; 11(8): 1055.     CrossRef
  • Uveal Melanoma Metastatic to the Liver: Treatment Trends and Outcomes
    Lucy T. Xu, Pauline F. Funchain, James F. Bena, Manshi Li, Ahmad Tarhini, Eren Berber, Arun D. Singh
    Ocular Oncology and Pathology.2019; 5(5): 323.     CrossRef
  • Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis
    Tao Jiang, Meng Qiao, Chao Zhao, Xuefei Li, Guanghui Gao, Chunxia Su, Shengxiang Ren, Caicun Zhou
    Cancer Immunology, Immunotherapy.2018; 67(5): 713.     CrossRef
  • Prognostic value of neutrophil-to-lymphocyte ratio in melanoma
    Yingguo Ding, Shan Zhang, Jianjun Qiao
    Medicine.2018; 97(30): e11446.     CrossRef
  • Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study
    Tony Ibrahim, Christine Mateus, Maria Baz, Caroline Robert
    Cancer Immunology, Immunotherapy.2018; 67(10): 1571.     CrossRef
  • Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta‐analysis
    Qiaoyun Tan, Shuxia Liu, Caixia Liang, Xiaohong Han, Yuankai Shi
    Thoracic Cancer.2018; 9(10): 1220.     CrossRef
  • Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma
    Francesco S. Mennini, Chiara Bini, Andrea Marcellusi, Michele Del Vecchio
    Clinical Drug Investigation.2018; 38(10): 967.     CrossRef
  • A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma
    Antoine Finon, Julia Zaragoza, Hervé Maillard, Nathalie Beneton, Guido Bens, Mahtab Samimi, Agnès Caille, Laurent Machet
    European Journal of Dermatology.2018; 28(1): 38.     CrossRef
  • Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review
    Markus V. Heppt, Theresa Steeb, Justin Gabriel Schlager, Stefanie Rosumeck, Corinna Dressler, Thomas Ruzicka, Alexander Nast, Carola Berking
    Cancer Treatment Reviews.2017; 60: 44.     CrossRef
  • Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
    Charissa A. C. Jessurun, Julien A. M. Vos, Jacqueline Limpens, Rosalie M. Luiten
    Frontiers in Oncology.2017;[Epub]     CrossRef
  • 11,239 View
  • 271 Download
  • 27 Web of Science
  • 25 Crossref
Close layer
Estimation of the Incidence of Hepatocellular Carcinoma and Cholangiocarcinoma in Songkhla, Thailand, 1989-2013, Using Multiple Imputation Method
Seesai Yeesoonsang, Surichai Bilheem, Edward McNeil, Sophon Iamsirithaworn, Chuleeporn Jiraphongsa, Hutcha Sriplung
Cancer Res Treat. 2017;49(1):54-60.   Published online May 18, 2016
DOI: https://doi.org/10.4143/crt.2016.045
AbstractAbstract PDFPubReaderePub
Purpose
Histological specimens are not required for diagnosis of liver and bile duct (LBD) cancer, resulting in a high percentage of unknown histologies. We compared estimates of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) incidences by imputing these unknown histologies.
Materials and Methods
A retrospective study was conducted using data from the Songkhla Cancer Registry, southern Thailand, from 1989 to 2013. Multivariate imputation by chained equations (mice) was used in re-classification of the unknown histologies. Age-standardized rates (ASR) of HCC and CCA by sex were calculated and the trends were compared. Results Of 2,387 LBD cases, 61% had unknown histology. After imputation, the ASR of HCC in males during 1989 to 2007 increased from 4 to 10 per 100,000 and then decreased after 2007. The ASR of CCA increased from 2 to 5.5 per 100,000, and the ASR of HCC in females decreased from 1.5 in 2009 to 1.3 in 2013 and that of CCA increased from less than 1 to 1.9 per 100,000 by 2013.
Results
of complete case analysis showed somewhat similar, although less dramatic, trends.
Conclusion
In Songkhla, the incidence of CCA appears to be stable after increasing for 20 years whereas the incidence of HCC is now declining. The decline in incidence of HCC among males since 2007 is probably due to implementation of the hepatitis B virus vaccine in the 1990s. The rise in incidence of CCA is a concern and highlights the need for case control studies to elucidate the risk factors.

Citations

Citations to this article as recorded by  
  • Comparison of Cholangiocarcinoma and Hepatocellular Carcinoma Incidence Trends from 1993 to 2012 in Lampang, Thailand
    Pianpian Cao, Laura S. Rozek, Donsuk Pongnikorn, Hutcha Sriplung, Rafael Meza
    International Journal of Environmental Research and Public Health.2022; 19(15): 9551.     CrossRef
  • Mitochondrial Dysfunction and Induction of Apoptosis in Hepatocellular Carcinoma and Cholangiocarcinoma Cell Lines by Thymoquinone
    Reem J. Abdualmjid, Consolato M. Sergi
    International Journal of Molecular Sciences.2022; 23(23): 14669.     CrossRef
  • Hepatocellular carcinoma incidence at national and provincial levels in Iran from 2000 to 2016: A meta-regression analysis
    Nima Fattahi, Negar Rezaei, Mohsen Asadi-Lari, Moein Yousefi, Zahra Madadi, Kimiya Gohari, Ali Sheidaei, Esmaeil Mohammadi, Nazila Rezaei, Mahboubeh Parsaeian, Farzad Kompani, Farshad Farzadfar, Amir Radfar
    PLOS ONE.2021; 16(1): e0245468.     CrossRef
  • Trends in Incidence of Two Major Subtypes of Liver and Bile Duct Cancer: Hepatocellular Carcinoma and Cholangiocarcinoma in Songkhla, Southern Thailand, 1989-2030
    Seesai Yeesoonsang, Edward McNeil, Shama Virani, Surichai Bilheem, Chakrarat Pittayawonganon, Chuleeporn Jiraphongsa, Hutcha Sriplung
    Journal of Cancer Epidemiology.2018; 2018: 1.     CrossRef
  • National and Subnational Population-Based Incidence of Cancer in Thailand: Assessing Cancers with the Highest Burdens
    Shama Virani, Surichai Bilheem, Wasan Chansaard, Imjai Chitapanarux, Karnchana Daoprasert, Somsak Khuanchana, Atit Leklob, Donsuk Pongnikorn, Laura Rozek, Surattaya Siriarechakul, Krittika Suwanrungruang, Sukit Tassanasunthornwong, Patravoot Vatanasapt, H
    Cancers.2017; 9(8): 108.     CrossRef
  • 9,944 View
  • 174 Download
  • 6 Web of Science
  • 5 Crossref
Close layer
Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07)
Hyejung Cha, Hee Chul Park, Jeong Il Yu, Tae Hyun Kim, Taek-Keun Nam, Sang Min Yoon, Won Sup Yoon, Jun Won Kim, Mi Sook Kim, Hong Seok Jang, Youngmin Choi, Jin Hee Kim, Chul Seung Kay, Inkyung Jung, Jinsil Seong
Cancer Res Treat. 2017;49(1):61-69.   Published online June 13, 2016
DOI: https://doi.org/10.4143/crt.2016.097
AbstractAbstract PDFPubReaderePub
Purpose
The aim of this study was to examine patterns of radiotherapy (RT) in Korean patients with hepatocellular carcinoma (HCC) according to the evolving guideline for HCC established by the Korean Liver Cancer Study Group-National Cancer Center (KLCSG-NCC).
Materials and Methods
We reviewed 765 patients with HCC who were treated with RT between January 2011 and December 2012 in 12 institutions.
Results
The median follow-up period was 13.3 months (range, 0.2 to 51.7 months). Compared with previous data between 2004 and 2005, the use of RT as a first treatment has increased (9.0% vs. 40.8%). Increased application of intensity-modulated RT resulted in an increase in radiation dose (fractional dose, 1.8 Gy vs. 2.5 Gy; biologically effective dose, 53.1 Gy10 vs. 56.3 Gy10). Median overall survival was 16.2 months, which is longer than that reported in previous data (12 months). In subgroup analysis, treatments were significantly different according to stage (p < 0.001). Stereotactic body RT was used in patients with early HCC, and most patients with advanced stage were treated with three-dimensional conformal RT.
Conclusion
Based on the evolving KLCSG-NCC practice guideline for HCC, clinical practice patterns of RT have changed. Although RT is still used mainly in advanced HCC, the number of patients with good performance status who were treated with RT as a first treatment has increased. This change in practice patterns could result in improvement in overall survival.

Citations

Citations to this article as recorded by  
  • Complications After Exosome Treatment for Aesthetic Skin Rejuvenation
    William J. Nahm, Sukruthi Thunga, Jane Yoo
    Dermatological Reviews.2024;[Epub]     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Journal of Liver Cancer.2023; 23(1): 1.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Clinical and Molecular Hepatology.2022; 28(4): 583.     CrossRef
  • 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2022; 23(12): 1126.     CrossRef
  • Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe
    Sung Uk Lee, Sang Min Yoon, Jason Chia-Hsien Cheng, Tae Hyun Kim, Bo Hyun Kim, Jin-hong Park, Jinhong Jung, Chiao-Ling Tsai, Yun Chiang, Joong-Won Park
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Patterns of definitive radiotherapy practice for cervical cancer in South Korea: a survey endorsed by the Korean Radiation Oncology Group (KROG 20-06)
    Nalee Kim, Won Park
    Journal of Gynecologic Oncology.2021;[Epub]     CrossRef
  • Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints
    Sunmin Park, Won Sup Yoon, Chai Hong Rim
    World Journal of Gastroenterology.2020; 26(4): 393.     CrossRef
  • Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma
    Changhoon Choi, Gyu Sang Yoo, Won Kyung Cho, Hee Chul Park
    World Journal of Gastroenterology.2019; 25(20): 2416.     CrossRef
  • 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
    KLCA Korean Liver Cancer Association, NCC National Cancer Center
    Gut and Liver.2019; 13(3): 227.     CrossRef
  • 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2019; 20(7): 1042.     CrossRef
  • Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05)
    Sun Hyun Bae, Hee Chul Park, Won Sup Yoon, Sang Min Yoon, In-Hye Jung, Ik Jae Lee, Jun Won Kim, Jinsil Seong, Tae Hyun Kim, Taek-Keun Nam, Youngmin Choi, Sun Young Lee, Hong Seok Jang, Dong Soo Lee, Jin Hee Kim
    Cancer Research and Treatment.2019; 51(4): 1589.     CrossRef
  • EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
    Peter R. Galle, Alejandro Forner, Josep M. Llovet, Vincenzo Mazzaferro, Fabio Piscaglia, Jean-Luc Raoul, Peter Schirmacher, Valérie Vilgrain
    Journal of Hepatology.2018; 69(1): 182.     CrossRef
  • 11,087 View
  • 279 Download
  • 13 Web of Science
  • 12 Crossref
Close layer
Risk Factors for Thyroid Cancer: A Hospital-Based Case-Control Study in Korean Adults
Seung-Kwon Myung, Chan Wha Lee, Jeonghee Lee, Jeongseon Kim, Hyeon Suk Kim
Cancer Res Treat. 2017;49(1):70-78.   Published online June 23, 2016
DOI: https://doi.org/10.4143/crt.2015.310
AbstractAbstract PDFPubReaderePub
Purpose
Although the incidence of thyroid cancer in Korea has rapidly increased over the past decade, few studies have investigated its risk factors. This study examined the risk factors for thyroid cancer in Korean adults.
Materials and Methods
The study design was a hospital-based case-control study. Between August 2002 and December 2011, a total of 802 thyroid cancer cases out of 34,211 patients screened from the Cancer Screenee. Cohort of the National Cancer Center in South Korea were included in the analysis. A total of 802 control cases were selected from the same cohort, and matched individually (1:1) by age (±2 years) and area of residence for control group 1 and additionally by sex for control group 2.
Results
Multivariate conditional logistic regression analysis using the control group 1 showed that females and those with a family history of thyroid cancer had an increased risk of thyroid cancer, whereas ever-smokers and those with a higher monthly household income had a decreased risk of thyroid cancer. On the other hand, the analysis using control group 2 showed that a family history of cancer and alcohol consumption were associated with a decreased risk of thyroid cancer, whereas higher body mass index (BMI) and family history of thyroid cancer were associated with an increased risk of thyroid cancer.
Conclusion
These findings suggest that females, those with a family history of thyroid cancer, those with a higher BMI, non-smokers, non-drinkers, and those with a lower monthly household income have an increased risk of developing thyroid cancer.

Citations

Citations to this article as recorded by  
  • Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea
    Hyemi Kwon, Kyung-Do Han, Sun Joon Moon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(3): e1095.     CrossRef
  • Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials
    Ke Wang, Ying Zhang, Yang Xing, Hong Wang, Minghua He, Rui Guo
    Discover Oncology.2024;[Epub]     CrossRef
  • Thyroid Cancer Prevalence, Risk Exposure, and Clinical Features Among Transgender Female Veterans
    John David Christensen, Hiba T Basheer, Jose Joaquin Lado Abeal
    Journal of the Endocrine Society.2024;[Epub]     CrossRef
  • Thyroid Malignancy in Patients Who Underwent Thyroidectomy for Multinodular Goiter and Solitary Thyroid Nodule
    Desalew Gedamu, Tariku Shimels, Daniel Kassie, Zewditu Chanyalew, Mebrahtu Eyasu
    JCO Global Oncology.2024;[Epub]     CrossRef
  • Emerging Strategies in Thyroid Cancer Immunotherapy: A Comprehensive Systematic Review and Meta-Analysis of Clinical Outcomes
    Daniel Alejandro Estrella Cornejo, Meylin Yalitza Carriel Alvarado, Norma Susana Chávez Villagómez, Alberto Dario Díaz Parra, María Fernanda Navas Espinosa
    Salud, Ciencia y Tecnología.2024; 4: 1241.     CrossRef
  • Prevalence of Thyroid Nodules and Predictive Factors for their Malignancy: Is there any Correlation between Level of TSH and Type of Malignancy?: A Cross Sectional Study
    Leila Moradi, Mohsen Hani Tabaei Zavareh, Ferdos Zaman, Anahita Shareghi Bruojeni, Seyed Amir Mohammad Taravati, Hossein Naderi Boldaji, Koushan Rostami, Seyedeh Ghazal Shahrokh
    Advanced Biomedical Research.2024;[Epub]     CrossRef
  • Research Progress on Risk Factors of Thyroid Cancer
    丽 焦
    Advances in Clinical Medicine.2024; 14(08): 400.     CrossRef
  • Relationship between Serum Levels of Selenium and Thyroid Cancer: A Systematic Review and Meta-Analysis
    Runhua Hao, Ping Yu, Lanlan Gui, Niannian Wang, Da Pan, Shaokang Wang
    Nutrition and Cancer.2023; 75(1): 14.     CrossRef
  • Oxidative stress mediates the associations between phthalate exposures and thyroid cancer/benign nodule risk
    Chong Liu, Long-Qiang Wang, Min Zhang, Yan-Ling Deng, Qiong Luo, Er-Nan Liu, Pan-Pan Chen, Yu Miao, Pan Yang, Qiang Zeng
    Environmental Pollution.2023; 326: 121462.     CrossRef
  • Selenium and thyroid diseases
    Fei Wang, Chunyu Li, Shaoxin Li, Lili Cui, Junyu Zhao, Lin Liao
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Preoperative evaluation of thyroid nodules – Diagnosis and management strategies
    Tapoi Dana Antonia, Lambrescu Ioana Maria, Gheorghisan-Galateanu Ancuta-Augustina
    Pathology - Research and Practice.2023; 246: 154516.     CrossRef
  • Evaluation of Thyroid Fine Needle Aspiration Biopsy Results: A Single Center Experience
    Baris KARAGÜN
    Acta Medica Alanya.2023; 7(1): 34.     CrossRef
  • Thyroid Nodules and Obesity
    Elpida Demetriou, Maria Fokou, Savvas Frangos, Panagiotis Papageorgis, Panayiotis A. Economides, Aliki Economides
    Life.2023; 13(6): 1292.     CrossRef
  • Per- and polyfluoroalkyl substances and the associated thyroid cancer risk: A case-control study in China
    Haoran Li, Ming Yang, Jing Yang, Samuel Seery, Chaoying Ma, Yi Liu, Xiaoguang Zhang, Ang Li, Huicai Guo
    Chemosphere.2023; 337: 139411.     CrossRef
  • Interaction between Genetic Risks and Socioeconomic Factors on Thyroid Cancer: Evidence from 0.5 Million UK Biobank Participants
    Yu Li, Yongle Zhan, Wei Mao, Baoxin Wang, Pin Dong, Rong Na
    Cancers.2023; 15(20): 5028.     CrossRef
  • Thyroid Cancer Diagnostics Related to Occupational and Environmental Risk Factors: An Integrated Risk Assessment Approach
    Gabriela Maria Berinde, Andreea Iulia Socaciu, Mihai Adrian Socaciu, Andreea Cozma, Armand Gabriel Rajnoveanu, Gabriel Emil Petre, Doina Piciu
    Diagnostics.2022; 12(2): 318.     CrossRef
  • Ferroptosis-Related APOE, BCL3 and ALOX5AP Gene Polymorphisms are Associated with the Risk of Thyroid Cancer
    Zhifu Xiao, Haixia Zhao
    Pharmacogenomics and Personalized Medicine.2022; Volume 15: 157.     CrossRef
  • The Effect of Gout on Thyroid Cancer Incidence: A Nested Case-Control Study Using a National Health Screening Cohort
    So Young Kim, Dae Myoung Yoo, Mi Jung Kwon, Ji Hee Kim, Joo-Hee Kim, Woo Jin Bang, Sung Kyun Kim, Hyo Geun Choi
    Journal of Personalized Medicine.2022; 12(6): 887.     CrossRef
  • Seaweed and Iodine Intakes and SLC5A5 rs77277498 in Relation to Thyroid Cancer
    Tung Hoang, Eun Kyung Lee, Jeonghee Lee, Yul Hwangbo, Jeongseon Kim
    Endocrinology and Metabolism.2022; 37(3): 513.     CrossRef
  • Thyroid Diseases and Thyroid Asymptomatic Dysfunction in People Living With HIV
    Cristina Micali, Ylenia Russotto, Benedetto Maurizio Celesia, Laura Santoro, Andrea Marino, Giovanni Francesco Pellicanò, Giuseppe Nunnari, Emmanuele Venanzi Rullo
    Infectious Disease Reports.2022; 14(5): 655.     CrossRef
  • Thyroid Cancer and Psoriasis: A Nested Case–Control Study
    So Young Kim, Dae Myoung Yoo, Juyong Chung, Hyo Geun Choi
    Diagnostics.2022; 12(10): 2297.     CrossRef
  • Association between Obesity Indexes and Thyroid Cancer Risk in Korean Women: Nested Case–Control Study
    Yoonyoung Jang, Taehwa Kim, Brian H. S. Kim, Boyoung Park
    Cancers.2022; 14(19): 4712.     CrossRef
  • Relationship Between Physical Activity Levels and Thyroid Cancer Risk: A Prospective Cohort Study in Korea
    Anh Quynh Bui, Madhawa Gunathilake, Jeonghee Lee, Eun Kyung Lee, Jeongseon Kim
    Thyroid.2022; 32(11): 1402.     CrossRef
  • Association Between Genetic Risk, Adherence to Healthy Lifestyle Behavior, and Thyroid Cancer Risk
    Xiuming Feng, Fei Wang, Wenjun Yang, Yuan Zheng, Chaoqun Liu, Lulu Huang, Longman Li, Hong Cheng, Haiqing Cai, Xiangzhi Li, Xing Chen, Xiaobo Yang
    JAMA Network Open.2022; 5(12): e2246311.     CrossRef
  • Insufficient iodine nutrition may affect the thyroid cancer incidence in China
    Lijun Fan, Fangang Meng, Yunyan Gao, Peng Liu
    British Journal of Nutrition.2021; 126(12): 1852.     CrossRef
  • Thyroid cancer and its associated factors: A population‐based case‐control study
    Mohammad Taher Parad, Mohammad Fararouei, Ali Reza Mirahmadizadeh, Sima Afrashteh
    International Journal of Cancer.2021; 149(3): 514.     CrossRef
  • Evaluation of the relationship between previous statin use and thyroid cancer using Korean National Health Insurance Service-Health Screening Cohort data
    So Young Kim, Young Shin Song, Jee Hye Wee, Chanyang Min, Dae Myoung Yoo, Chang-Ho Lee, Chang Myeon Song, Bumjung Park, Hyo Geun Choi
    Scientific Reports.2021;[Epub]     CrossRef
  • Association among Body Mass Index, Genetic Variants of FTO, and Thyroid Cancer Risk: A Hospital-Based Case-Control Study of the Cancer Screenee Cohort in Korea
    Tung Hoang, Dayoung Song, Jeonghee Lee, Eun Kyung Lee, Yul Hwangbo, Jeongseon Kim
    Cancer Research and Treatment.2021; 53(3): 857.     CrossRef
  • Reproductive and menstrual factors for papillary thyroid cancer risk: A case-control study in Chinese women
    Jia-liu He, Chi Zhang, Ming-jun Hu, Hua-bing Wu, Xue-lei Lu, Jia-hu Hao, Fen Huang
    Cancer Epidemiology.2021; 73: 101964.     CrossRef
  • Advanced thyroid carcinomas: neural network analysis of ultrasonographic characteristics
    Michael Cordes, Theresa Ida Götz, Elmar Wolfgang Lang, Stephan Coerper, Torsten Kuwert, Christian Schmidkonz
    Thyroid Research.2021;[Epub]     CrossRef
  • Effect of Cigarette Smoking on Thyroid Cancer: Meta-Analysis
    Joon-Hyop Lee, Young Jun Chai, Ka Hee Yi
    Endocrinology and Metabolism.2021; 36(3): 590.     CrossRef
  • Epidemiologic, Clinical, Ultrasonographic, and Cytological Features of Thyroid Nodules in Predicting Malignancy Risk: A Retrospective Study of 442 French Afro-Caribbean Patients
    Johan Joseph-Auguste, Lucien Lin, Magalie Demar, Olivier Duffas, Vincent Molinie, Caroline Sulpicy, Marie-Josée Dorival, Olivier Luxembourger, Nadia Sabbah
    International Journal of Endocrinology.2020; 2020: 1.     CrossRef
  • Serous BMP8A has Clinical Significance in the Ultrasonic Diagnosis of Thyroid Cancer and Promotes Thyroid Cancer Cell Progression
    Kun Liu, Min Gao, Dongdong Qin, Hongjun Wang, Qixiu Lu
    Endocrine, Metabolic & Immune Disorders - Drug Targets.2020; 20(4): 591.     CrossRef
  • Association between Family Histories of Thyroid Cancer and Thyroid Cancer Incidence: A Cross-Sectional Study Using the Korean Genome and Epidemiology Study Data
    Soo-Hwan Byun, Chanyang Min, Hyo-Geun Choi, Seok-Jin Hong
    Genes.2020; 11(9): 1039.     CrossRef
  • Obesity is positively related and tobacco smoking and alcohol consumption are negatively related to an increased risk of thyroid cancer
    Soo-Youn An, So Young Kim, Dong Jun Oh, Chanyang Min, Songyoung Sim, Hyo Geun Choi
    Scientific Reports.2020;[Epub]     CrossRef
  • Radiation and Second Primary Thyroid Cancer Following Index Head and Neck Cancer
    Katherine M. Polednik, Matthew C. Simpson, Eric Adjei Boakye, Kahee A. Mohammed, John J. Dombrowski, Mark A. Varvares, Nosayaba Osazuwa‐Peters
    The Laryngoscope.2019; 129(4): 1014.     CrossRef
  • Active and Passive Smoking, BRAFV600E Mutation Status, and the Risk of Papillary Thyroid Cancer: A Large-Scale Case-Control and Case-Only Study
    Kyoung-Nam Kim, Yunji Hwang, Kyungsik Kim, Kyu Eun Lee, Young Joo Park, June Young Choi, Do Joon Park, BeLong Cho, Daehee Kang, Sue K. Park
    Cancer Research and Treatment.2019; 51(4): 1392.     CrossRef
  • Association of obesity with the clinicopathological features of thyroid cancer in a large, operative population
    Sitong Zhao, Xiaomeng Jia, Xiaojing Fan, Ling Zhao, Ping Pang, Yajing Wang, Yukun Luo, Fulin Wang, Guoqing Yang, Xianling Wang, Weijun Gu, Li Zang, Yu Pei, Jin Du, Jianming Ba, Jingtao Dou, Yiming Mu, Zhaohui Lyu
    Medicine.2019; 98(50): e18213.     CrossRef
  • Bethesda thyroid categories and family history of thyroid disease
    D. Kust, J. Staničić, N. Mateša
    Clinical Endocrinology.2018; 88(3): 468.     CrossRef
  • Thyroid cancer among female workers in Korea, 2007–2015
    Seonghoon Kang, Jinho Song, Taehwan Koh, One Park, Jong-Tae Park, Won-Jin Lee
    Annals of Occupational and Environmental Medicine.2018;[Epub]     CrossRef
  • Cigarette smoking and thyroid cancer risk: a cohort study
    Ara Cho, Yoosoo Chang, Jiin Ahn, Hocheol Shin, Seungho Ryu
    British Journal of Cancer.2018; 119(5): 638.     CrossRef
  • Interplay between Body Size Measures and Thyroid Cancer Aggressiveness: A Retrospective Analysis
    Thaís Gomes de Melo, Ligia Vera Montali da Assumpção, Denise Engelbrecht Zantut-Wittmann
    International Journal of Endocrinology.2018; 2018: 1.     CrossRef
  • Genetic variations in TAS2R3 and TAS2R4 bitterness receptors modify papillary carcinoma risk and thyroid function in Korean females
    Jeong-Hwa Choi, Jeonghee Lee, Sarah Yang, Eun Kyung Lee, Yul Hwangbo, Jeongseon Kim
    Scientific Reports.2018;[Epub]     CrossRef
  • The Relationship Between Human Development Index and Its Components with Thyroid Cancer Incidence and Mortality: Using the Decomposition Approach
    Mokhtar Soheylizad, Salman Khazaei, Ensiyeh Jenabi, Ali Delpisheh, Yousef Veisani
    International Journal of Endocrinology and Metabolism.2018;[Epub]     CrossRef
  • Modern view on the risk factors for malignant tumors of the thyroid gland: a systematic review
    В. І. Ткаченко, Я. Ю. Рімар
    Family medicine.2018; (3): 57.     CrossRef
  • 14,422 View
  • 439 Download
  • 50 Web of Science
  • 45 Crossref
Close layer
Anti-proliferative Effect of Engineered Neural Stem Cells Expressing Cytosine Deaminase and Interferon-β against Lymph Node–Derived Metastatic Colorectal Adenocarcinoma in Cellular and Xenograft Mouse Models
Geon-Tae Park, Seung U. Kim, Kyung-Chul Choi
Cancer Res Treat. 2017;49(1):79-91.   Published online May 3, 2016
DOI: https://doi.org/10.4143/crt.2015.503
AbstractAbstract PDFPubReaderePub
Purpose
Genetically engineered stem cells may be advantageous for gene therapy against various human cancers due to their inherent tumor-tropic properties. In this study, genetically engineered human neural stem cells (HB1.F3) expressing Escherichia coli cytosine deaminase (CD) (HB1.F3.CD) and human interferon-β (IFN-β) (HB1.F3.CD.IFN-β) were employed against lymph node–derived metastatic colorectal adenocarcinoma.
Materials and Methods
CD can convert a prodrug, 5-fluorocytosine (5-FC), to active 5-fluorouracil, which inhibits tumor growth through the inhibition of DNA synthesis,while IFN-β also strongly inhibits tumor growth by inducing the apoptotic process. In reverse transcription polymerase chain reaction analysis, we confirmed that HB1.F3.CD cells expressed the CD gene and HB1.F3.CD.IFN-β cells expressed both CD and IFN-β genes.
Results
In results of a modified trans-well migration assay, HB1.F3.CD and HB1.F3.CD.IFN-β cells selectively migrated toward SW-620, human lymph node–derived metastatic colorectal adenocarcinoma cells. The viability of SW-620 cells was significantly reduced when co-cultured with HB1.F3.CD or HB1.F3.CD.IFN-β cells in the presence of 5-FC. In addition, it was found that the tumor-tropic properties of these engineered human neural stem cells (hNSCs) were attributed to chemoattractant molecules including stromal cell-derived factor 1, c-Kit, urokinase receptor, urokinase-type plasminogen activator, and C-C chemokine receptor type 2 secreted by SW-620 cells. In a xenograft mouse model, treatment with hNSC resulted in significantly inhibited growth of the tumor mass without virulent effects on the animals.
Conclusion
The current results indicate that engineered hNSCs and a prodrug treatment inhibited the growth of SW-620 cells. Therefore, hNSC therapy may be a clinically effective tool for the treatment of lymph node metastatic colorectal cancer.

Citations

Citations to this article as recorded by  
  • Enhanced anti-tumor efficacy with multi-transgene armed mesenchymal stem cells for treating peritoneal carcinomatosis
    Yoon Khei Ho, Jun Yung Woo, Kin Man Loke, Lih-Wen Deng, Heng-Phon Too
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Genetically engineered neural stem cells expressing cytosine deaminase and interferon-beta enhanced T cell-mediated antitumor immunity against gastric cancer in a humanized mouse model
    Youngdong Choi, Hong Kyu Lee, Dohee Ahn, Min-Woo Nam, Ryeo-Eun Go, Kyung-Chul Choi
    Life Sciences.2023; 328: 121866.     CrossRef
  • Carboxylesterase-overexpressing hTERT-immortalized human adipose stem cells in prostate tumor growth inhibition by irinotecan
    Jae Heon Kim, Eunjeong Oh, Eun Seop Song, Chul Won Yun, Sang Hun Lee, Yun Seob Song
    Journal of Cancer Research and Therapeutics.2023; 19(7): 1731.     CrossRef
  • Nerves in gastrointestinal cancer: from mechanism to modulations
    Nathalie Vaes, Musa Idris, Werend Boesmans, Maria M. Alves, Veerle Melotte
    Nature Reviews Gastroenterology & Hepatology.2022; 19(12): 768.     CrossRef
  • Genetically-modified Stem Cell in Regenerative Medicine and Cancer Therapy; A New Era
    Ali Hassanzadeh, Somayeh Shamlou , Niloufar Yousefi, Marzieh Nikoo, Javad Verdi
    Current Gene Therapy.2021; 22(1): 23.     CrossRef
  • Antithyroid cancer effects of human neural stem cells expressing therapeutic genes on anaplastic thyroid cancer cells
    Hye‐Ji Shin, Kyung‐A. Hwang, Ryeo‐Eun Go, Seung U. Kim, Kyung‐Chul Choi
    Journal of Cellular Biochemistry.2020; 121(2): 1586.     CrossRef
  • Antitumor efficacy of cytosine deaminase-armed vaccinia virus plus 5-fluorocytosine in colorectal cancers
    Yuedi Ding, Jun Fan, Lili Deng, Biao Huang, Bin Zhou
    Cancer Cell International.2020;[Epub]     CrossRef
  • A highly efficient non-viral process for programming mesenchymal stem cells for gene directed enzyme prodrug cancer therapy
    Yoon Khei Ho, Jun Yung Woo, Geraldine Xue En Tu, Lih-Wen Deng, Heng-Phon Too
    Scientific Reports.2020;[Epub]     CrossRef
  • A Potential Therapy Using Engineered Stem Cells Prevented Malignant Melanoma in Cellular and Xenograft Mouse Models
    Jae-Rim Heo, Kyung-A Hwang, Seung U. Kim, Kyung-Chul Choi
    Cancer Research and Treatment.2019; 51(2): 797.     CrossRef
  • The growth inhibitory effect of human gingiva-derived mesenchymal stromal cells expressing interferon-β on tongue squamous cell carcinoma cells and xenograft model
    Lingqian Du, Qianyu Liang, Shaohua Ge, Chengzhe Yang, Pishan Yang
    Stem Cell Research & Therapy.2019;[Epub]     CrossRef
  • A promising therapeutic strategy for metastatic gestational trophoblastic disease: Engineered anticancer gene‑expressing stem cells to selectively target choriocarcinoma (Review)
    Gyu‑Sik Kim, Kyung‑A Hwang, Kyung‑Chul Choi
    Oncology Letters.2019;[Epub]     CrossRef
  • Cancer-Specific Inhibitory Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-β Against Choriocarcinoma in Xenografted Metastatic Mouse Models
    Gyu-Sik Kim, Jae-Rim Heo, Seung U. Kim, Kyung-Chul Choi
    Translational Oncology.2018; 11(1): 74.     CrossRef
  • The growth of K562 human leukemia cells was inhibited by therapeutic neural stem cells in cellular and xenograft mouse models
    GEON-TAE PARK, JAE-RIM HEO, SEUNG U. KIM, KYUNG-CHUL CHOI
    Cytotherapy.2018; 20(9): 1191.     CrossRef
  • Cytotoxic effect of co-expression of human hepatitis A virus 3C protease and bifunctional suicide protein FCU1 genes in a bicistronic vector
    Alexey Komissarov, Ilya Demidyuk, Dina Safina, Marina Roschina, Andrey Shubin, Nataliya Lunina, Maria Karaseva, Sergey Kostrov
    Molecular Biology Reports.2017; 44(4): 323.     CrossRef
  • Cell-mediated enzyme prodrug cancer therapies
    Rachael Mooney, Asma Abdul Majid, Jennifer Batalla, Alexander J. Annala, Karen S. Aboody
    Advanced Drug Delivery Reviews.2017; 118: 35.     CrossRef
  • Combination of Fe/Cu -chelators and docosahexaenoic acid: an exploration for the treatment of colorectal cancer
    Nanhui Yu, Hong Zhu, Yuan Yang, Yiming Tao, Fengbo Tan, Qian Pei, Yuan Zhou, Xiangping Song, Qiurong Tan, Haiping Pei
    Oncotarget.2017; 8(31): 51478.     CrossRef
  • 12,052 View
  • 163 Download
  • 18 Web of Science
  • 16 Crossref
Close layer
Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma
Chi Hoon Maeng, Young Hyeh Ko, Do Hoon Lim, Eun Suk Kang, Joon Young Choi, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2017;49(1):92-103.   Published online May 9, 2016
DOI: https://doi.org/10.4143/crt.2015.476
AbstractAbstract PDFPubReaderePub
Purpose
This retrospective study was conducted for comparison of survival outcomes and toxicities of autologous stem cell transplantation (ASCT) based on the use of total body irradiation (TBI) as a part of the conditioning regimen in patients with mature T- and natural killer (NK)-cell lymphomas.
Materials and Methods
Patients who underwent ASCT in the upfront or salvage setting between January 2000 and December 2013 were analyzed. Patients were dichotomized according to the TBI group (n=38) and non-TBI group (n=60) based on the type of conditioning regimen for ASCT.
Results
Patients with responsive disease underwent upfront ASCT (TBI, n=16; non-TBI, n=29) whereas patients with refractory disease (TBI, n=9; non-TBI, n=12) or relapsed disease (TBI, n=13; non-TBI, n=19) underwent ASCT after salvage treatment. Hematologic and non-hematologic toxicities were manageable, and the median cumulative toxicity score according to Seattle criteria was estimated as 2 (range, 0 to 7) in both groups. No significant difference in 100-day mortality was observed between the TBI (13%, 5/38) and non-TBI (12%, 12/60) groups, and most deaths were related to disease progression. There was no difference in overall and progression-free survival; however, the TBI group showed a trend of better survival in upfront and salvage ASCT than the non-TBI group. However, patients with refractory disease showed the worst outcome regardless of the use of TBI. Patients who showed complete response before ASCT showed better progression-free survival than thosewho showed partial response.
Conclusion
TBI could be used as an effective part of conditioning for ASCT in patients with mature T- and NK-cell lymphomas.

Citations

Citations to this article as recorded by  
  • Whole body irradiation with intensity-modulated helical tomotherapy prior to haematopoietic stem cell transplantation: analysis of organs at risk by dose and its effect on blood kinetics
    Mümtaz Köksal, Jonathan Baumert, Danny Jazmati, Felix Schoroth, Stephan Garbe, David Koch, Davide Scafa, Gustavo R. Sarria, Christina Leitzen, Gregor Massoth, Achilles Delis, Annkristin Heine, Tobias Holderried, Peter Brossart, Thomas Müdder, Leonard C. S
    Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7007.     CrossRef
  • The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation
    Hao Wang, Kristin N. Berger, Elizabeth L. Miller, Wei Fu, Larisa Broglie, Frederick D. Goldman, Heiko Konig, Su Jin Lim, Arthur S. Berg, Julie-An Talano, Melanie A. Comito, Sherif S. Farag, Jeffrey J. Pu
    Therapeutic Advances in Hematology.2023;[Epub]     CrossRef
  • Helical versus static approaches to delivering tomotherapy to the junctional target for patients taller than 135 cm undergoing total body irradiation
    Mümtaz Köksal, Jonathan Baumert, Felix Schoroth, Thomas Müdder, Davide Scafa, David Koch, Christina Leitzen, Gustavo R. Sarria, Leonard C. Schmeel, Frank A. Giordano
    European Journal of Medical Research.2022;[Epub]     CrossRef
  • National survey of myeloablative total body irradiation prior to hematopoietic stem cell transplantation in Japan: survey of the Japanese Radiation Oncology Study Group (JROSG)
    Naoya Ishibashi, Toshinori Soejima, Hiroki Kawaguchi, Takeshi Akiba, Masatoshi Hasegawa, Kouichi Isobe, Hitoshi Ito, Michiko Imai, Yasuo Ejima, Masaharu Hata, Keisuke Sasai, Emiko Shimoda, Toshiya Maebayashi, Masahiko Oguchi, Tetsuo Akimoto
    Journal of Radiation Research.2018; 59(4): 477.     CrossRef
  • 9,943 View
  • 186 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Curative Resection for Metachronous Pulmonary Metastases from Colorectal Cancer: Analysis of Survival Rates and Prognostic Factors
Myong Hoon Ihn, Duck-Woo Kim, Sukki Cho, Heung-Kwon Oh, Sanghoon Jheon, Kwhanmien Kim, Eun Shin, Hye Seung Lee, Jin-Haeng Chung, Sung-Bum Kang
Cancer Res Treat. 2017;49(1):104-115.   Published online May 9, 2016
DOI: https://doi.org/10.4143/crt.2015.367
AbstractAbstract PDFPubReaderePub
Purpose
Prognostic factors in patients with pulmonary metastases (PM) from colorectal cancer (CRC) are still controversial. This study assessed oncologic outcomes and prognostic factors in patients with metachronous PM from CRC.
Materials and Methods
Between June 2003 and December 2011, 122 patients with CRC underwent curative resection of PM detected at least 4 months after CRC resection. Clinico-pathological factors selected from the prospectively maintained database were analyzed retrospectively.
Results
The median disease-free interval (DFI) between resection of the primary tumor and detection of PM was 22.0 months (range, 4 to 85 months). Solitary PM were detected in 77 patients (63.1%), with a median maximal tumor diameter of 12.0 mm (range, 2 to 70 mm). Of 52 patients who underwent mediastinal lymph node (LN) dissection, eight patients had LN involvement. Five-year overall survival and disease-free survival (DFS) rates after initial pulmonary metastasectomy were 66.4% and 50.9%, respectively. DFI, mediastinal LN involvement, and the number and distribution of PM were significantly prognostic factors for DFS. In multivariable analysis DFI ≥ 12 months, solitary lesion, and absence of mediastinal LN involvement were independently prognostic for DFS. Of the 122 patients, 48 patients (39.3%) developed recurrent PM a median 13.0 months after initial pulmonary metastasectomy. Recurrent DFI was independently prognostic of DFS in patients who underwent repeated pulmonary metastasectomy.
Conclusion
There is a potential survival benefit for patients with metachronous PM from CRC who undergo pulmonary metastasectomy, even those with recurrent PM. Pulmonary metastasectomy should be considered in selected patients, particularly those with longer DFI, solitary lesions, and absence of mediastinal LN involvement.

Citations

Citations to this article as recorded by  
  • Outcomes and prognostic factors of repeat pulmonary metastasectomy
    Ryu Kanzaki, Hirokazu Watari, Akiisa Omura, Sachi Kawagishi, Ryo Tanaka, Tomohiro Maniwa, Jiro Okami
    Interdisciplinary CardioVascular and Thoracic Surgery.2024;[Epub]     CrossRef
  • Development of a protocol for whole-lung in vivo lung perfusion-assisted photodynamic therapy using a porcine model
    Khaled Ramadan, Tina Saeidi, Edson Brambate, Vanderlei Bagnato, Marcelo Cypel, Lothar Lilge
    Journal of Biomedical Optics.2024;[Epub]     CrossRef
  • circEIF3I Promotes Colorectal Cancer Metastasis by Regulating the miR‐328‐3p/NCAPH Axis
    Yali Zhao, Yan He, Zhiyuan Xiao, Le Xin, Mingjing Deng, Mingxia Yao, Guan Huang
    Molecular Carcinogenesis.2024;[Epub]     CrossRef
  • Role of Pulmonary Metastasectomy in Colorectal Cancer
    Zamaan Hooda, Michael Eisenberg, Mara B. Antonoff
    Thoracic Surgery Clinics.2024;[Epub]     CrossRef
  • Preoperative prognostic factors for 5-year survival following pulmonary metastasectomy from colorectal cancer: a systematic review and meta-analysis
    Andreas Gkikas, Christos Kakos, Savvas Lampridis, Peter J Godolphin, Davide Patrini
    European Journal of Cardio-Thoracic Surgery.2023;[Epub]     CrossRef
  • FUT2 inhibits the EMT and metastasis of colorectal cancer by increasing LRP1 fucosylation
    Lingnan He, Zijun Guo, Weijun Wang, Shuxin Tian, Rong Lin
    Cell Communication and Signaling.2023;[Epub]     CrossRef
  • PET/MRI in colorectal and anal cancers: an update
    Vetri Sudar Jayaprakasam, Semra Ince, Garima Suman, Pankaj Nepal, Thomas A. Hope, Raj Mohan Paspulati, Tyler J. Fraum
    Abdominal Radiology.2023; 48(12): 3558.     CrossRef
  • A review of surgery for lung metastasis from colorectal cancer
    Yu-Kwang Lee, Mong-Wei Lin, Ke-Cheng Chen, Pei-Ming Huang, Shuenn-Wen Kuo, Jang-Ming Lee
    Formosan Journal of Surgery.2023;[Epub]     CrossRef
  • Long-term outcomes and early recurrence after resection for metachronous pulmonary metastases from colorectal cancer
    Shintaro Hashimoto, Tetsuro Tominaga, Takashi Nonaka, Keisuke Noda, Soishiro Kiya, Toshio Shiraishi, Kaido Oishi, Yuma Takamura, Shoto Yamazaki, Masato Araki, Yorihisa Sumida, Takuro Miyazaki, Ryotaro Kamohara, Shigeyuki Morino, Keitaro Matsumoto, Akihiro
    Langenbeck's Archives of Surgery.2023;[Epub]     CrossRef
  • Survival and prognostic factors of isolated pulmonary metastases originating from colorectal cancer: An 8-year single-center experience
    Ameera S. Balhareth, Abdullah S. AlQattan, Hassan M. Alshaqaq, Abdullah M. Alkhalifa, Alaa A. Al Abdrabalnabi, Muna S. Alnamlah, Deborah MacNamara
    Annals of Medicine and Surgery.2022; 77: 103559.     CrossRef
  • Long term survival after multiple microwave ablations for colorectal cancer lung metastases: A case report
    Victoria T. Y Lee, Yueh-Hsin Lin, Derek Glenn, Suhrid Lodh, David L. Morris
    Radiology Case Reports.2022; 17(6): 2038.     CrossRef
  • A model to assess acute and delayed lung toxicity of oxaliplatin during in vivo lung perfusion
    Khaled Ramadan, Bruno Gomes, Mauricio Pipkin, Mariola Olkowicz, Barbara Bojko, Arnaud Romeo Mbadjeu Hondjeu, Shaf Keshavjee, Thomas Waddell, Janusz Pawliszyn, Marcelo Cypel
    The Journal of Thoracic and Cardiovascular Surgery.2021; 161(5): 1626.     CrossRef
  • Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis
    Junfeng Huang, Qing Zang, Yaokai Wen, Zhe Pan, Zhiyuan Yao, Mingkai Huang, Jiongqiang Huang, Jingsong Chen, Rongchang Wang
    Critical Reviews in Oncology/Hematology.2021; 160: 103308.     CrossRef
  • Systematic Review of Treatments for Colorectal Metastases in Elderly Patients to Guide Surveillance Cessation Following Hepatic Resection for Colorectal Liver Metastases
    Edward Alabraba, Dhanny Gomez
    American Journal of Clinical Oncology.2021; 44(5): 210.     CrossRef
  • Determination of Optical Properties and Photodynamic Threshold of Lung Tissue for Treatment Planning of In Vivo Lung Perfusion Assisted Photodynamic Therapy
    Khaled T. Ramadan, Christopher McFadden, Bruno Gomes, Fynn Schwiegelshohn, Rafaela V.P. Ribeiro, Harley H.L. Chan, Vaughn Betz, Marcelo Cypel, Lothar Lilge
    Photodiagnosis and Photodynamic Therapy.2021; 35: 102353.     CrossRef
  • Survival outcome of pulmonary metastasectomy among the patients with colorectal cancers
    Oya Yıldız, Shute Ailia Dae, Alper Fındıkcıoglu, Fatih Kose
    Revista da Associação Médica Brasileira.2021; 67(7): 1015.     CrossRef
  • Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer
    Jiehua He, Ziqiang Chu, Wei Lai, Qiusheng Lan, Yujie Zeng, Daning Lu, Shaowen Jin, Heyang Xu, Pengwei Su, Dong Yin, Zhonghua Chu, Lu Liu
    Journal of Hematology & Oncology.2021;[Epub]     CrossRef
  • Vaccines for colorectal cancer: an update
    Mostafa Sarvizadeh, Faezeh Ghasemi, Fatemeh Tavakoli, Sara Sadat Khatami, Ebrahim Razi, Hossein Sharifi, Nousin Moussavi Biouki, Mohsen Taghizadeh
    Journal of Cellular Biochemistry.2019; 120(6): 8815.     CrossRef
  • Surgical management of colorectal lung metastases
    Joseph D. Phillips, Rian M. Hasson
    Journal of Surgical Oncology.2019; 119(5): 629.     CrossRef
  • Chemotherapy for resected colorectal cancer pulmonary metastases: Utilization and outcomes in routine clinical practice
    S. Karim, S. Nanji, K. Brennan, C.S. Pramesh, C.M. Booth
    European Journal of Surgical Oncology (EJSO).2017; 43(8): 1481.     CrossRef
  • The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study
    Hiroyuki Sakae, Hiromitsu Kanzaki, Junichiro Nasu, Yutaka Akimoto, Kazuhiro Matsueda, Masao Yoshioka, Masahiro Nakagawa, Shinichiro Hori, Masafumi Inoue, Tomoki Inaba, Atsushi Imagawa, Masahiro Takatani, Ryuta Takenaka, Seiyu Suzuki, Toshiyoshi Fujiwara,
    British Journal of Cancer.2017; 117(11): 1607.     CrossRef
  • 10,332 View
  • 197 Download
  • 23 Web of Science
  • 21 Crossref
Close layer
Use of a Combined Gene Expression Profile in Implementing a Drug Sensitivity Predictive Model for Breast Cancer
Xianglan Zhang, In-Ho Cha, Ki-Yeol Kim
Cancer Res Treat. 2017;49(1):116-128.   Published online May 18, 2016
DOI: https://doi.org/10.4143/crt.2016.085
AbstractAbstract PDFPubReaderePub
Purpose
Chemotherapy targets all rapidly growing cells, not only cancer cells, and thus is often associated with unpleasant side effects. Therefore, examination of the chemosensitivity based on genotypes is needed in order to reduce the side effects. Materials and Methods Various computational approaches have been proposed for predicting chemosensitivity based on gene expression profiles. A linear regression model can be used to predict the response of cancer cells to chemotherapeutic drugs, based on genomic features of the cells, and appropriate sample size for this method depends on the number of predictors. We used principal component analysis and identified a combined gene expression profile to reduce the number of predictors
Results
The coefficients of determinanation (R2) of prediction models with combined gene expression and several independent gene expressions were similar. Corresponding F values, which represent model significances were improved by use of a combined gene expression profile, indicating that the use of a combined gene expression profile is helpful in predicting drug sensitivity. Even better, a prediction model can be used even with small samples because of the reduced number of predictors. Conclusion Combined gene expression analysis is expected to contribute to more personalized management of breast cancer cases by enabling more effective targeting of existing therapies. This procedure for identifying a cell-type-specific gene expression profile can be extended to other chemotherapeutic treatments and many other heterogeneous cancer types.

Citations

Citations to this article as recorded by  
  • Clinical Oncogenomics and Personalized Medicine in Colorectal Cancer for the Surgeon: What We Need to Know and What the Future Holds
    I. S. Reynolds, E. O’Connell, D. A. McNamara, J. H. M. Prehn, S. J. Furney, J. P. Burke
    SN Comprehensive Clinical Medicine.2022;[Epub]     CrossRef
  • OBIF: an omics-based interaction framework to reveal molecular drivers of synergy
    Jezreel Pantaleón García, Vikram V Kulkarni, Tanner C Reese, Shradha Wali, Saima J Wase, Jiexin Zhang, Ratnakar Singh, Mauricio S Caetano, Humam Kadara, Seyed Javad Moghaddam, Faye M Johnson, Jing Wang, Yongxing Wang, Scott E Evans
    NAR Genomics and Bioinformatics.2022;[Epub]     CrossRef
  • Screening and Identification of Differentially Expressed Genes Expressed among Left and Right Colon Adenocarcinoma
    Jing Han, Xue Zhang, Yang Yang, Li Feng, Gui-Ying Wang, Nan Zhang
    BioMed Research International.2020; 2020: 1.     CrossRef
  • Overexpression of miR-331 Indicates Poor Prognosis and Promotes Progression of Breast Cancer
    Fuguo Jiang, Lei Zhang, Yunxia Liu, Yanhua Zhou, Honggang Wang
    Oncology Research and Treatment.2020; 43(9): 441.     CrossRef
  • Six novel immunoglobulin genes as biomarkers for better prognosis in triple-negative breast cancer by gene co-expression network analysis
    Huan-Ming Hsu, Chi-Ming Chu, Yu-Jia Chang, Jyh-Cherng Yu, Chien-Ting Chen, Chen-En Jian, Chia-Yi Lee, Yueh-Tao Chiang, Chi-Wen Chang, Yu-Tien Chang
    Scientific Reports.2019;[Epub]     CrossRef
  • Prediction of Drug Target Sensitivity in Cancer Cell Lines Using Apache Spark
    Shahid Hussain, Javed Ferzund, Raza Ul-Haq
    Journal of Computational Biology.2019; 26(8): 882.     CrossRef
  • Artificial Intelligence and Pharmacogenomics
    Ravishankar K. Iyer, Arjun P. Athreya, Liewei Wang, Richard M. Weinshilboum
    Advances in Molecular Pathology.2019; 2(1): 111.     CrossRef
  • 11,071 View
  • 162 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma
Yongjun Cha, Yu Jung Kim, Se-Hoon Lee, Tae-Min Kim, Seung Hong Choi, Dong-Wan Kim, Chul-Kee Park, Il Han Kim, Jee Hyun Kim, Eunhee Kim, Byungse Choi, Chae-Yong Kim, In Ah Kim, Dae Seog Heo
Cancer Res Treat. 2017;49(1):129-140.   Published online May 18, 2016
DOI: https://doi.org/10.4143/crt.2015.466
AbstractAbstract PDFPubReaderePub
Purpose
Bevacizumab±irinotecan is effective for treatment of recurrent malignant gliomas. However, the optimal duration of treatment has not been established.
Materials and Methods
Ninety-four consecutive patients with recurrent malignant glioma who were treated with bevacizumab at our institutions were identified. Patients who continued bevacizumab until tumor progression were enrolled in a late discontinuation (LD) group, while those who stopped bevacizumab before tumor progression were enrolled in an early discontinuation (ED) group. Landmark analyses were performed at weeks 9, 18, and 26 for comparison of patient survival between the two groups.
Results
Among 89 assessable patients, 62 (69.7%) and 27 (30.3%) patients were categorized as the LD and ED groups, respectively. According to landmark analysis, survival times from weeks 9, 18, and 26 were not significantly different between the two groups in the overall population. However, the LD group showed a trend toward increased survival compared to the ED group among responders. In the ED group, the median time from discontinuation to disease progression was 11.4 weeks, and none of the patients showed a definite rebound phenomenon. Similar median survival times after disease progression were observed between groups (14.4 weeks vs. 15.7 weeks, p=0.251). Of 83 patients, 38 (45.8%) received further therapy at progression, and those who received further therapy showed longer survival in both the LD and ED groups.
Conclusion
In recurrent malignant glioma, duration of bevacizumab was not associated with survival time in the overall population. However, ED of bevacizumab in responding patients might be associated with decreased survival.

Citations

Citations to this article as recorded by  
  • The Vascular Microenvironment in Glioblastoma: A Comprehensive Review
    Alejandra Mosteiro, Leire Pedrosa, Abel Ferrés, Diouldé Diao, Àngels Sierra, José Juan González
    Biomedicines.2022; 10(6): 1285.     CrossRef
  • Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors
    Tiziana Annese, Mariella Errede, Antonio d’Amati, Michelina De Giorgis, Loredana Lorusso, Roberto Tamma, Domenico Ribatti
    Diagnostics.2022; 12(12): 3120.     CrossRef
  • Identification of diverse tumor endothelial cell populations in malignant glioma
    Jeff C Carlson, Manuel Cantu Gutierrez, Brittney Lozzi, Emmet Huang-Hobbs, Williamson D Turner, Burak Tepe, Yiqun Zhang, Alexander M Herman, Ganesh Rao, Chad J Creighton, Joshua D Wythe, Benjamin Deneen
    Neuro-Oncology.2021; 23(6): 932.     CrossRef
  • Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy
    Charlotte Bronnimann, Cristina Izquierdo, Stéphanie Cartalat, Laure Thomas, Bastien Joubert, Laura Delpech, Marc Barritault, David Meyronet, Jérôme Honnorat, François Ducray
    Journal of Neuro-Oncology.2018; 138(1): 141.     CrossRef
  • 10,164 View
  • 181 Download
  • 5 Web of Science
  • 4 Crossref
Close layer
Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
Seung Hyeun Lee, Sue In Choi, Ji Sung Lee, Chul Hwan Kim, Won Jai Jung, Eun Joo Lee, Kyung Hoon Min, Gyu Young Hur, Seung Heon Lee, Sung Yong Lee, Je Hyeong Kim, Sang Yeub Lee, Chol Shin, Jae Jeong Shim, Kyung Ho Kang, Kwang Ho In
Cancer Res Treat. 2017;49(1):141-149.   Published online May 18, 2016
DOI: https://doi.org/10.4143/crt.2016.133
AbstractAbstract PDFPubReaderePub
Purpose
Reactive oxygen species modulator 1 (Romo1) is a key mediator of intracellular reactive oxygen species production. However, examination of the clinical usefulness of Romo1 in cancers has been limited. We evaluated the association of Romo1 expression with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Materials and Methods
Romo1 expression in tumor tissue was examined by immunohistochemistry and evaluated by histological score. Survival analyses were performed according to Romo1 expression and the association between Romo1 expression and clinical parameters was evaluated.
Results
A total of 88 tumor specimens were analyzed. Significantly shorter median progression-free survival (PFS) was observed in the high Romo1 group compared with the low Romo1 group (4.5 months vs. 9.8 months, p < 0.001), and the median overall survival (OS) of the high Romo1 group was also significantly shorter than that of the low Romo1 group (8.4 months vs. 15.5 months, p < 0.001). Results of multivariate analyses showed significant association of high Romo1 expression with both poor PFS (hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.71 to 4.44) and poor OS (HR, 3.99; 95% CI, 2.36 to 6.74). Results of the subgroup analysis showed a similar association regardless of tumor histology. Romo1 expression showed no association with any clinical parameter including age, sex, smoking status, stage, differentiation, or tumor histology.
Conclusion
Romo1 overexpression was associated with poor response to treatment and shorter survival in advanced NSCLC patients treated with platinum-based chemotherapy. Romo1 could be a potential adverse predictive marker in this setting.

Citations

Citations to this article as recorded by  
  • Prognostic Impact of Reactive Oxygen Species Modulator 1 in Surgically Resected Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas
    Tae-Woo Kim, Kiyong Na, Junyang Jung, Heejin Lim, Hyewon Seo, Seung Hyeun Lee
    Oncology.2024; 102(11): 969.     CrossRef
  • ROMO1 – a potential immunohistochemical prognostic marker for cancer development
    Eva Tsoneva, Mariela B. Vasileva-Slaveva, Stoyan G. Kostov, Angel D. Yordanov
    Oncologie.2023; 25(6): 753.     CrossRef
  • Serum Reactive Oxygen Species Modulator 1 as a Novel Predictive Biomarker for Resected Lung Adenocarcinoma: A Retrospective Pilot Study
    Boksoon Chang, In Kyung Hwang, Seung Hyeun Lee
    OncoTargets and Therapy.2021; Volume 14: 5097.     CrossRef
  • Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy
    Won Gun Kwack, Ji-Youn Sung, Seung Hyeun Lee
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Overexpression of reactive oxygen species modulator 1 is associated with advanced grades of bladder cancer
    Hadi Ghasemi, Mohammad Amin Amini, Atefeh Pegah, Ebrahim Azizi, Heidar Tayebinia, Shima Khanverdilou, Seyed Habibollah Mousavibahar, Aida Alizamir
    Molecular Biology Reports.2020; 47(9): 6497.     CrossRef

  • Reactive Oxygen Species Modulator 1 is Associated with Poor Survival in Patients with Non-Small Cell Lung Cancer After Stereotactic Fractionated Radiosurgery: A Retrospective Pilot Study


    Moonkyoo Kong, Ji-Youn Sung, Seung Hyeun Lee
    OncoTargets and Therapy.2020; Volume 13: 8173.     CrossRef
  • Reactive oxygen species modulator 1 expression predicts lymph node metastasis and survival in early-stage non-small cell lung cancer
    Taehee Kim, Yoon Jin Cha, Ji Hyun Park, Arum Kim, Yong Jun Choi, Hye Jung Park, Jung Weon Lee
    PLOS ONE.2020; 15(12): e0239670.     CrossRef
  • Reactive Oxygen Species Modulator 1 (ROMO1), a New Potential Target for Cancer Diagnosis and Treatment
    Mohammad Amin Amini, Seyed Saman Talebi, Jamshid Karimi
    Chonnam Medical Journal.2019; 55(3): 136.     CrossRef
  • Reactive oxygen species modulator 1 (Romo1) as a novel diagnostic marker for lung cancer-related malignant effusion
    Seung Hyeun Lee, Myung Jae Park, Sue In Choi, Eun Joo Lee, Sang Yeub Lee, Kwang Ho In
    Medicine.2017; 96(4): e5975.     CrossRef
  • 12,281 View
  • 182 Download
  • 11 Web of Science
  • 9 Crossref
Close layer
Gastric Carcinogenesis in the miR-222/221 Transgenic Mouse Model
Boram Choi, Jieun Yu, Tae-Su Han, Young-Kook Kim, Keun Hur, Byeong-Cheol Kang, Woo-Ho Kim, Dae-Yong Kim, Hyuk-Joon Lee, V. Narry Kim, Han-Kwang Yang
Cancer Res Treat. 2017;49(1):150-160.   Published online June 23, 2016
DOI: https://doi.org/10.4143/crt.2015.462
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
MicroRNAs (miRNAs) regulate various cellular functions, including development, cell proliferation, apoptosis, and tumorigenesis. Different signatures associated with various tissue types, diagnosis, progression, prognosis, staging, and treatment response have been identified by miRNA expression profiling of human tumors. miRNAs function as oncogenes or as tumor suppressors. The relationship between gastric cancer and miRNA garnered attention due to the high incidence of gastric cancer in Asian countries. miR-222/221 expression increases in gastric tumor tissues. The oncogenic effect of miR-222/221 was previously determined in functional studies and xenograft models. In this study, transgenic mice overexpressing miR-222/221 were generated to confirm the effect of miR-222/221 on gastric carcinogenesis. Materials and Methods At 6 weeks of age, 65 transgenic mice and 53 wild-type mice were given drinking water containing N-nitroso-N-methylurea (MNU) for 5 alternating weeks to induce gastric cancer. The mice were euthanized at 36 weeks of age and histologic analysis was performed.
Results
Hyperplasia was observed in 3.77% of the wild-type mice and in 18.46% of the transgenic mice (p=0.020). Adenoma was observed in 20.75% of the wild-type mice and 26.15% of the transgenic mice (p=0.522). Carcinoma was observed in 32.08% of the wild-type mice and 41.54% of the transgenic mice (p=0.341). The frequency of hyperplasia, adenoma, and carcinoma was higher in transgenic mice, but the difference was statistically significant only in hyperplasia. Conclusion These results suggest that hyperplasia, a gastric pre-cancerous lesion, is associated with miR-222/221 expression but miR-222/221 expression does not affect tumorigenesis itself.

Citations

Citations to this article as recorded by  
  • The Mechanism of miR-222 Targets Matrix Metalloproteinase 1 in Regulating Fibroblast Proliferation in Hypertrophic Scars
    Yi Zhang, Wei-Long Hong, Zhi-Ming Li, Qi-Yu Zhang, Kang Zeng
    Aesthetic Plastic Surgery.2021; 45(2): 749.     CrossRef
  • Fraser extracellular matrix complex subunit 1 promotes liver metastasis of gastric cancer
    Shinichi Umeda, Mitsuro Kanda, Takashi Miwa, Haruyoshi Tanaka, Chie Tanaka, Daisuke Kobayashi, Masamichi Hayashi, Suguru Yamada, Goro Nakayama, Masahiko Koike, Yasuhiro Kodera
    International Journal of Cancer.2020; 146(10): 2865.     CrossRef
  • Aldehyde dehydrogenase 1, a target of miR‑222, is expressed at elevated levels in cervical cancer
    Changde Liu, Yan Zhang, Shanghua Liang, Yuhua Ying
    Experimental and Therapeutic Medicine.2020;[Epub]     CrossRef
  • Expression and regulatory role of miRNA-222 in intervertebral disc degeneration (IDD)
    Chen Ge, Changwei Li
    Biotechnology & Biotechnological Equipment.2019; 33(1): 1553.     CrossRef
  • MicroRNA-222 regulates the viability of fibroblasts in hypertrophic scars via matrix metalloproteinase 1
    Yi Zhang, Xiaohua Lin, Li Zhang, Weilong Hong, Kang Zeng
    Experimental and Therapeutic Medicine.2017;[Epub]     CrossRef
  • 13,848 View
  • 296 Download
  • 6 Web of Science
  • 5 Crossref
Close layer
Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer
Kyu-pyo Kim, Jeong-Eun Kim, Yong Sang Hong, Sung-Min Ahn, Sung Min Chun, Seung-Mo Hong, Se Jin Jang, Chang Sik Yu, Jin Cheon Kim, Tae Won Kim
Cancer Res Treat. 2017;49(1):161-167.   Published online July 4, 2016
DOI: https://doi.org/10.4143/crt.2015.490
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Although the mutation status of KRAS is highly concordant in primary and metastatic lesions, it has not been generalized to other major pathway genes.
Materials and Methods
In this study, 41 genes were evaluated and the mutational profiles were compared in 46 colorectal cancer patients with paired surgical specimens of primary and metastatic lesions: synchronous (n=27) and metachronous (n=19) lesions. A high-throughput mass spectrometry-based genotyping platform validated by orthogonal chemistry, OncoMap v.4.4, was used to evaluate the formalin-fixed, paraffin-embedded surgical specimens. The patients’ demographics, tumor characteristics, and microsatellite instability status were analyzed by a retrospective chart review.
Results
In this study,with OncoMap, mutationswere identified in 80.4% of patientswith the following frequency: KRAS (39.1%), TP53 (28.3%), APC (28.3%), PIK3CA (6.5%), BRAF (6.5%), and NRAS (4.3%). Although 19.6% (9/46) of the patients showed no gene mutations, 43.5% (20/46) and 37.0% (17/46) had mutations in one and two or more genes, respectively. The synchronous and metachronous lesions showed similar mutational profiles. Paired samples between primary and metastatic tumors differed in 7.4% (2/27) and 10.5% (2/19) for synchronous and metachronous according to OncoMap.
Conclusion
These findings indicate the major pathway genes, including KRAS, TP53, APC, PIK3CA, BRAF, and NRAS, are often concordant between the primary and metastatic lesions regardless of the temporal relationship of metastasis.

Citations

Citations to this article as recorded by  
  • Mutation characteristics and molecular evolution of ovarian metastasis from gastric cancer and potential biomarkers for paclitaxel treatment
    Pengfei Yu, Can Hu, Guangyu Ding, Xiaoliang Shi, Jingli Xu, Yang Cao, Xiangliu Chen, Wei Wu, Qi Xu, Jingquan Fang, Xingmao Huang, Shaohua Yuan, Hui Chen, Zhizheng Wang, Ling Huang, Fei Pang, Yian Du, Xiangdong Cheng
    Nature Communications.2024;[Epub]     CrossRef
  • The varied clonal trajectory of liver and lung metastases of colorectal cancer
    Ofer N. Gofrit, Ben Gofrit, S. Nahum Goldberg, Aron Popovtzer, Jacob Sosna, Ayala Hubert
    Advances in Cancer Biology - Metastasis.2024; 11: 100122.     CrossRef
  • Whole-Exome Sequencing Reveals High Mutational Concordance between Primary and Matched Recurrent Triple-Negative Breast Cancers
    Jaspreet Kaur, Darshan S. Chandrashekar, Zsuzsanna Varga, Bettina Sobottka, Emiel Janssen, Khanjan Gandhi, Jeanne Kowalski, Umay Kiraz, Sooryanarayana Varambally, Ritu Aneja
    Genes.2023; 14(9): 1690.     CrossRef
  • The different clonal origins of metachronous and synchronous metastases
    Ofer N. Gofrit, Ben Gofrit, Yuval Roditi, Aron Popovtzer, Steve Frank, Jacob Sosna, Marina Orevi, S. Nahum Goldberg
    Journal of Cancer Research and Clinical Oncology.2023; 149(13): 11085.     CrossRef
  • Inoperable de novo metastatic colorectal cancer with primary tumour in situ: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish
    Ruba Hamed, Sam Marks, Helen Mcelligott, Roshni Kalachand, Hawa Ibrahim, Said Atyani, Greg Korpanty, Nemer Osman
    Molecular and Clinical Oncology.2021;[Epub]     CrossRef
  • Association of DNA repair gene polymorphisms with colorectal cancer risk and treatment outcomes
    Fawaz N. Al-Shaheri, Kamal M. Al-Shami, Eshrak H. Gamal, Amjad A. Mahasneh, Nehad M. Ayoub
    Experimental and Molecular Pathology.2020; 113: 104364.     CrossRef
  • High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases
    Tuva Høst Brunsell, Anita Sveen, Bjørn Atle Bjørnbeth, Bård I. Røsok, Stine Aske Danielsen, Kristoffer Watten Brudvik, Kaja C.G. Berg, Bjarne Johannessen, Vanja Cengija, Andreas Abildgaard, Marianne Grønlie Guren, Arild Nesbakken, Ragnhild A. Lothe
    Clinical Colorectal Cancer.2020; 19(1): e26.     CrossRef
  • Case report: recurrent pituitary adenoma has increased load of somatic variants
    Raitis Peculis, Inga Balcere, Ilze Radovica-Spalvina, Ilze Konrade, Olivija Caune, Kaspars Megnis, Vita Rovite, Janis Stukens, Jurijs Nazarovs, Austra Breiksa, Aigars Kiecis, Ivars Silamikelis, Valdis Pirags, Janis Klovins
    BMC Endocrine Disorders.2020;[Epub]     CrossRef
  • Transcriptomic analysis by RNA sequencing characterises malignant progression of canine insulinoma from normal tissue to metastatic disease
    Y. Capodanno, F. O. Buishand, L. Y. Pang, J. Kirpensteijn, J. A. Mol, R. Elders, D. J. Argyle
    Scientific Reports.2020;[Epub]     CrossRef
  • Genetic Alterations of Metastatic Colorectal Cancer
    Ugo Testa, Germana Castelli, Elvira Pelosi
    Biomedicines.2020; 8(10): 414.     CrossRef
  • Prognostic impact of the Fusobacterium nucleatum status in colorectal cancers
    Yanglong Chen, Ying Lu, Yuting Ke, Yanling Li
    Medicine.2019; 98(39): e17221.     CrossRef
  • Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer
    Camille Evrard, Gaëlle Tachon, Violaine Randrian, Lucie Karayan-Tapon, David Tougeron
    Cancers.2019; 11(10): 1567.     CrossRef
  • Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting
    William Hankey, Wendy L. Frankel, Joanna Groden
    Cancer and Metastasis Reviews.2018; 37(1): 159.     CrossRef
  • Colorectal Cancer: Genetic Abnormalities, Tumor Progression, Tumor Heterogeneity, Clonal Evolution and Tumor-Initiating Cells
    Ugo Testa, Elvira Pelosi, Germana Castelli
    Medical Sciences.2018; 6(2): 31.     CrossRef
  • Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-naïve advanced non-squamous non-small cell lung cancer patients
    Fangfang Xie, Yujun Zhang, Xiaowei Mao, Xiaoxuan Zheng, Han Han-Zhang, Junyi Ye, Ruiying Zhao, Xueyan Zhang, Jiayuan Sun
    Lung Cancer.2018; 121: 54.     CrossRef
  • Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer
    Georgios Antonios Margonis, Stefan Buettner, Nikolaos Andreatos, Yuhree Kim, Doris Wagner, Kazunari Sasaki, Andrea Beer, Christoph Schwarz, Inger Marie Løes, Maria Smolle, Carsten Kamphues, Jin He, Timothy M. Pawlik, Klaus Kaczirek, George Poultsides, Per
    JAMA Surgery.2018; 153(7): e180996.     CrossRef
  • Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
    Chiara Molinari, Giorgia Marisi, Alessandro Passardi, Laura Matteucci, Giulia De Maio, Paola Ulivi
    International Journal of Molecular Sciences.2018; 19(12): 3733.     CrossRef
  • 10,438 View
  • 279 Download
  • 20 Web of Science
  • 17 Crossref
Close layer
Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective
Kyung Hwan Kim, Jee Suk Chang, Ji Hye Cha, Ik Jae Lee, Dae Joon Kim, Byoung Chul Cho, Kyung Ran Park, Chang Geol Lee
Cancer Res Treat. 2017;49(1):168-177.   Published online June 23, 2016
DOI: https://doi.org/10.4143/crt.2016.142
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate the benefits of adjuvant treatment for curatively resected thoracic esophageal squamous cell carcinoma (ESCC) and determine the optimal adjuvant treatments.
Materials and Methods
One hundred ninety-five patients who underwent a curative resection for thoracic ESCC between 1994 and 2014 were reviewed retrospectively. Postoperatively, the patients received no adjuvant treatment (no-adjuvant group, n=68), adjuvant chemotherapy (AC group, n=62), radiotherapy (RT group, n=41), or chemoradiotherapy (CRT group, n=24). Chemotherapy comprised cisplatin and 5-fluorouracil administration every 3 weeks. The median RT dose was 45.0 Gy (range, 34.8 to 59.4 Gy). The overall survival (OS), disease-free survival (DFS), locoregional recurrence (LRR), and distant metastasis (DM) rates were estimated.
Results
At a median follow-up duration of 42.2 months (range, 6.3 to 215.2 months), the 5-year OS and DFS were 37.6% and 31.4%, respectively. After adjusting for other clinicopathologic variables, the AC and CRT groups had a significantly better OS and DFS compared to the no-adjuvant group (p < 0.05). The LRR rate was significantly lower in the RT and CRT groups than in the no-adjuvant group (p < 0.05), whereas no significant difference was observed in the AC group. In the no-adjuvant and AC groups, 25% of patients received high-dose salvage RT due to LRR. The DM rates were similar. The anastomotic stenosis and leakage were similar in the treatment groups.
Conclusion
Adjuvant treatment might prolong survival after an ESCC resection, and RT contributes to a reduction of the LRR. Overall, the risks and benefits should be weighed properly when selecting the optimal adjuvant treatment.

Citations

Citations to this article as recorded by  
  • The Society of Thoracic Surgeons/American Society for Radiation Oncology Updated Clinical Practice Guidelines on Multimodality Therapy for Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
    Stephanie G. Worrell, Karyn A. Goodman, Nasser K. Altorki, Jonathan B. Ashman, Traves D. Crabtree, Jennifer Dorth, Scott Firestone, David H. Harpole, Wayne L. Hofstetter, Theodore S. Hong, Kalie Kissoon, Geoffrey Y. Ku, Daniela Molena, Joel E. Tepper, Tho
    Practical Radiation Oncology.2024; 14(1): 28.     CrossRef
  • The Society of Thoracic Surgeons/American Society for Radiation Oncology Updated Clinical Practice Guidelines on Multimodality Therapy for Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
    Stephanie G. Worrell, Karyn A. Goodman, Nasser K. Altorki, Jonathan B. Ashman, Traves D. Crabtree, Jennifer Dorth, Scott Firestone, David H. Harpole, Wayne L. Hofstetter, Theodore S. Hong, Kalie Kissoon, Geoffrey Y. Ku, Daniela Molena, Joel E. Tepper, Tho
    The Annals of Thoracic Surgery.2024; 117(1): 15.     CrossRef
  • Esophageal cancer: Treatment challenges and controversies
    Piyush Kumar, Ankita Mehta
    Journal of Current Oncology.2021; 4(1): 41.     CrossRef
  • Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?
    Bingwen Zou, Yan Tu, Duwen Liao, Yong Xu, Jin Wang, Meijuan Huang, Li Ren, Jiang Zhu, Youling Gong, Yongmei Liu, Lin Zhou, Xiaojuan Zhou, Feng Peng, You Lu
    Thoracic Cancer.2020; 11(3): 631.     CrossRef
  • A meta-analysis on surgery with or without postoperative radiotherapy to treat squamous cell esophageal carcinoma
    Hao-Nan Lin, Long-Qi Chen, Qi-Xin Shang, Yong Yuan, Yu-Shang Yang
    International Journal of Surgery.2020; 80: 184.     CrossRef
  • Homeobox D10, a tumor suppressor, inhibits the proliferation and migration of esophageal squamous cell carcinoma
    Jin Zhang, Shiyuan Liu, Danjie Zhang, Zhenchuan Ma, Liangzhang Sun
    Journal of Cellular Biochemistry.2019; 120(8): 13717.     CrossRef
  • Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two‐center study
    Wenjie Ni, Junqiang Chen, Zefen Xiao, Shufei Yu, Wencheng Zhang, Zongmei Zhou, Dongfu Chen, Qinfu Feng, Xiaohui Chen, Yu Lin, Kunshou Zhu, Shugeng Gao, Qi Xue, Yousheng Mao, Guiyu Cheng, Kelin Sun, Xiangyang Liu, Dekang Fang
    Thoracic Cancer.2019; 10(6): 1431.     CrossRef
  • Comparison of the effect of postoperative radiotherapy with surgery alone for esophagus squamous cell carcinoma patients
    Xiao-han Zhao, Duo Wang, Fang Wang, Shu-chai Zhu
    Medicine.2018; 97(47): e13168.     CrossRef
  • The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma
    Yichun Wang, Liyang Zhu, Wanli Xia, Liming Wu, Fan Wang
    World Journal of Surgical Oncology.2018;[Epub]     CrossRef
  • A retrospective study of pattern of recurrence after radical surgery for thoracic esophageal carcinoma with or without postoperative radiotherapy
    Yichun Wang, Li Zhang, Dongmei Ye, Wanli Xia, Jun Jiang, Xiumei Wang, Mingxia Zhang, Fan Wang
    Oncology Letters.2018;[Epub]     CrossRef
  • Pattern of lymph node metastasis in thoracic esophageal squamous cell carcinoma with poor differentiation
    Jinling Zhang, Yuanyuan Liu, Fengyuan Che, Yi Luo, Wei Huang, Xueyuan Heng, Baosheng Li
    Molecular and Clinical Oncology.2018;[Epub]     CrossRef
  • Negative lymph node at station 108 is a strong predictor of overall survival in esophageal cancer
    Jinling Zhang, Xueyuan Heng, Yi Luo, Luning Li, Haiyan Zhang, Fengyuan Che, Baosheng Li
    Oncology Letters.2018;[Epub]     CrossRef
  • 10,280 View
  • 180 Download
  • 14 Web of Science
  • 12 Crossref
Close layer
Tumor Stage-Related Role of Radiotherapy in Patients with an External Auditory Canal and Middle Ear Carcinoma
Jinhyun Choi, Se-Heon Kim, Yoon Woo Koh, Eun Chang Choi, Chang Geol Lee, Ki Chang Keum
Cancer Res Treat. 2017;49(1):178-184.   Published online July 4, 2016
DOI: https://doi.org/10.4143/crt.2016.165
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate the clinical outcomes of patients treated with radiotherapy (RT) for a carcinoma of the external auditory canal (EAC) and middle ear.
Materials and Methods
The records of 32 patients who received RT from 1990 to 2013 were reviewed retrospectively. The Pittsburgh classification was used to stage all the cancers (early stage, T1/T2 [n=12]; advanced stage, T3/T4 or N positive [n=20]). Twenty-one patients (65.6%) were treated with postoperative RT and 11 patients (34.4%) were treated with definitive RT. The median radiation doses for postoperative and definitive RT were 60 Gy and 64.8 Gy, respectively. Chemotherapy was administered to seven patients (21.9%).
Results
The 5-year overall survival and disease-free survival rates for all patients were 57% and 52%, respectively. The disease control rates for the patients with early stage versus advanced stage carcinomawere 55.6% (5/9) and 50% (6/12) in the postoperative RT group and 66.7% (2/3) and 37.5% (3/8) in the definitive RT group, respectively. Overall, 15 cases (14 patients, 46.7%) experienced treatment failure; these failures were classified as local in four cases, regional in one case, and distant in 10 cases. The median follow-up period after RT was 51 months (range, 7 to 286 months).
Conclusion
Patients with early stage carcinoma achieved better outcomes when definitive RT was used. Advanced stage carcinoma patients experienced better outcomes with postoperative RT. The high rate of distant failure after RT, with or without surgery, reflected the lack of a consensus regarding the best therapeutic approach for treating carcinoma of the EAC and middle ear.

Citations

Citations to this article as recorded by  
  • Survival Outcomes of Temporal Bone Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis
    Krystelle Sioufi, Aaron David Haynes, Paul W. Gidley, Anastasios Maniakas, Dianna Roberts, Marc‐Elie Nader
    Otolaryngology–Head and Neck Surgery.2024; 171(1): 1.     CrossRef
  • The international expert consensus on management of external auditory canal carcinoma
    Pei Zhou, Rubens de Brito, Yong Cui, Simon Lloyd, Henricus Kunst, J. Walter Kutz, Navin Mani, In Seok Moon, Badr Eldin Mostafa, Cindy Nabuurs, Sampath Chandra Prasad Rao, Bingbin Xie, Yibo Zhang, Chunfu Dai
    European Archives of Oto-Rhino-Laryngology.2024;[Epub]     CrossRef
  • Clinical outcomes of temporal bone squamous cell carcinoma: A single‐institution experience
    Yongbo Zheng, Ke Qiu, Yangju Fu, Wenjie Yang, Danni Cheng, Yufang Rao, Minzi Mao, Yao Song, Wei Xu, Jianjun Ren, Yu Zhao
    Cancer Medicine.2023; 12(5): 5304.     CrossRef
  • Analysis of Prognostic Factors For External Auditory Canal Carcinoma: A 22‐Year Experience
    Isabelle J. H. Jang, Jiun Fong Thong, Constance E. H. Teo, Kiattisa Sommat
    The Laryngoscope.2023; 133(9): 2203.     CrossRef
  • Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: Expecting Its Application in Temporal Bone Squamous Cell Carcinoma
    Meng-wen Shi, Jing Huang, Yu Sun
    Current Medical Science.2023; 43(2): 213.     CrossRef
  • Preoperative simulation using three‐dimensional printer in four temporal bone surgeries
    Ichiro Fukumoto, Yukiyoshi Mita, Rie Shimmi, Yuri Sonobe, Tomohisa Iinuma, Kazuki Yamasaki, Shuji Yonekura, Toshimitsu Nemoto, Toyoyuki Hanazawa
    Clinical Case Reports.2023;[Epub]     CrossRef
  • The Efficacy of Radiotherapy without Surgery for External Auditory Canal Squamous Cell Carcinoma
    Naoto Osu, Atsushi Musha, Hikaru Yumisaki, Kohei Okada, Nobuteru Kubo, Naoko Okano, Yukihiko Takayasu, Masato Shino, Osamu Nikkuni, Shota Ida, Hidemasa Kawamura, Kazuaki Chikamatsu, Tatsuya Ohno
    Journal of Clinical Medicine.2022; 11(19): 5905.     CrossRef
  • Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma
    Ke Qiu, Wendu Pang, Jianqing Qiu, Junhong Li, Danni Cheng, Yufang Rao, Yijun Dong, Minzi Mao, Qiurui Liu, Xiaosong Mu, Wei Zhang, Wei Xu, Jianjun Ren, Yu Zhao
    Cancer Medicine.2021; 10(22): 7958.     CrossRef
  • Evaluation of the modified Pittsburgh classification for predicting the disease‐free survival outcome of squamous cell carcinoma of the external auditory canal
    Cindy H. Nabuurs, Wietske Kievit, Nilou Labbé, C. René Leemans, Conrad F. G. M. Smit, Michiel W. M. van den Brekel, Robert J. Pauw, Bernard F. A. M. van der Laan, Jeroen C. Jansen, Martin Lacko, Weibel W. Braunius, Shinya Morita, Małgorzata Wierzbicka, Ta
    Head & Neck.2020; 42(12): 3609.     CrossRef
  • Management of Temporal Bone Malignancy in Ireland
    Robbie S. R. Woods, Anel Naude, John Barry O'Sullivan, Daniel Rawluk, Mohsen Javadpour, Peter Walshe, Peter D. Lacy, James Paul O'Neill, Rory McConn-Walsh
    Journal of Neurological Surgery Part B: Skull Base.2020; 81(06): 680.     CrossRef
  • A retrospective multicenter study of carbon‐ion radiotherapy for external auditory canal and middle ear carcinomas
    Kazuhiko Hayashi, Masashi Koto, Yusuke Demizu, Jun‐ichi Saitoh, Hiroaki Suefuji, Tomoaki Okimoto, Tatsuya Ohno, Yoshiyuki Shioyama, Ryo Takagi, Hiroaki Ikawa, Kenji Nemoto, Takashi Nakano, Tadashi Kamada
    Cancer Medicine.2019; 8(1): 51.     CrossRef
  • Squamous cell carcinoma of the temporal bone: A current review
    Benjamin D. Lovin, Paul W. Gidley
    Laryngoscope Investigative Otolaryngology.2019; 4(6): 684.     CrossRef
  • Carcinoma of middle ear
    Dragoslava Đerić
    Биомедицинска истраживања.2019; 10(2): 179.     CrossRef
  • Surgery With or Without Postoperative Radiation Therapy for Early-stage External Auditory Canal Squamous Cell Carcinoma: A Meta-analysis
    Ryohei Oya, Yukinori Takenaka, Kazuya Takemura, Naoki Ashida, Kotaro Shimizu, Takahiro Kitamura, Yoshifumi Yamamoto, Atsuhiko Uno
    Otology & Neurotology.2017; 38(9): 1333.     CrossRef
  • 10,138 View
  • 239 Download
  • 15 Web of Science
  • 14 Crossref
Close layer
Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma
Sun Min Lim, Jeong Eun Yoo, Kiat Hon Lim, David Wai Meng Tai, Byoung Chul Cho, Young Nyun Park
Cancer Res Treat. 2017;49(1):185-192.   Published online April 27, 2016
DOI: https://doi.org/10.4143/crt.2015.497
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The recent discovery and characterization of an oncogenic ROS1 gene rearrangement has raised significant interest because small molecule inhibitors are effective in these tumors. The aim of this study was to determine frequency and clinicopathological features associated with ROS1 rearrangement in patients with cholangiocarcinoma (CCA).
Materials and Methods
A total of 261 patients who underwent surgery for CCA between October 1997 and August 2013 were identified from an international, multi-institutional database. ROS1 rearrangement was evaluated by break-apart fluorescence in situ hybridization using tissue microarrays of these patients.
Results
Of 261 CCA evaluated, three cases (1.1%) showed ROS1 rearrangement by fluorescence in situ hybridization (FISH), all of which were derived from intrahepatic origin. ROS1 protein expression was observed in 38 samples (19.1%). Significantly larger tumor size was observed in ROS1 immunohistochemistry (IHC)–negative patients compared with ROS1 IHC–positive patients. ROS1 FISH–positive patients had a single tumor with a median size of 4 cm and well-to-moderate differentiation. Overall, there was no difference in terms of baseline characteristics, overall survival, and recurrence-free survival between ROS1-positive and -negative patients.
Conclusion
ROS1 rearrangement was detected in 1.1% of CCA patients. Although rare, conduct of clinical trials using ROS1 inhibitors in these genetically unique patients is warranted.

Citations

Citations to this article as recorded by  
  • Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors
    Shizhe Li, He Zhang, Ting Chen, Xiaowen Zhang, Guanning Shang
    Cancer Medicine.2024;[Epub]     CrossRef
  • Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker
    Patrick S. Plum, Timo Hess, Denis Bertrand, Isabelle Morgenstern, Oscar Velazquez Camacho, Christoph Jonas, Christina Alidousty, Britta Wagner, Stephanie Roessler, Thomas Albrecht, Jessica Becker, Vanessa Richartz, Barbara Holz, Sascha Hoppe, Huay Mei Poh
    Clinical and Translational Medicine.2024;[Epub]     CrossRef
  • Molecular Analysis of Biliary Tract Cancers with the Custom 3′ RACE-Based NGS Panel
    Natalia V. Mitiushkina, Vladislav I. Tiurin, Aleksandra A. Anuskina, Natalia A. Bordovskaya, Anna D. Shestakova, Aleksandr S. Martianov, Mikhail G. Bubnov, Anna S. Shishkina, Maria V. Semina, Aleksandr A. Romanko, Ekaterina S. Kuligina, Evgeny N. Imyanito
    Diagnostics.2023; 13(20): 3168.     CrossRef
  • ROS1-dependent cancers — biology, diagnostics and therapeutics
    Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A. Davare
    Nature Reviews Clinical Oncology.2021; 18(1): 35.     CrossRef
  • A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine‐based chemotherapy in patients with advanced solid tumors
    Christos Fountzilas, Alex Adjei, Mateusz Opyrchal, Rachel Evans, Mohammad Ghasemi, Kristopher Attwood, Adrienne Groman, Wiam Bshara, Andrew Goey, John Wilton, Wen Wee Ma, Renuka Iyer
    International Journal of Cancer.2021; 149(12): 2063.     CrossRef
  • Liver Mass in a Young Male With Ollier Disease
    Rajalakshmi Govalan, Maha Guindi, Ju Dong Yang
    Gastroenterology.2021; 161(5): e4.     CrossRef
  • Characteristics of Patients With ROS1+ Cancers: Results From the First Patient-Designed, Global, Pan-Cancer ROS1 Data Repository
    Divya A. Parikh, Guneet Walia, Janet Freeman-Daily, Merel Hennink, Tori Tomalia, Lysa Buonanno, Lisa Goldman, Bonnie Addario, Manali I. Patel
    JCO Oncology Practice.2020; 16(2): e183.     CrossRef
  • Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas
    Jeremy Augustin, Caroline Gabignon, Aurélie Scriva, Laëtitia Menu, Claire Calmel, Olivier Scatton, François Paye, Jean-François Fléjou, Françoise Praz, Pascale Cervera, Dominique Wendum
    Virchows Archiv.2020; 477(1): 33.     CrossRef
  • Response to Crizotinib in ROS1 Fusion–Positive Intrahepatic Cholangiocarcinoma
    Christopher D. Jakubowski, Aditya A. Mohan, Ihab R. Kamel, Mark Yarchoan
    JCO Precision Oncology.2020; (4): 825.     CrossRef
  • Emerging pathways for precision medicine in management of cholangiocarcinoma
    Amir A. Rahnemai-Azar, Arezou Abbasi, Alexandra W. Acher, Sharon M. Weber, Timothy M. Pawlik
    Surgical Oncology.2020; 35: 47.     CrossRef
  • Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients
    Se-Hoon Lee, Boram Lee, Joon Ho Shim, Kwang Woo Lee, Jae Won Yun, Sook-Young Kim, Tae-You Kim, Yeul Hong Kim, Young Hyeh Ko, Hyun Cheol Chung, Chang Sik Yu, Jeeyun Lee, Sun Young Rha, Tae Won Kim, Kyung Hae Jung, Seock-Ah Im, Hyeong-Gon Moon, Sukki Cho, J
    Cancer Research and Treatment.2019; 51(1): 211.     CrossRef
  • Molecular genetic aspects of intrahepatic cholangiocarcinoma: literature review
    B. N. Gurmikov, Yu. A. Kovalenko, V. A. Vishnevsky, A. V. Chzhao
    Advances in molecular oncology.2019; 6(1): 37.     CrossRef
  • Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives
    Roberto Filippi, Pasquale Lombardi, Virginia Quarà, Elisabetta Fenocchio, Giacomo Aimar, Michela Milanesio, Francesco Leone, Massimo Aglietta
    Expert Opinion on Pharmacotherapy.2019; 20(17): 2121.     CrossRef
  • Intrahepatic cholangiocarcinoma: current management and emerging therapies
    Amir A. Rahnemai-Azar, Allison B. Weisbrod, Mary Dillhoff, Carl Schmidt, Timothy M. Pawlik
    Expert Review of Gastroenterology & Hepatology.2017; 11(5): 439.     CrossRef
  • ROS1-1
    Prodipto Pal, Zanobia Khan
    Journal of Clinical Pathology.2017; 70(12): 1001.     CrossRef
  • 11,001 View
  • 160 Download
  • 16 Web of Science
  • 15 Crossref
Close layer
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
Byung Sup Kim, Ho Jun Seol, Do-Hyun Nam, Chul-Kee Park, Il Han Kim, Tae Min Kim, Jeong Hoon Kim, Young Hyun Cho, Sang Min Yoon, Jong Hee Chang, Seok-Gu Kang, Eui Hyun Kim, Chang-Ok Suh, Tae-Young Jung, Kyung-Hwa Lee, Chae-Yong Kim, In Ah Kim, Chang-Ki Hong, Heon Yoo, Jin Hee Kim, Shin-Hyuk Kang, Min Kyu Kang, Eun-Young Kim, Sun-Hwan Kim, Dong-Sup Chung, Sun-Chul Hwang, Joon-Ho Song, Sung Jin Cho, Sun-Il Lee, Youn-Soo Lee, Kook-Jin Ahn, Se Hoon Kim, Do Hun Lim, Ho-Shin Gwak, Se-Hoon Lee, Yong-Kil Hong
Cancer Res Treat. 2017;49(1):193-203.   Published online June 27, 2016
DOI: https://doi.org/10.4143/crt.2015.473
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample.
Materials and Methods
A total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who received concurrent chemoradiotherapy with TMZ (CCRT) and adjuvant TMZ from January 2006 until June 2011, were analyzed retrospectively.
Results
After the first operation, a gross total resection (GTR), subtotal resection (STR), partial resection (PR), biopsy alone were achieved in 388 (51.7%), 159 (21.2%), 96 (12.8%), and 107 (14.3%) patients,respectively. The methylation status of O6-methylguanine-DNA methyltransferase (MGMT) was reviewed retrospectively in 217 patients. The median follow-up period was 16.3 months and the median overall survival (OS) was 17.5 months. The actuarial survival rates at the 1-, 3-, and 5-year OS were 72.1%, 21.0%, and 9.0%, respectively. The median progression-free survival (PFS) was 10.1 months, and the actuarial PFS at 1-, 3-, and 5-year PFS were 42.2%, 13.0%, and 7.8%, respectively. The patients who received GTR showed a significantly longer OS and PFS than those who received STR, PR, or biopsy alone, regardless of the methylation status of the MGMT promoter. Patients with a methylated MGMT promoter also showed a significantly longer OS and PFS than those with an unmethylated MGMT promoter. Patients who received more than six cycles of adjuvant TMZ had a longer OS and PFS than those who received six or fewer cycles. Hematologic toxicity of grade 3 or 4 was observed in 8.4% of patients during the CCRT period and in 10.2% during the adjuvant TMZ period.
Conclusion
Patients treated with CCRT followed by adjuvant TMZ had more favorable survival rates and tolerable toxicity than those who did not undergo this treatment.

Citations

Citations to this article as recorded by  
  • Letter to the Editor Regarding Cerebral Blood Flow Role in Delineating Treatment Effect from True Tumor Progression in Glioblastoma Multiforme
    Inibehe Ime Okon, Tolulope Judah Gbayisomore, Samuel Berchi Kankam, Mohammad Jalloh
    World Neurosurgery.2024; 186: 269.     CrossRef
  • NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors
    Eric Eunshik Kim, Chul-Kee Park, Seung-Ki Kim, Ji Hoon Phi, Sun Ha Paek, Jung Yoon Choi, Hyoung Jin Kang, Joo Ho Lee, Jae Kyung Won, Hongseok Yun, Sung-Hye Park
    Acta Neuropathologica Communications.2024;[Epub]     CrossRef
  • Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection
    Masayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda, Yukinori Akiyama, Takaaki Beppu, Shigeo Ohba, Toshiyuki Enomoto, Takahiro Ono, Yuta Mitobe, Mitsuto Hanihara, Yohei Mineharu, Joji Ishida, Kenichiro Asano, Yasuyuki Yoshida, Manabu Natsumeda, Sadahir
    International Journal of Clinical Oncology.2024;[Epub]     CrossRef
  • The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Recommendation Using the Delphi Method (Version 2023.1)
    Min-Sung Kim, Se-Il Go, Chan Woo Wee, Min Ho Lee, Seok-Gu Kang, Kyeong-O Go, Sae Min Kwon, Woohyun Kim, Yun-Sik Dho, Sung-Hye Park, Youngbeom Seo, Sang Woo Song, Stephen Ahn, Hyuk-Jin Oh, Hong In Yoon, Sea-Won Lee, Joo Ho Lee, Kyung Rae Cho, Jung Won Choi
    Brain Tumor Research and Treatment.2023; 11(2): 123.     CrossRef
  • Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges
    Daisuke Sato, Hirokazu Takami, Shunsaku Takayanagi, Kazuki Taoka, Mariko Tanaka, Reiko Matsuura, Shota Tanaka, Nobuhito Saito
    BMC Neurology.2023;[Epub]     CrossRef
  • Glioma angiogenesis is boosted by ELK3 activating the HIF-1$$alpha$$/VEGF-A signaling axis
    Mou Yueyang, Hu Yaqin, Xue Guolian, Zhao Wenjian, Jiao Yang, Li Chen, Cao Haiyan, Chao Min, Deng Jianping, Dai Penggao, Zhu Hongli, Wang Liang
    BMC Cancer.2023;[Epub]     CrossRef
  • Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open‐label phase 2 study
    Kihwan Hwang, Junhyung Kim, Seok‐Gu Kang, Tae‐Young Jung, Jeong Hoon Kim, Se‐Hyuk Kim, Shin‐Hyuk Kang, Yong‐Kil Hong, Tae Min Kim, Yu Jung Kim, Byung Se Choi, Jong Hee Chang, Chae‐Yong Kim
    Cancer Medicine.2022; 11(2): 371.     CrossRef
  • Prognostic Value and Risk Factors of Treatment-Related Lymphopenia in Malignant Glioma Patients Treated With Chemoradiotherapy: A Systematic Review and Meta-Analysis
    Yongchao Zhang, Shichao Chen, Hualei Chen, Shanshan Chen, Zhen Li, Enshan Feng, Wei Li
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • PrACTiC: A Predictive Algorithm for Chemoradiotherapy-Induced Cytopenia in Glioblastoma Patients
    Alireza Amouheidari, Zahra Alirezaei, Stefan Rauh, Masoud Hassanpour, Ozkan Kanat
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Relapsing High—Grade Glioma from Peritumoral Zone: Critical Review of Radiotherapy Treatment Options
    Maria Chiara Lo Greco, Roberto Milazzotto, Rocco Luca Emanuele Liardo, Grazia Acquaviva, Madalina La Rocca, Roberto Altieri, Francesco Certo, Giuseppe Maria Barbagallo, Antonio Basile, Pietro Valerio Foti, Stefano Palmucci, Stefano Pergolizzi, Antonio Pon
    Brain Sciences.2022; 12(4): 416.     CrossRef
  • Effect of Choline Alphoscerate on the Survival of Glioblastoma Patients: A Retrospective, Single-Center Study
    Yeong Jin Kim, Tae-Kyu Lee, Myung-Giun Noh, Tae-Young Jung, In-Young Kim, Shin Jung, Kyung-Hwa Lee, Kyung-Sub Moon
    Journal of Clinical Medicine.2022; 11(20): 6052.     CrossRef
  • Evaluating survival in subjects with astrocytic brain tumors by dynamic susceptibility-weighted perfusion MR imaging
    Matthew L. White, Yan Zhang, Syed A. Jaffar Kazmi, Michele Aizenberg, Nicole Shonka, Fang Yu, Adams Kusi Appiah, Michael C. Burger
    PLOS ONE.2021; 16(1): e0244275.     CrossRef
  • Prognostic value of test(s) for O6-methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
    Alexandra McAleenan, Claire Kelly, Francesca Spiga, Ashleigh Kernohan, Hung-Yuan Cheng, Sarah Dawson, Lena Schmidt, Tomos Robinson, Sebastian Brandner, Claire L Faulkner, Christopher Wragg, Sarah Jefferies, Amy Howell, Luke Vale, Julian P T Higgins, Kathr
    Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
  • Mixed malignant glioblastoma and schwannoma in spinal cord with metachronous ependymoma: A case report
    Mostafa Farzin, Mohamadreza Hajiabadi, Mohammad Rahmani, Kasra Kolahdouzan
    Clinical Case Reports.2021;[Epub]     CrossRef
  • Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study
    Srinivas Annavarapu, Anagha Gogate, Trang Pham, Kalatu Davies, Prianka Singh, Nicholas Robert
    CNS Oncology.2021;[Epub]     CrossRef
  • A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
    Fahimeh Attarian, Farzad Taghizadeh-Hesary, Azar Fanipakdel, Seyed Alireza Javadinia, Pejman Porouhan, Babak PeyroShabany, Danial Fazilat-Panah
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial
    Chae-Yong Kim, Sun Ha Paek, Do-hyun Nam, Jong-Hee Chang, Yong-Kil Hong, Jeong Hoon Kim, Oh Lyong Kim, Se-Hyuk Kim
    Journal of Neuro-Oncology.2020; 146(3): 399.     CrossRef
  • Risk Factors for Cognitive Impairment in High-Grade Glioma Patients Treated with Postoperative Radiochemotherapy
    Qiang Wang, Fengxia Xiao, Fei Qi, Xiaopeng Song, Yonghua Yu
    Cancer Research and Treatment.2020; 52(2): 586.     CrossRef
  • Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
    Maria B. Garcia-Fabiani, Maria Ventosa, Andrea Comba, Marianela Candolfi, Alejandro J. Nicola Candia, Mahmoud S. Alghamri, Padma Kadiyala, Stephen Carney, Syed M. Faisal, Anna Schwendeman, James J. Moon, Lindsay Scheetz, Joerg Lahann, Ava Mauser, Pedro R.
    Expert Opinion on Investigational Drugs.2020; 29(7): 659.     CrossRef

  • Long Intergenic Non-Protein Coding RNA 1094 Promotes Initiation and Progression of Glioblastoma by Promoting microRNA-577-Regulated Stabilization of Brain-Derived Neurotrophic Factor


    Xiaoyan Dong, Xiuxin Fu, Miao Yu, Zengfen Li
    Cancer Management and Research.2020; Volume 12: 5619.     CrossRef
  • SNHG7 Facilitates Glioblastoma Progression by Functioning as a Molecular Sponge for MicroRNA-449b-5p and Thereby Increasing MYCN Expression
    Yaogang Chen, Shaoyong Yuan, Tieying Ning, Huiqing Xu, Bo Guan
    Technology in Cancer Research & Treatment.2020;[Epub]     CrossRef
  • Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres
    Hyeong-Cheol Oh, Jin-Kyoung Shim, Junseong Park, Ji-Hyun Lee, Ran Joo Choi, Nam Hee Kim, Hyun Sil Kim, Ju Hyung Moon, Eui Hyun Kim, Jong Hee Chang, Jong In Yook, Seok-Gu Kang
    Journal of Cancer Research and Clinical Oncology.2020; 146(11): 2817.     CrossRef
  • Clinical Characteristics of High-Grade Glioma with Primary Leptomeningeal Seeding at Initial Diagnosis in a Single Center Study
    Ji-Eyon Kwon, Kihwan Hwang, Kyeong-O Go, Chan Woo Wee, In Ah Kim, Yu Jung Kim, Gheeyoung Choe, Byung Se Choi, Jung Ho Han, Chae-Yong Kim
    Brain Tumor Research and Treatment.2020; 8(2): 77.     CrossRef
  • A Longitudinal Study of Lipid Peroxidation and Symptom Clusters in Patients With Brain Cancers
    Sanghee Kim
    Nursing Research.2018; 67(5): 387.     CrossRef
  • Dynamic Susceptibility Contrast (DSC) Perfusion MR in the Prediction of Long-Term Survival of Glioblastomas (GBM): Correlation with MGMT Promoter Methylation and 1p/19q Deletions
    Yong Wonn Kwon, Won-Jin Moon, Mina Park, Hong Gee Roh, Young Cho Koh, Sang Woo Song, Jin Woo Choi
    Investigative Magnetic Resonance Imaging.2018; 22(3): 158.     CrossRef
  • Notch1ablation radiosensitizes glioblastoma cells
    Na Han, Guangyuan Hu, Lei Shi, Guoxian Long, Lin Yang, Qingsong Xi, Qiuyun Guo, Jianhua Wang, Zhen Dong, Mengxian Zhang
    Oncotarget.2017; 8(50): 88059.     CrossRef
  • Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system
    Haihui Jiang, Yong Cui, Junmei Wang, Song Lin
    Oncotarget.2017; 8(12): 20354.     CrossRef
  • 15,758 View
  • 314 Download
  • 24 Web of Science
  • 27 Crossref
Close layer
Analysis of the Clinicopathological Characteristics of Gastric Cancer in Extremely Old Patients
Il Woong Sohn, Da Hyun Jung, Jie-Hyun Kim, Hyun Soo Chung, Jun Chul Park, Sung Kwan Shin, Sang Kil Lee, Yong Chan Lee
Cancer Res Treat. 2017;49(1):204-212.   Published online June 27, 2016
DOI: https://doi.org/10.4143/crt.2016.163
AbstractAbstract PDFPubReaderePub
Purpose
Gastric cancer is the third-leading cause of cancer-related death in Korea. As the Korean population is ageing, the number of extremely old patients with this disease is increasing. This study examined the clinicopathological characteristics of gastric cancer in extremely old (over 85 years) patients who received treatment or conservative observations and compared the treatment outcomes according to the treatment modality.
Materials and Methods
A total of 170 patients over 85 years of age were diagnosed with gastric cancer. Of these, 81 underwent treatment for gastric cancer and 89 received conservative observations. The clinicopathological characteristics of the treatment and conservative groupswere compared.
Results
The mean age of the patients was 86.5 years. The conservative group included significantly more patients with older ages, macroscopically advanced cancer and upper-middle located cancer. The overall survival rate of the treatment group was significantly higher than that of the conservative group. The disease-specific mortality rate was significantly lower in the treatment group than in the conservative group. Multivariate analysis revealed the clinical course, alarm sign, and macroscopic classification to be independent prognosis factors.
Conclusion
By itself, the chronological age should not be used as a strategy to determine whether treatmentwill be administered for gastric cancer. Patientswho have early gastric cancer or lower-risk preexisting comorbidities should not be discouraged from treatment, even if they are older than 85 years.

Citations

Citations to this article as recorded by  
  • Efficacy of Pd-1/Pd-L1 Inhibitors in Advanced Gastroesophageal Cancer Based on Characteristics: A Meta-Analysis
    Wenjie Liu, Gengwei Huo, Peng Chen
    Immunotherapy.2023; 15(10): 751.     CrossRef
  • Gastric Cancer in Older Patients: A Retrospective Study and Literature Review
    Yonghoon Choi, Nayoung Kim, Ki Wook Kim, Hyeong Ho Jo, Jaehyung Park, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee
    Annals of Geriatric Medicine and Research.2022; 26(1): 33.     CrossRef
  • Survival benefits of gastrectomy compared to conservative observation for older patients with resectable gastric cancer: a propensity score matched analysis
    Shuhei Ito, Kippei Ohgaki, Tetsuro Kawazoe, Huanlin Wang, Toshihiko Nakamura, Shinichiro Maehara, Eisuke Adachi, Yoichi Ikeda, Yoshihiko Maehara
    Langenbeck's Archives of Surgery.2022; 407(6): 2281.     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Utility of monthly minodronate for osteoporosis after gastrectomy: Prospective multicenter randomized controlled trials
    Masashi Hirota, Tsuyoshi Takahashi, Yurina Saito, Ryohei Kawabata, Rie Nakatsuka, Hiroshi Imamura, Masaaki Motoori, Yoichi Makari, Atsushi Takeno, Kentaro Kishi, Shinichi Adachi, Hiromichi Miyagaki, Yukinori Kurokawa, Makoto Yamasaki, Hidetoshi Eguchi, Yu
    Annals of Gastroenterological Surgery.2021; 5(6): 754.     CrossRef
  • Is surgery the best treatment for elderly gastric cancer patients?
    Yoshihiko Kawaguchi, Hidenori Akaike, Katsutoshi Shoda, Shinji Furuya, Naohiro Hosomura, Hidetake Amemiya, Hiromichi Kawaida, Hiroshi Kono, Daisuke Ichikawa
    World Journal of Gastrointestinal Surgery.2021; 13(11): 1351.     CrossRef
  • The role of surgery in patients aged 85 years or older with resectable gastric cancer: a propensity score matching analysis of the SEER database
    Jing Guo, Junhui Yu, Zhengshui Xu, Xuejun Sun, Jianbao Zheng
    Scandinavian Journal of Gastroenterology.2020; 55(6): 694.     CrossRef
  • Elderly patients with cancer admitted to intensive care unit: A multicenter study in a middle-income country
    Antonio Paulo Nassar Junior, Mariane da Silva Trevisani, Barbara Beltrame Bettim, Fernando Godinho Zampieri, José Albani Carvalho, Amilton Silva, Flávio Geraldo Rezende de Freitas, Jorge Eduardo da Silva Soares Pinto, Edson Romano, Silvia Regina Ramos, Gu
    PLOS ONE.2020; 15(8): e0238124.     CrossRef
  • Optimal treatment for elderly patients with resectable proximal gastric carcinoma: a real world study based on National Cancer Database
    Xuefei Wang, Junjie Zhao, Mark Fairweather, Tingsong Yang, Yihong Sun, Jiping Wang
    BMC Cancer.2019;[Epub]     CrossRef
  • Hypermethylated long noncoding RNA MEG3 promotes the progression of gastric cancer
    Lei Ding, Yuan Tian, Ling Wang, Miaomiao Bi, Dengke Teng, Sen Hong
    Aging.2019; 11(19): 8139.     CrossRef
  • Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW
    Kei Muro, Jae Yong Cho, Gyorgy Bodoky, Chanchal Goswami, Yee Chao, Lucas V dos Santos, Yasuhiro Shimada, Eldar Topuzov, Eric Van Cutsem, Josep Tabernero, John Zalcberg, Ian Chau, Stefano Cascinu, Rebecca Cheng, Yanzhi Hsu, Michael Emig, Mauro Orlando, Cha
    Journal of Gastroenterology and Hepatology.2018; 33(4): 814.     CrossRef
  • 10,014 View
  • 180 Download
  • 12 Web of Science
  • 11 Crossref
Close layer
Clinicopathological Features of Low-Grade Thyroid-like Nasopharyngeal Papillary Adenocarcinoma
Minhua Li, Jiangguo Wei, Xiaofei Yao, Cheng Wang
Cancer Res Treat. 2017;49(1):213-218.   Published online July 4, 2016
DOI: https://doi.org/10.4143/crt.2016.195
AbstractAbstract PDFPubReaderePub
Purpose
Primary low-grade thyroid-like papillary adenocarcinomas are extremely rare neoplasms that generally originate in the nasopharynx. Here, we describe a novel case of a 15-year-old Chinese girl who was diagnosed with low-grade thyroid-like papillary adenocarcinoma, including a brief review of the literature to reveal the clinicopathological features of low-grade thyroid-like nasopharyngeal papillary adenocarcinoma.
Materials and Methods
Immunohistochemistry was used to evaluate the expression of pan-cytokeratin (CKpan), cytokeratin (CK) 7, thyroid transcription factor 1 (TTF-1), vimentin, epithelial membrane antigen (EMA), thyroglobulin, CD15, S100, P40, CK20, CDX-2, glial fibrillary acidic protein (GFAP), and Ki-67. Additionally, in situ hybridization investigation was utilized to identify the presence of small Epstein-Barr virus (EBV)–encoded RNA.
Results
Histopathological analysis revealed florid proliferation of papillary structures lined by columnar epithelial cells with fibrovascular cores. Immunohistochemically, the neoplastic cells were positive for CKpan, CK7, TTF-1, vimentin, and EMA, but negative for thyroglobulin, CD15, S100, P40, CK20, CDX-2, and GFAP. The Ki-67–labeling index reached 5% in the most concentrated spot. In situ hybridization for EBV was negative.
Conclusion
Due to the distinct rarity of low-grade thyroid-like papillary adenocarcinomaswith a favorable clinical outcome, a nationwide effort to raise public awareness of this neoplasm is required.

Citations

Citations to this article as recorded by  
  • Clinicopathologic features of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma
    Weiwei Chen, Jing Zhao
    Asian Journal of Surgery.2024; 47(5): 2433.     CrossRef
  • Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: a clinicopathological and molecular study of four cases
    Lei Wang, Xiao-tong Wang, Yuan Fang, Wei Qiu, Qiu-yuan Xia, Ru Fang, Qiu Rao, Hong-lin Yin
    Human Pathology.2023; 134: 66.     CrossRef
  • Epstein–Barr virus-associated poorly differentiated nasopharyngeal adenocarcinoma: a case report and literature review
    Shuai Zhang, Xiao-Peng Huang, Hai-Hong Li, Ze-Tan Chen
    Journal of International Medical Research.2023;[Epub]     CrossRef
  • Nasopharyngeal Papillary Adenocarcinoma: A Cotton Swab Appearance on Computer Tomography
    Jae-Hoon Lee, Jung-Hun Kown
    Ear, Nose & Throat Journal.2022; 101(1): NP28.     CrossRef
  • Cribriform adenocarcinoma of minor salivary glands presented as a nasopharyngeal tumor: A case report highlighting the significance of cytology
    Olga Kuczkiewicz-Siemion, Emilia Wnuk, Monika Durzyńska
    Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2022; 133(4): e91.     CrossRef
  • Genetic profile identification and clinicopathologic characteristics analysis of the thyroid-like low-grade nasopharyngeal papillary adenocarcinoma
    Tiansheng Wang, Xinrong Liu, Wentao Yu, Lin Gao, Wenzhi Deng, Qiongzhi He, Feifei Liao, Ling Chu
    Pathology - Research and Practice.2022; 236: 153980.     CrossRef
  • A Rare Case of Low-grade Nasopharyngeal Papillary Adenocarcinoma in a Young Adult Woman
    Yasir Nuhu Jibril, Abubakar Danjuma Salisu, Muhammad Inuwa Mustapha, Olatunde Olaniyi Abiodun Oluwafemi
    Journal of West African College of Surgeons.2022; 12(1): 107.     CrossRef
  • Endoscopic Low-Temperature Plasma Radiofrequency Ablation for Primary Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma
    Qing-Yao Zhong, Qiang Sun, Zhao-Hui Liu
    Ear, Nose & Throat Journal.2021; 100(7): 563.     CrossRef
  • A novel low‐grade nasopharyngeal adenocarcinoma characterized by a GOLGB1‐BRAF fusion gene
    Justin Bubola, Cristina R. Antonescu, Ilan Weinreb, David Swanson, John R. De Almeida, Christina M. MacMillan, Brendan C. Dickson
    Genes, Chromosomes and Cancer.2021; 60(1): 49.     CrossRef
  • Low-Grade Nasopharyngeal Papillary Adenocarcinoma: A Review of 28 Patients in a Single Institution
    Yuting Lai, Wanpeng Li, Changwen Zhai, Xiaole Song, Jingyi Yang, Xicai Sun, Dehui Wang
    Cancer Management and Research.2021; Volume 13: 1271.     CrossRef
  • Patología del tabique nasal (a excepción de la desviación septal)
    D. Malinvaud, P. Bonfils
    EMC - Otorrinolaringología.2021; 50(3): 1.     CrossRef
  • Patologia del setto nasale (deviazione del setto esclusa)
    D. Malinvaud, P. Bonfils
    EMC - Otorinolaringoiatria.2021; 20(3): 1.     CrossRef
  • Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with squamous differentiation in the posterior nasal septum
    Li Yi, Honglei Liu
    Medicine.2021; 100(51): e28349.     CrossRef
  • A Case of Thyroid-like Low Grade Nasopharyngeal Papillary Adenocarcinoma of the Posterior Nasal Septum
    Arisa Oguchi, Takumi Kumai, Kan Kishibe, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Yasuaki Harabuchi
    Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology).2021; 60(4): 495.     CrossRef
  • Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma with Biphasic Histology
    Rusella Mirza, Nestor Dela Cruz, Guillermo A. Herrera
    Case Reports in Pathology.2020; 2020: 1.     CrossRef
  • Primary papillary epithelial tumour of the sella: expanding the spectrum of TTF‐1‐positive sellar lesions
    F. Roncaroli, D. Chatterjee, C. Giannini, M. Pereira, S. La Rosa, J. P. Brouland, K. Gnanalingham, C. Galli, B. Fernandes, A. Lania, B. Radotra
    Neuropathology and Applied Neurobiology.2020; 46(5): 493.     CrossRef
  • Primary thyroid-like low-grade nasopharyngeal papillary adenocarcinoma in a 11-year-old male patient: The first case report in Indonesia
    Emilia Theresia, Ery Kus Dwianingsih, Hanggoro Tri Rinonce, Rita Cempaka, Camelia Herdini, Irianiwati
    Human Pathology: Case Reports.2020; 21: 200392.     CrossRef
  • Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma
    Li Maocai, Liu Fuxing, Li Lianqing, Gong Lili, Duan WenChao, Liu ShouZhou
    Medicine.2020; 99(33): e21599.     CrossRef
  • A Case of Low Grade Thyroid Like Nasopharyngeal Papillary Adenocarcinoma in Posterior Nasal Septum
    Chang Lok Ji, Geun Hyung Park, Soo Kweon Koo, Hwaseon Lee
    Journal of Clinical Otolaryngology Head and Neck Surgery.2020; 31(1): 70.     CrossRef
  • Biphasic Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma with a Prominent Spindle Cell Component: A Case Report
    Sang Hwa Lee, Hyunjin Kim, Min Ju Kim, Byungwha Kim, Hyun-Soo Kim
    Diagnostics.2020; 10(5): 323.     CrossRef
  • Clinicopathological Features of Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma: A Case Report and Review of the Literature
    Hiromasa Takakura, Takeru Hamashima, Hirohiko Tachino, Akira Nakazato, Hiroshi Minato, Masakiyo Sasahara, Hideo Shojaku
    Frontiers in Surgery.2020;[Epub]     CrossRef
  • Nasopharyngeal Papillary Adenocarcinoma as a Second Head and Neck Malignancy
    Aanchal Kakkar, Pirabu Sakthivel, Swati Mahajan, Alok Thakar
    Head and Neck Pathology.2019; 13(4): 699.     CrossRef
  • Thyroid-like low-grade papillary adenocarcinoma of nasopharynx
    Ainaz Sourati, Mona Malekzadeh, Azadeh Rakhshan
    BMJ Case Reports.2019; 12(6): e226949.     CrossRef
  • Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma
    Fengbo Huang, Xueping Xiang, Bo Hong, Jie Min, Jinfan Li
    American Journal of Clinical Pathology.2019; 152(5): 582.     CrossRef
  • Progressive Bilateral Nasal Obstruction Due to Nasopharyngeal Mass
    Hyun Jin Min, Kyung Soo Kim
    JAMA Otolaryngology–Head & Neck Surgery.2019; 145(10): 971.     CrossRef
  • Clinicopathologic Characteristics of Thyroid-like Low-grade Nasopharyngeal Papillary Adenocarcinoma: A Case Report
    Liang Li, Fengjuan Zhou, Fanzhong Lin, Cuihong Han
    Applied Immunohistochemistry & Molecular Morphology.2019; 27(8): e81.     CrossRef
  • The specific immunophenotypic features of nasopharyngeal carcinoma
    G. A. Demyashkin, I. V. Kastyro, A. V. Sidorin, Ya. S. Borisov
    Vestnik otorinolaringologii.2018; 83(5): 40.     CrossRef
  • Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with squamous differentiation: a novel histological finding
    Takashi Oide, Osamu Kadosono, Jun Matsushima, Di Wu, Hiroaki Nagashima, Hideto Saigusa, Atsuko Masunaga, Yukio Nakatani, Kenzo Hiroshima
    Human Pathology.2017; 70: 43.     CrossRef
  • Primary thyroid-like low-grade nasopharyngeal papillary adenocarcinoma
    Wan-Lin Zhang, Shuang Ma, Lauren Havrilla, Lin Cai, Cheng-Qian Yu, Shuai Shen, Hong-Tao Xu, Liang Wang, Juan-Han Yu, Xu-Yong Lin, Endi Wang, Lian-He Yang
    Medicine.2017; 96(47): e8851.     CrossRef
  • 11,302 View
  • 240 Download
  • 29 Web of Science
  • 29 Crossref
Close layer
Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE2
Ivan Ho Yuen Pun, Dessy Chan, Sau Hing Chan, Po Yee Chung, Yuan Yuan Zhou, Simon Law, Alfred King Yin Lam, Chung Hin Chui, Albert Sun Chi Chan, Kim Hung Lam, Johnny Cheuk On Tang
Cancer Res Treat. 2017;49(1):219-229.   Published online July 18, 2016
DOI: https://doi.org/10.4143/crt.2016.190
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
83b1 is a novel quinoline derivative that has been shown to inhibit cancer growth in human esophageal squamous cell carcinoma (ESCC). This study was conducted to comprehensively evaluate the cytotoxic effects of 83b1 on a series of ESCC cell lines and investigate the mechanisms by which 83b1 suppresses cancer growth based on molecular docking analysis.
Materials and Methods
A series of ESCC and nontumor immortalized cell lines were exposed to 83b1 and cisplatin (CDDP) in a dose-dependent manner, and the cytotoxicity was examined by a MTS assay kit. Prediction of the molecular targets of 83b1 was conducted by molecular docking analysis. Expression of cyclooxygenase 2 (COX-2) mRNA and COX-2–derived prostaglandin E2 (PGE2) were measured by quantitative real-time polymerase chain reaction and enzymelinked immuno-sorbent assay, respectively. In vivo anti-tumor effect was determined using a nude mice xenografted model transplanted with an ESCC cell line, KYSE-450.
Results
83b1 showed the significant anti-cancer effects on all ESCC cell lines compared to CDDP; however, 83b1 revealed much lower toxic effects on non-tumor cell lines than CDDP. The predicted molecular target of 83b1 is peroxisome proliferator-activated receptor delta (PPARδ), which is a widely known oncoprotein. Additionally the expression of COX-2 mRNA and COX-2–derived PGE2 were down-regulated by 83b1 in a dose-dependent manner in ESCC cell lines. Furthermore, 83b1 was shown to significantly reduce the tumor size in nude mice xenograft.
Conclusion
The results of this study suggest that the potential anti-cancer effects of 83b1 on human esophageal cancers occur through the possible oncotarget, PPARδ, and down-regulation of the cancer related genes and molecules.

Citations

Citations to this article as recorded by  
  • Synthesis and biological evaluation of novel 2-morpholino-4-anilinoquinoline derivatives as antitumor agents against HepG2 cell line
    Ahmed Al-Sheikh, Malak A. Jaber, Hana'a Khalaf, Nour AlKhawaja, Duaa Abuarqoub
    RSC Advances.2024; 14(5): 3304.     CrossRef
  • Natural alkaloids as potential treatments for esophageal squamous-cell carcinoma: A comprehensive review
    Eugene Jamot Ndebia, Gabriel Tchuente Kamsu
    Gastroenterology & Endoscopy.2024; 2(3): 131.     CrossRef
  • Arachidonic acid metabolism as a novel pathogenic factor in gastrointestinal cancers
    Weiqin Lu, Aihemaitijiang Aihaiti, Paziliya Abudukeranmu, Yajun Liu, Huihui Gao
    Molecular and Cellular Biochemistry.2024;[Epub]     CrossRef
  • Downregulation of chemokine (C‑C motif) ligand 5 induced by a novel 8‑hydroxyquinoline derivative (91b1) suppresses tumor invasiveness in esophageal carcinoma
    Johnny Tang, Dessy Chan, Po-Yee Chung, Yijiang Liu, Alfred Lam, Simon Law, Wolin Huang, Albert Chan, Kim-Hung Lam, Yuanyuan Zhou
    International Journal of Molecular Medicine.2024;[Epub]     CrossRef
  • Peroxisome proliferator-activated receptors regulate the progression and treatment of gastrointestinal cancers
    Min Zhang, Shujie He
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Roles of Nuclear Receptors in Esophageal Cancer
    Lihao Deng, Jiaxuan Liu, Wei-Dong Chen, Yan-Dong Wang
    Current Pharmaceutical Biotechnology.2023; 24(12): 1489.     CrossRef
  • Synthesis and biological activities of new phthalimide and thiazolidine derivatives
    Flaviana A. Santos, Marcel L. Almeida, Vitor A. S. Silva, Douglas C. F. Viana, Michelly C. Pereira, André S. L. Lucena, Maira G. R. Pitta, Marina R. Galdino-Pitta, Moacyr J. B. de Melo Rêgo, Ivan da Rocha Pitta
    Medicinal Chemistry Research.2022; 31(1): 108.     CrossRef
  • Role of Prostaglandin E2 in the Progression of Gastrointestinal Cancer
    David Jay Wilson, Raymond N. DuBois
    Cancer Prevention Research.2022; 15(6): 355.     CrossRef
  • The Anticancer Effect of a Novel Quinoline Derivative 91b1 through Downregulation of Lumican
    Yuanyuan Zhou, Zhongguo Zhou, Dessy Chan, Po yee Chung, Yongqi Wang, Albert Sun chi Chan, Simon Law, Kim hung Lam, Johnny Cheuk On Tang
    International Journal of Molecular Sciences.2022; 23(21): 13181.     CrossRef
  • Synthesis and biological evaluations of N′-substituted methylene-4-(quinoline-4-amino) benzoylhydrazides as potential anti-hepatoma agents
    Baicun Li, Feifeng Zhu, Fengming He, Qingqing Huang, Xiaoguang Liu, Tong Wu, Taige Zhao, Yingkun Qiu, Zhen Wu, Yuhua Xue, Meijuan Fang
    Bioorganic Chemistry.2020; 96: 103592.     CrossRef
  • Feasibility of Repurposing Clioquinol for Cancer Therapy
    Raheel Khan, Harras Khan, Yassen Abdullah, Q. Ping Dou
    Recent Patents on Anti-Cancer Drug Discovery.2020; 15(1): 14.     CrossRef
  • DFIQ, a Novel Quinoline Derivative, Shows Anticancer Potential by Inducing Apoptosis and Autophagy in NSCLC Cell and In Vivo Zebrafish Xenograft Models
    Hurng-Wern Huang, Yung-Ding Bow, Chia-Yih Wang, Yen-Chun Chen, Pei-Rong Fu, Kuo-Feng Chang, Tso-Wen Wang, Chih-Hua Tseng, Yeh-Long Chen, Chien-Chih Chiu
    Cancers.2020; 12(5): 1348.     CrossRef
  • Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds
    Hongbin Huang, Guigui Zhang, Yuquan Zhou, Chenru Lin, Suling Chen, Yutong Lin, Shangkang Mai, Zunnan Huang
    Frontiers in Chemistry.2018;[Epub]     CrossRef
  • The roles of the COX2/PGE2/EP axis in therapeutic resistance
    Dali Tong, Qiuli Liu, Lin-ang Wang, Qiubo Xie, Jian Pang, Yiqiang Huang, Luofu Wang, Gaolei Liu, Dianzheng Zhang, Weihua Lan, Jun Jiang
    Cancer and Metastasis Reviews.2018; 37(2-3): 355.     CrossRef
  • Expression of Insulin-Like Growth Factor Binding Protein-5 (IGFBP5) Reverses Cisplatin-Resistance in Esophageal Carcinoma
    Dessy Chan, Yuanyuan Zhou, Chung Hin Chui, Kim Hung Lam, Simon Law, Albert Sun-chi Chan, Xingshu Li, Alfred King-yin Lam, Johnny Cheuk On Tang
    Cells.2018; 7(10): 143.     CrossRef
  • Targeting DNA Binding for NF-κB as an Anticancer Approach in Hepatocellular Carcinoma
    Po Chung, Pik Lam, Yuanyuan Zhou, Jessica Gasparello, Alessia Finotti, Adriana Chilin, Giovanni Marzaro, Roberto Gambari, Zhaoxiang Bian, Wai Kwok, Wai Wong, Xi Wang, Alfred Lam, Albert Chan, Xingshu Li, Jessica Ma, Chung Chui, Kim Lam, Johnny Tang
    Cells.2018; 7(10): 177.     CrossRef
  • 10,917 View
  • 255 Download
  • 20 Web of Science
  • 16 Crossref
Close layer
Studying the Effect of Downregulating Autophagy-Related Gene LC3 on TLR3 Apoptotic Pathway Mediated by dsRNA in Hepatocellular Carcinoma Cells
Guilan Wang, Maona Zhang, Yunlong Li, Jiaming Zhou, Li Chen
Cancer Res Treat. 2017;49(1):230-245.   Published online June 13, 2016
DOI: https://doi.org/10.4143/crt.2015.506
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to examine the role of the double-stranded RNA (dsRNA) activated Toll–interleukin-1 receptor domain-containing adaptor inducing interferon β (TRIF) signal pathway in triggering apoptosis in hepatocellular carcinoma (HCC) cells.
Materials and Methods
First, siRNA targeted autophagy–related gene LC3 (pU6H1-LC3 siRNA and siLC3) and a dsRNA used as a Toll-like receptor 3 (TLR3) ligand was constructed and synthesized, respectively. Then, a human HCC cell line was transfected with dsRNA, siLC3, and cotransfected with siLC3 and dsRNA (siLC3+dsRNA), respectively. Finally, quantification real-time polymerase chain reaction, western blotting, and immunofluorescence staining were used in the HCC line (SMMC7721), and MTT assay, flow cytometry, terminal deoxynucleotidyl transferase-mediated dUTP nick-end-labeling, and transmission electron microscopy were used in an HCC xenograft model of nude mice. Human umbilical vein endothelial cell tube forming assay, color Doppler ultrasonographic flow image examination, and CD34-positive microvessel density were used in vitro and in vivo.
Results
Compared with untreated cells, the protein and mRNA expression of TLR3 and TRIF was up-regulated, in order, siLC3+dsRNA, dsRNA, and siLC3. Expression of LC3 was obviously down-regulated and the autophagosomes were significantly decreased in siLC3+dsRNA and siLC3, whereas in dsRNA (p < 0.05). LC3 and TRIF colocation was observed in HepG2 cells. Decreased cell viability, increased apoptosis, decrease in xenograft tumor volume, and angiogenesis potential were also observed in order (p < 0.05).
Conclusion
Suppression of intracellular autophagy resulted in decreased degradation of TRIF protein, which can promote triggering of apoptosis by the TLR3-TRIF pathway. dsRNA and siLC3 could play anticancer roles in coordination.

Citations

Citations to this article as recorded by  
  • The Role of Autophagy in Liver Cancer: Crosstalk in Signaling Pathways and Potential Therapeutic Targets
    Jianzhou Cui, Han-Ming Shen, Lina Hsiu Kim Lim
    Pharmaceuticals.2020; 13(12): 432.     CrossRef
  • MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9
    Chuangzhou Rao, Xiaobo Miao, Guofang Zhao, Chen Zhang, Haibo Shen, Caijun Dong, Minglei Yang
    Biomedicine & Pharmacotherapy.2019; 114: 108662.     CrossRef
  • Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J
    Lin Shi, Zhaozhong Xu, Gang Wu, Xiaoting Chen, Yuanyuan Huang, Yanjing Wang, Weiqiang Jiang, Bin Ke
    BMC Cancer.2017;[Epub]     CrossRef
  • 14,233 View
  • 181 Download
  • 7 Web of Science
  • 3 Crossref
Close layer
Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Hae Il Jung, Dongjun Jeong, Sanghee Ji, Tae Sung Ahn, Sang Ho Bae, Susie Chin, Jun Chul Chung, Hyung Chul Kim, Moon Soo Lee, Moo-Jun Baek
Cancer Res Treat. 2017;49(1):246-254.   Published online July 7, 2016
DOI: https://doi.org/10.4143/crt.2016.066
AbstractAbstract PDFPubReaderePub
Purpose
Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies. Recently, the overexpression of programmed cell death 1 (PD-1) and PD-1 ligand 1 (PD-L1) has been shown to correlate with poor prognosis in many cancers. However, the expression of PD-L1 or PD-1 ligand 2 (PD-L2) and clinical outcomes have not been fully investigated in HCC.
Materials and Methods
Formalin-fixed paraffin-embedded samples were obtained from 85 patients with HCC who underwent surgery. The expression of PD-Ls (PD-L1, PD-L2) was evaluated by immunohistochemical analysis.
Results
The proportion of high expression groups of PD-L1 and PD-L2 was 27.1% and 23.5%, respectively. Univariate analysis revealed that tumor size (p < 0.001), histological differentiation (p=0.010), PD-L1 expression (p < 0.001), and PD-L2 expression (p=0.039) were significant prognostic factors of overall survival in patients with HCC. Multivariate analysis revealed that overall tumor size (hazard ratio [HR], 4.131; 95% confidence interval [CI], 2.233 to 7.643; p < 0.001 and HR, 3.455; 95% CI, 1.967 to 6.067; p < 0.001) and PD-L1 expression (HR, 5.172; 95% CI, 2.661 to 10.054; p < 0.001 and HR, 3.730; 95% CI, 1.453 to 9.574; p=0.006) were independent prognostic values for overall and disease-free survival. Patients with high expression of PD-Ls had a significantly poorer survival than those with low expression (p < 0.001, p=0.034).
Conclusion
The overexpression of PD-Ls in HCC patients is correlated with survival and tumor recurrence. Further evaluation of PD-1 and PD-Ls as therapeutic targets and predictive biomarkers for HCC is warranted.

Citations

Citations to this article as recorded by  
  • The tumor microenvironment: a key player in multidrug resistance in cancer
    Lingnan Meng, Ying Zheng, Hao Liu, Daiming Fan
    Oncologie.2024; 26(1): 41.     CrossRef
  • MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
    Anju G. S. Phoolchund, Salim I. Khakoo
    Cancers.2024; 16(2): 259.     CrossRef
  • Codelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint Inhibitors
    Wookhyun Kim, Zhou Ye, Vera Simonenko, Aashirwad Shahi, Asra Malikzay, Steven Z Long, John J Xu, Alan Lu, Jau-Hau Horng, Chang-Ru Wu, Pei-Jer Chen, Patrick Y Lu, David M Evans
    NAR Cancer.2024;[Epub]     CrossRef
  • Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells
    Sua Cho, Wonjin Kim, Dayoung Yoo, Yeonju Han, Hyemin Hwang, Seunghwan Kim, Jimin Kim, Sanghee Park, Yusun Park, HanHee Jo, Jae-chul Pyun, Misu Lee
    Scientific Reports.2024;[Epub]     CrossRef
  • Exosomal circ_0032704 confers sorafenib resistance to hepatocellular carcinoma and contributes to cancer malignant progression by modulating the miR‐514a‐3p/PD‐L1 pathway
    Chengyun Dou, Hongbo Zhu, Xia Xie, Cuiqin Huang, Hui Tan, Chuangjie Cao
    Annals of Gastroenterological Surgery.2024; 8(3): 507.     CrossRef
  • A programmed cell death-related gene signature to predict prognosis and therapeutic responses in liver hepatocellular carcinoma
    Xinyu Gu, Jie Pan, Yanle Li, Liushun Feng
    Discover Oncology.2024;[Epub]     CrossRef
  • Programmed cell death-ligand 2: new insights in cancer
    Yukang Yang, Xia Yan, Xueqi Bai, Jiayang Yang, Jianbo Song
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Extracellular Vesicle-Related Non-Coding RNAs in Hepatocellular Carcinoma: An Overview
    Giuseppa Augello, Alessandra Cusimano, Melchiorre Cervello, Antonella Cusimano
    Cancers.2024; 16(7): 1415.     CrossRef
  • Programmed Death 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Gene Expression in Peripheral Blood Mononuclear Cells Can Serve as Prognostic Biomarkers for Hepatocellular Carcinoma
    Ji Ah Lee, Hei-Gwon Choi, Hyuk Soo Eun, Jiyoon Bu, Tae Min Jang, Jeongdong Lee, Chae Yeon Son, Min Seok Kim, Woo Sun Rou, Seok Hyun Kim, Byung Seok Lee, Ha Neul Kim, Tae Hee Lee, Hong Jae Jeon
    Cancers.2024; 16(8): 1493.     CrossRef
  • Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways
    Keith L. Knutson
    The Journal of Immunology.2024; 212(9): 1397.     CrossRef
  • Comparison of Clinical Trial Results of the Recently Approved Immunotherapeutic Drugs for Advanced Biliary Tract Cancers
    Samayita Das
    Reviews on Recent Clinical Trials.2024; 19(2): 81.     CrossRef
  • Gene signature developed based on programmed cell death to predict the therapeutic response and prognosis for liver hepatocellular carcinoma
    Lijun Tian, Yujie Sang, Bing Han, Yujing Sun, Xueyan Li, Yuemin Feng, Chengyong Qin, Jianni Qi
    Heliyon.2024; 10(14): e34704.     CrossRef
  • Immune cells and checkpoints in pancreatic adenocarcinoma: Association with clinical and pathological characteristics
    Maria Auxiliadora de Paula Carneiro Cysneiros, Magno Belém Cirqueira, Lucas de Figueiredo Barbosa, Ênio Chaves de Oliveira, Lucio Kenny Morais, Isabela Jubé Wastowski, Vitor Gonçalves Floriano, Afsheen Raza
    PLOS ONE.2024; 19(7): e0305648.     CrossRef
  • Synergistic upregulation of PD‑L1 in tumor cells and CD39 in tumor‑infiltrating CD8+ T cells leads to poor prognosis in patients with hepatocellular carcinoma
    Xi Kang, Sinan Zhao, Shan Lin, Jing Li, Shunxiang Wang
    Oncology Letters.2024;[Epub]     CrossRef
  • Prognostic factors for hepatocellular carcinoma recurrence after liver transplantation or resection – single-center experience
    Maciej Gryziak, Rafał Stec, Krzysztof Woźniak, Benedykt Szczepankiewicz, Maciej Krasnodębski, Michał Grąt, Leszek Kraj
    Heliyon.2024; 10(22): e40228.     CrossRef
  • Penfluridol suppresses MYC-driven ANLN expression and liver cancer progression by disrupting the KEAP1–NRF2 interaction
    Minh Tuan Nguyen, Gi Jeong Lee, Boram Kim, Hyun Ji Kim, Jihoon Tak, Mi Kyung Park, Eun Ji Kim, Gyeoung Jin Kang, Seung Bae Rho, Ho Lee, Kyung Lee, Sang Geon Kim, Chang Hoon Lee
    Pharmacological Research.2024; 210: 107512.     CrossRef
  • Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma
    Mahsa Pourhamzeh, Samieh Asadian, Hamed Mirzaei, Azita Minaei, Elahe Shahriari, Anastasia Shpichka, Hamidreza Aboulkheyr Es, Peter Timashev, Moustapha Hassan, Massoud Vosough
    Molecular and Cellular Biochemistry.2023; 478(1): 23.     CrossRef
  • Immunohistochemical expression of immune check point protein PDL-1 in hepatocellular carcinoma denotes its prognostic significance and association with survival
    Dina Omar Helmy, Fatma Khattab, Azza Elsayed Hegazy, Rania Mohamed Sabry
    Journal of Immunoassay and Immunochemistry.2023; 44(3): 213.     CrossRef
  • HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma
    Hongxia Cheng, Sikai Wang, Aidan Huang, Jing Ma, Dongmei Gao, Miaomiao Li, Huaping Chen, Kun Guo
    Cancer Biology & Therapy.2023; 24(1): 1.     CrossRef
  • Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
    Cedric Brackenier, Lisa Kinget, Sarah Cappuyns, Chris Verslype, Benoit Beuselinck, Jeroen Dekervel
    Cancers.2023; 15(2): 348.     CrossRef
  • Radiomic Analysis Based on Magnetic Resonance Imaging for Predicting PD-L2 Expression in Hepatocellular Carcinoma
    Yun-Yun Tao, Yue Shi, Xue-Qin Gong, Li Li, Zu-Mao Li, Lin Yang, Xiao-Ming Zhang
    Cancers.2023; 15(2): 365.     CrossRef
  • Network Analysis for the Discovery of Common Oncogenic Biomarkers in Liver Cancer Experimental Models
    Loraine Cabral, Pablo Giraudi, Gianluigi Giannelli, Francesco Dituri, Roberto Negro, Claudio Tiribelli, Caecilia Sukowati
    Biomedicines.2023; 11(2): 342.     CrossRef
  • Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment
    Muhammad Joan Ailia, Jeong Heo, So Young Yoo
    International Journal of Molecular Sciences.2023; 24(7): 6495.     CrossRef
  • Current Trends in Immuno-Oncology
    Tulsi Dipakbhai Patel, Venkata Gangadhar Vanteddu, Bawari Sweta
    Cardiovascular & Hematological Agents in Medicinal Chemistry.2023; 21(2): 96.     CrossRef
  • Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
    Feng Xian, Dacheng Ren, Jun Bie, Guohui Xu
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • SYVN1 ubiquitinates FoxO1 to induce β-catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma
    Wei Xie, Lei Shi, Hu Quan, Hua Xiao, Jie Chen, Jia Liu, Jean de Dieu Habimana, Rongqi Huang, Jia Luo, Pan Chen, Zhiyuan Li
    Cellular Oncology.2023; 46(5): 1285.     CrossRef
  • Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma
    Xue-Qin Gong, Ning Liu, Yun-Yun Tao, Li Li, Zu-Mao Li, Lin Yang, Xiao-Ming Zhang
    Scientific Reports.2023;[Epub]     CrossRef
  • Potential Immunotherapy Targets for Liver-Directed Therapies, and the Current Scope of Immunotherapeutics for Liver-Related Malignancies
    Jonathan Charles, Andrea Vrionis, Arian Mansur, Trevor Mathias, Jamil Shaikh, Aaron Ciner, Yixing Jiang, Nariman Nezami
    Cancers.2023; 15(9): 2624.     CrossRef
  • The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma
    Nicolò Brandi, Matteo Renzulli
    International Journal of Molecular Sciences.2023; 24(10): 8598.     CrossRef
  • PD-L1 is Fascinating but IDO Needs Attention in Non-HCV and Non-HBV-Associated Hepatocellular Carcinoma Patients
    Kashif Asghar, Shaarif Bashir, Iftikhar Ali Rana, Muhammad Abu Bakar, Asim Farooq, Muhammad Hassan, Zukhruf Asif, Mahnoor Afzal, Iqra Masood, Muhammad Ishaq, Muhammad Tahseen, Sundus Bilal, Shafqat Mehmood, Nosheen Kanwal, Islah Ud Din, Asif Loya
    Journal of Hepatocellular Carcinoma.2023; Volume 10: 921.     CrossRef
  • Co-Expression of Immunohistochemical Markers MRP2, CXCR4, and PD-L1 in Gallbladder Tumors Is Associated with Prolonged Patient Survival
    Andrés Tittarelli, Omar Barría, Evy Sanders, Anna Bergqvist, Daniel Uribe Brange, Mabel Vidal, María Alejandra Gleisner, Jorge Ramón Vergara, Ignacio Niechi, Iván Flores, Cristián Pereda, Cristian Carrasco, Claudia Quezada-Monrás, Flavio Salazar-Onfray
    Cancers.2023; 15(13): 3440.     CrossRef
  • Oncoviruses: How do they hijack their host and current treatment regimes
    Kainat Ahmed, Sudhakar Jha
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2023; 1878(5): 188960.     CrossRef
  • Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors
    Ludovico Abenavoli, Michele Montori, Gianluca Svegliati Baroni, Maria Eva Argenziano, Francesca Giorgi, Giuseppe Guido Maria Scarlata, Francesca Ponziani, Emidio Scarpellini
    Medicina.2023; 59(8): 1427.     CrossRef
  • PD-L1 Downregulation and DNA Methylation Inhibition for Molecular Therapy against Cancer Stem Cells in Hepatocellular Carcinoma
    Caecilia Sukowati, Loraine Kay D. Cabral, Beatrice Anfuso, Francesco Dituri, Roberto Negro, Gianluigi Giannelli, Claudio Tiribelli
    International Journal of Molecular Sciences.2023; 24(17): 13357.     CrossRef
  • Autophagy as a Target for Non-Immune Intrinsic Functions of Programmed Cell Death-Ligand 1 in Cancer
    Blanca Estela García-Pérez, Christian Pérez-Torres, Shantal Lizbeth Baltierra-Uribe, Juan Castillo-Cruz, Nayeli Shantal Castrejón-Jiménez
    International Journal of Molecular Sciences.2023; 24(19): 15016.     CrossRef
  • The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma
    Liqiu Kou, Xiaolu Xie, Xiu Chen, Bo Li, Jun Li, Yaling Li
    Cancer Immunology, Immunotherapy.2023; 72(12): 3953.     CrossRef
  • Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers
    Guoying Zhou, Patrick P. C. Boor, Marco J. Bruno, Dave Sprengers, Jaap Kwekkeboom
    British Journal of Cancer.2022; 126(1): 10.     CrossRef
  • Synergistic antitumor efficacy of PD-1-conjugated PTX- and ZSQ-loaded nanoliposomes against multidrug-resistant liver cancers
    Mingjia Gu, Fang Yin, Yuening Qin, Yali Tian, Xinjie Xiu, Hanjing Shen, Jiebin Zhu
    Drug Delivery and Translational Research.2022; 12(10): 2550.     CrossRef
  • Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data
    Uasim Harkus, Miriam Wankell, Pranavan Palamuthusingam, Craig McFarlane, Lionel Hebbard
    Seminars in Cancer Biology.2022; 86: 799.     CrossRef
  • Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis
    Ramy R. Saleh, Jordan L. Scott, Nicholas Meti, Danielle Perlon, Rouhi Fazelzad, Alberto Ocana, Eitan Amir
    Molecular Diagnosis & Therapy.2022; 26(2): 153.     CrossRef
  • Identification of Potential Immune Checkpoint Inhibitor Targets in Gliomas via Bioinformatic Analyses
    Mengmeng Ding, Yong-an Li, Zhimin Lu, Guoxin Hou, Aziz ur Rehman Aziz
    BioMed Research International.2022; 2022: 1.     CrossRef
  • LINC00244 suppresses cell growth and metastasis in hepatocellular carcinoma by downregulating programmed cell death ligand 1
    Zhijia Sun, Chunyuan Xue, Jiangbo Li, Hui Zhao, Yimeng Du, Nan Du
    Bioengineered.2022; 13(3): 7635.     CrossRef
  • Metformin modulate immune fitness in hepatocellular carcinoma: Molecular and cellular approach
    Eslam E. Abd El-Fattah, Amr Y. Zakaria
    International Immunopharmacology.2022; 109: 108889.     CrossRef
  • Association of Increased Programmed Death Ligand 1 Expression and Regulatory T Cells Infiltration with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection
    Long-Bin Jeng, Tsai-Chung Li, Shih-Chao Hsu, Chiao-Fang Teng
    Viruses.2022; 14(6): 1346.     CrossRef
  • Risk predictive model based on three immune-related gene pairs to assess prognosis and therapeutic sensitivity for hepatocellular carcinoma
    Baifeng Qian, Haozhong Lin, Tian Lan, Muqi Li, Xiwen Wu, Shuirong Lin, Zimin Song, Shunli Shen, Baogang Peng
    World Journal of Surgical Oncology.2022;[Epub]     CrossRef
  • Pilot Study: Immune Checkpoints Polymorphisms in Greek Primary Breast Cancer Patients
    Nyanbol Kuol, Xu Yan, Vanessa Barriga, Jimsheena Karakkat, Stamatis Vassilaros, Ioannis Fyssas, Anastasios Tsimpanis, Sarah Fraser, Kulmira Nurgali, Vasso Apostolopoulos
    Biomedicines.2022; 10(8): 1827.     CrossRef
  • Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma
    Shengkui Tan, Xuefeng Guo, Chunhua Bei, Huixia Zhang, Di Li, Xiaonian Zhu, Hongzhuan Tan
    BMC Cancer.2022;[Epub]     CrossRef
  • PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity
    Shuang Guo, Xinyue Wang, Hanxiao Zhou, Yue Gao, Peng Wang, Hui Zhi, Yue Sun, Yakun Zhang, Jing Gan, Yun Xiao, Shangwei Ning
    Biomolecules.2022; 12(9): 1226.     CrossRef
  • The Clinicopathological Significance and Prognostic Value of PD-L2 in Patients with HCC, ICC and PAAD: A Meta-Analysis
    Meng Gao, Yonghua Guo, Jinghua Li, Xi Chen, Yufeng Yuan, Weijie Ma
    International Journal of Surgery Oncology.2022; 7(1): 81.     CrossRef
  • Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells
    Enrico Munari, Linda Quatrini, Cecilia Ciancaglini, Albino Eccher, Giuseppe Bogina, Lorenzo Moretta, Francesca Romana Mariotti
    Seminars in Immunology.2022; 61-64: 101660.     CrossRef
  • A retrospective study of PD-L1 immunohistochemistry for hepatocellular carcinoma
    Min Du, Yumeng Cai, Yanrui Pang, Yuan Ji
    iLIVER.2022; 1(3): 187.     CrossRef
  • Highlighting novel targets in immunotherapy for liver cancer
    Samantha M. Ruff, Alexander H. Shannon, Joal D. Beane, Timothy M. Pawlik
    Expert Review of Gastroenterology & Hepatology.2022; 16(11-12): 1029.     CrossRef
  • Hepatocellular Carcinoma: Current Therapeutic Algorithm for Localized and Advanced Disease
    Anju Jose, Maria Grazia Bavetta, Erika Martinelli, Fabrizio Bronte, Emilio Francesco Giunta, Kanjoormana Aryan Manu, Alessandro Granito
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma
    Fei Fan, Keji Chen, Xiaoliang Lu, Aijun Li, Caifeng Liu, Bin Wu
    Hepatology International.2021; 15(2): 444.     CrossRef
  • High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence
    Ryo Muranushi, Kenichiro Araki, Takehiko Yokobori, Batbayar Chingunjav, Kouki Hoshino, Gantumur Dolgormaa, Kei Hagiwara, Takahiro Yamanaka, Norihiro Ishii, Mariko Tsukagoshi, Takamichi Igarashi, Akira Watanabe, Norio Kubo, Norifumi Harimoto, Yuki Shimoda,
    Cancer Science.2021; 112(8): 3314.     CrossRef
  • Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers
    Qingzhu Liu, Lei Jiang, Ke Li, Hang Li, Gaochao Lv, Jianguo Lin, Ling Qiu
    Cancer Immunology, Immunotherapy.2021; 70(6): 1721.     CrossRef
  • ANO9 regulates PD‐L2 expression and binding ability to PD‐1 in gastric cancer
    Keita Katsurahara, Atsushi Shiozaki, Toshiyuki Kosuga, Hiroki Shimizu, Michihiro Kudou, Tomohiro Arita, Hirotaka Konishi, Shuhei Komatsu, Takeshi Kubota, Hitoshi Fujiwara, Kazuma Okamoto, Mitsuo Kishimoto, Eiichi Konishi, Eigo Otsuji
    Cancer Science.2021; 112(3): 1026.     CrossRef
  • Association between PD-L1 expression and 18F-FDG uptake in ovarian cancer
    Yun Jung Choi, KwanHyeong Jo, Sang Hyun Hwang, YongHyu Jeong, Jung-Yun Lee, Sunghoon Kim, Sang Wun Kim, Young Tae Kim, Won Jun Kang
    Annals of Nuclear Medicine.2021; 35(4): 415.     CrossRef
  • Association of TNIP1 polymorphisms with hepatocellular carcinoma in a Northwest Chinese Han population
    Yuting Shi, Lihua Zhang, Yang Bao, Pengfei Wu, Xiaoli Zhang
    Medicine.2021; 100(12): e24843.     CrossRef
  • PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research
    Yu Zhang, Guang-Ze Mou, Tian-Zhu Li, Wan-Ting Xu, Tong Zhang, Hui Xue, Wen-Bo Zuo, Yan-Nan Li, Ying-Hua Luo, Cheng-Hao Jin
    Technology in Cancer Research & Treatment.2021;[Epub]     CrossRef
  • High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition
    Nishant Thakur, Kwang Yeol Paik, Gyoyeon Hwang, Yosep Chong
    Diagnostics.2021; 11(4): 597.     CrossRef
  • ALPPS Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma
    Albert Chan, Wei Yi Zhang, Kenneth Chok, Jeff Dai, Ren Ji, Crystal Kwan, Nancy Man, Ronnie Poon, Chung Mau Lo
    Annals of Surgery.2021; 273(5): 957.     CrossRef
  • Hepatitis B Virus Pre-S Gene Deletions and Pre-S Deleted Proteins: Clinical and Molecular Implications in Hepatocellular Carcinoma
    Yueh-Te Lin, Long-Bin Jeng, Wen-Ling Chan, Ih-Jen Su, Chiao-Fang Teng
    Viruses.2021; 13(5): 862.     CrossRef
  • The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
    Patrizia Leone, Antonio Giovanni Solimando, Rossella Fasano, Antonella Argentiero, Eleonora Malerba, Alessio Buonavoglia, Luigi Giovanni Lupo, Valli De Re, Nicola Silvestris, Vito Racanelli
    Vaccines.2021; 9(5): 532.     CrossRef
  • Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?
    Alice Boilève, Marc Hilmi, Matthieu Delaye, Annemilaï Tijeras-Raballand, Cindy Neuzillet
    Cancers.2021; 13(11): 2708.     CrossRef
  • Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma
    Qianhui Gu, Jing Li, Zhuolin Chen, Jie Zhang, Hui Shen, Xiaobing Miao, Ying Zhou, Xiaohong Xu, Song He
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells
    Caecilia H C Sukowati, Korri Elvanita El-Khobar, Claudio Tiribelli
    World Journal of Stem Cells.2021; 13(7): 795.     CrossRef
  • Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
    Alessandro Di Federico, Andrea De Giglio, Claudia Parisi, Francesco Gelsomino, Luca Boni, Andrea Ardizzoni
    JTO Clinical and Research Reports.2021; 2(9): 100214.     CrossRef
  • Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment
    Min Luo, Yan Lin, Rong Liang, Yongqiang Li, Lianying Ge
    Journal of Inflammation Research.2021; Volume 14: 4217.     CrossRef
  • Tumor Mutation Burden-Associated LINC00638/miR-4732-3p/ULBP1 Axis Promotes Immune Escape via PD-L1 in Hepatocellular Carcinoma
    Feng Qi, Xiaojing Du, Zhiying Zhao, Ding Zhang, Mengli Huang, Yuezong Bai, Biwei Yang, Wenxing Qin, Jinglin Xia
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model
    Shahrokh Abdolahi, Zeinab Ghazvinian, Samad Muhammadnejad, Mohammad Ahmadvand, Hamid Asadzadeh Aghdaei, Somayeh Ebrahimi-Barough, Jafar Ai, Mohammad Reza Zali, Javad Verdi, Kaveh Baghaei
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy
    Rossella Fasano, Mahdi Abdoli Shadbad, Oronzo Brunetti, Antonella Argentiero, Angela Calabrese, Patrizia Nardulli, Roberto Calbi, Behzad Baradaran, Nicola Silvestris
    Life.2021; 11(12): 1355.     CrossRef
  • An RNA–RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity
    Yanping Wei, Xuewu Tang, Yibin Ren, Yun Yang, Fengliang Song, Jingbo Fu, Shuowu Liu, Miao Yu, Jing Chen, Suyang Wang, Kecheng Zhang, Yexiong Tan, Zhipeng Han, Lixin Wei, Baohua Zhang, Zhangjun Cheng, Liang Li, Hongyang Wang
    Signal Transduction and Targeted Therapy.2021;[Epub]     CrossRef
  • Identification and Validation of a Prognostic Prediction Model of m6A Regulator-Related LncRNAs in Hepatocellular Carcinoma
    Chen Jin, Rui Li, Tuo Deng, Jialiang Li, Yan Yang, Haoqi Li, Kaiyu Chen, Huihua Xiong, Gang Chen, Yi Wang
    Frontiers in Molecular Biosciences.2021;[Epub]     CrossRef
  • Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
    Huang Ao, Zhang Xin, Zhou Jian
    Biomarker Research.2021;[Epub]     CrossRef
  • Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
    Vishakha Singh, Amit Khurana, Prince Allawadhi, Anil Kumar Banothu, Kala Kumar Bharani, Ralf Weiskirchen
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis
    Cheng Zeng, Shaojun Ye, Yu Chen, Qu Zhang, Yan Luo, Liang Gai, Bo Luo, Xiao-Jie Lu
    Journal of Immunology Research.2021; 2021: 1.     CrossRef
  • Construction and validation of an N6‑methyladenosine‑associated prognostic signature in hepatocellular carcinoma
    Peng Zhu, Qianqian Ren, Nan He, Cheng Zhou, Qianna Jin, Zhao Gong
    Oncology Letters.2021;[Epub]     CrossRef
  • Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials
    Yangxun Pan, Ruojing Wang, Dandan Hu, Wa Xie, Yizhen Fu, Jiajie Hou, Li Xu, Yaojun Zhang, Minshan Chen, Zhongguo Zhou
    Frontiers in Bioscience-Landmark.2021;[Epub]     CrossRef
  • Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?
    Hye Won Lee, Kyung Joo Cho, Jun Yong Park
    Immune Network.2020;[Epub]     CrossRef
  • Developments in predictive biomarkers for hepatocellular carcinoma therapy
    Andrea Casadei-Gardini, Orsi Giulia, Caputo Francesco, Ercolani Giorgio
    Expert Review of Anticancer Therapy.2020; 20(1): 63.     CrossRef
  • Immune-based therapies for hepatocellular carcinoma
    David J. Pinato, Nadia Guerra, Petros Fessas, Ravindhi Murphy, Takashi Mineo, Francesco A. Mauri, Sujit K. Mukherjee, Mark Thursz, Ching Ngar Wong, Rohini Sharma, Lorenza Rimassa
    Oncogene.2020; 39(18): 3620.     CrossRef
  • Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
    Xiao-Song Li, Jun-Wei Li, Hui Li, Tao Jiang
    Bioscience Reports.2020;[Epub]     CrossRef
  • Polymorphisms in Interleukin 13 Signaling and Interacting Genes Predict Advanced Fibrosis and Hepatocellular Carcinoma Development in Non-Alcoholic Steatohepatitis
    Marwa O. El-Derany
    Biology.2020; 9(4): 75.     CrossRef
  • PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions
    Yu Toda, Kenichi Kohashi, Yuichi Yamada, Masato Yoshimoto, Shin Ishihara, Yoshihiro Ito, Takeshi Iwasaki, Hidetaka Yamamoto, Yoshihiro Matsumoto, Yasuharu Nakashima, Masaaki Mawatari, Yoshinao Oda
    Journal of Cancer Research and Clinical Oncology.2020; 146(10): 2607.     CrossRef
  • The roles of programmed death ligand 1 in virus-associated cancers
    Morvarid Golrokh Mofrad, Donya Taghizadeh Maleki, Ebrahim Faghihloo
    Infection, Genetics and Evolution.2020; 84: 104368.     CrossRef
  • Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis
    Jinlan Piao, Hyun Ji Lim, Maria Lee
    Obstetrics & Gynecology Science.2020; 63(3): 346.     CrossRef
  • Downexpression of HSD17B6 correlates with clinical prognosis and tumor immune infiltrates in hepatocellular carcinoma
    Lei Lv, Yujia Zhao, Qinqin Wei, Ye Zhao, Qiyi Yi
    Cancer Cell International.2020;[Epub]     CrossRef
  • Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer
    Heejae Lee, Young-Ae Kim, Youngho Kim, Hye Seon Park, Jeong-Han Seo, Hyun Lee, Gyungyub Gong, Hee Jin Lee
    Cancer Immunology, Immunotherapy.2020; 69(11): 2381.     CrossRef
  • TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma
    Ritu Shrestha, Kim Bridle, Darrell Crawford, Aparna Jayachandran
    Molecular Medicine Reports.2020;[Epub]     CrossRef
  • Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines
    Qian Qian, Changping Wu, Jianping Chen, Weibing Wang
    BioMed Research International.2020; 2020: 1.     CrossRef
  • Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden
    Annie He Ren, Ioannis Prassas, Antoninus Soosaipillai, Stephanie Jarvi, Steven Gallinger, Vathany Kulasingam, Eleftherios P. Diamandis
    F1000Research.2020; 9: 732.     CrossRef
  • Integrative bioinformatics analysis of a prognostic index and immunotherapeutic targets in renal cell carcinoma
    Hongmiao Tao, Zeyu Li, Yuan Mei, Xiaoling Li, Hongqiang Lou, Lihua Dong, Liangcheng Zhou
    International Immunopharmacology.2020; 87: 106832.     CrossRef

  • Development and Validation of a Novel 8 Immune Gene Prognostic Signature Based on the Immune Expression Profile for Hepatocellular Carcinoma


    Dafeng Xu, Yu Wang, Kailun Zhou, Jincai Wu, Zhensheng Zhang, Jiachao Zhang, Zhiwei Yu, Luzheng Liu, Xiangmei Liu, Bidan Li, Jinfang Zheng
    OncoTargets and Therapy.2020; Volume 13: 8125.     CrossRef
  • New landscapes and horizons in hepatocellular carcinoma therapy
    Melchiorre Cervello, Maria R. Emma, Giuseppa Augello, Antonella Cusimano, Lydia Giannitrapani, Maurizio Soresi, Shaw M. Akula, Stephen L. Abrams, Linda S. Steelman, Alessandro Gulino, Beatrice Belmonte, Giuseppe Montalto, James A. McCubrey
    Aging.2020; 12(3): 3053.     CrossRef
  • Immuno-oncology for Hepatocellular Carcinoma
    Samantha A. Armstrong, Aiwu Ruth He
    Clinics in Liver Disease.2020; 24(4): 739.     CrossRef
  • Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis
    Xiaochun Lin, Kunpeng Lin, Chunxuan Lin, Jiakang Wang, Yunqiang Tang
    International Immunopharmacology.2020; 88: 106946.     CrossRef
  • Immunotherapy for Hepatocellular Carcinoma: A 2021 Update
    Christo Kole, Nikolaos Charalampakis, Sergios Tsakatikas, Michail Vailas, Dimitrios Moris, Efthymios Gkotsis, Stylianos Kykalos, Michalis V. Karamouzis, Dimitrios Schizas
    Cancers.2020; 12(10): 2859.     CrossRef
  • Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations
    Qi Zhang, Yiwen Chen, Xueli Bai, Tingbo Liang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
    Piera Federico, Angelica Petrillo, Pasqualina Giordano, Davide Bosso, Antonietta Fabbrocini, Margaret Ottaviano, Mario Rosanova, Antonia Silvestri, Andrea Tufo, Antonio Cozzolino, Bruno Daniele
    Cancers.2020; 12(10): 3025.     CrossRef
  • Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
    Yuqing Cao, Xiaoyu Wang, Tianqiang Jin, Yu Tian, Chaoliu Dai, Crystal Widarma, Rui Song, Feng Xu
    Signal Transduction and Targeted Therapy.2020;[Epub]     CrossRef
  • Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
    Yanjie Zhao, Feng Shi, Quan Zhou, Yuchen Li, Jiangping Wu, Ruibin Wang, Qingkun Song
    Medicine.2020; 99(45): e23172.     CrossRef
  • Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma
    Qiu-Ju Sheng, Wen-Yue Tian, Xiao-Guang Dou, Chong Zhang, Yan-Wei Li, Chao Han, Yao-Xin Fan, Ping-Ping Lai, Yang Ding
    World Journal of Gastrointestinal Oncology.2020; 12(11): 1255.     CrossRef
  • Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden
    Annie He Ren, Ioannis Prassas, Antoninus Soosaipillai, Stephanie Jarvi, Steven Gallinger, Vathany Kulasingam, Eleftherios P. Diamandis
    F1000Research.2020; 9: 732.     CrossRef
  • Comprehensive Assessment of PD-L1 and PD-L2 Dysregulation in Gastrointestinal Cancers
    Qijie Zhao, Jinan Guo, Yueshui Zhao, Jing Shen, Parham Jabbarzadeh Kaboli, Shixin Xiang, Fukuan Du, Xu Wu, Mingxing Li, Lin Wan, Xiang Li, Qinglian Wen, Jing Li, Chang Zou, Zhangang Xiao
    Epigenomics.2020; 12(24): 2155.     CrossRef
  • PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer
    Xiao-Li Wei, Xuan Luo, Hui Sheng, Yun Wang, Dong-Liang Chen, Jia-Ning Li, Feng-Hua Wang, Rui-Hua Xu
    Journal of Translational Medicine.2020;[Epub]     CrossRef
  • PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
    Lingyu Tian, Jiaqiang Ma, Lijie Ma, Bohao Zheng, Longzi Liu, Danjun Song, Yining Wang, Zhao Zhang, Qiang Gao, Kang Song, Xiaoying Wang
    World Journal of Surgical Oncology.2020;[Epub]     CrossRef

  • Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant


    Chiao-Fang Teng, Tsai-Chung Li, Ting Wang, Tzu-Hua Wu, John Wang, Han-Chieh Wu, Woei-Cherng Shyu, Ih-Jen Su, Long-Bin Jeng
    Journal of Hepatocellular Carcinoma.2020; Volume 7: 385.     CrossRef
  • Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma
    Bryan Mckiver, Mohamad Imad Damaj, Devanand Sarkar
    Gastrointestinal Disorders.2020; 2(4): 469.     CrossRef
  • Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1
    Naoshi Nishida, Kazuko Sakai, Masahiro Morita, Tomoko Aoki, Masahiro Takita, Satoru Hagiwara, Yoriaki Komeda, Mamoru Takenaka, Yasunori Minami, Hiroshi Ida, Kazuomi Ueshima, Kazuto Nishio, Masatoshi Kudo
    Liver Cancer.2020; 9(4): 426.     CrossRef
  • Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment
    Amblessed E. Onuma, Hongji Zhang, Hai Huang, Terence M. Williams, Anne Noonan, Allan Tsung
    Gene Expression.2020; 20(1): 53.     CrossRef
  • Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma
    Xue Han, Yang-kui Gu, Shao-long Li, Hao Chen, Min-shan Chen, Qing-qing Cai, Han-xia Deng, Meng-xuan Zuo, Jin-hua Huang
    Journal of Cancer Research and Clinical Oncology.2019; 145(2): 303.     CrossRef
  • Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives
    T. Mocan, Z. Sparchez, R. Craciun, C. N. Bora, D. C. Leucuta
    Clinical and Translational Oncology.2019; 21(6): 702.     CrossRef
  • Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile
    Manuel Weber, Falk Wehrhan, Christoph Baran, Abbas Agaimy, Maike Büttner‐Herold, Marco Kesting, Jutta Ries
    Cancer Medicine.2019; 8(3): 1124.     CrossRef
  • Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis
    Gao-Min Liu, Xu-Gang Li, Yao-Min Zhang
    Cancer Cell International.2019;[Epub]     CrossRef
  • Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas
    Takafumi Nakano, Katsumi Takizawa, Azusa Uezato, Kenichi Taguchi, Satoshi Toh, Muneyuki Masuda
    Oral Oncology.2019; 90: 30.     CrossRef
  • Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma
    Christian Ihling, Bartholomew Naughton, Yue Zhang, P. Alexander Rolfe, Eveline Frick-Krieger, Luigi M. Terracciano, Isabelle Dussault
    Frontiers in Medicine.2019;[Epub]     CrossRef
  • Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis
    Huayu Yang, Xiaoxiang Zhou, Lejia Sun, Yilei Mao
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in?
    Jared H. Gans, Jeffrey Lipman, Yosef Golowa, Milan Kinkhabwala, Andreas Kaubisch
    Seminars in Nuclear Medicine.2019; 49(3): 170.     CrossRef
  • Clinicopathological, Immune and Molecular Correlates of PD-L2 Methylation in Gastric Adenocarcinomas
    Philipp Lingohr, Jonas Dohmen, Alexander Semaan, Vittorio Branchi, Jörn Dietrich, Friedrich Bootz, Jörg C Kalff, Hanno Matthaei, Dimo Dietrich
    Epigenomics.2019; 11(6): 639.     CrossRef
  • Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors
    Yutaka Fujiwara, Haruo Iguchi, Noboru Yamamoto, Manabu Hayama, Masahiro Nii, Shinya Ueda, Keiko Komuro, Mariko Sugimoto, Gordana Vlahovic, Toshiyuki Kozuki
    Cancer Science.2019; 110(5): 1715.     CrossRef
  • Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study
    Lin Wang
    Journal of Ovarian Research.2019;[Epub]     CrossRef
  • Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges
    Lifeng Wang, Fu-Sheng Wang
    Hepatology International.2019; 13(5): 521.     CrossRef
  • Histology of Hepatocellular Carcinoma: Association with Clinical Features, Radiological Findings, and Locoregional Therapy Outcomes
    Benjamin V. Park, Ron C. Gaba, Yu-Hui Huang, Yi-Fan Chen, Grace Guzman, R. Peter Lokken
    Journal of Clinical Imaging Science.2019; 9: 52.     CrossRef
  • Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
    Valli De Re, Laura Caggiari, Ombretta Repetto, Lara Mussolin, Maurizio Mascarin
    Journal of Clinical Medicine.2019; 8(10): 1596.     CrossRef
  • A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma
    Yiyin Zhang, Jin Xu, Jie Hua, Jiang Liu, Chen Liang, Qingcai Meng, Miaoyan Wei, Bo Zhang, Xianjun Yu, Si Shi
    Journal for ImmunoTherapy of Cancer.2019;[Epub]     CrossRef
  • Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
    Zuzana Macek Jilkova, Caroline Aspord, Thomas Decaens
    Cancers.2019; 11(10): 1554.     CrossRef
  • Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma
    Hye Won Lee, Kyung Joo Cho, Soon Young Shin, Ha Yan Kim, Eun Ju Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han
    Journal of Liver Cancer.2019; 19(2): 108.     CrossRef
  • Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
    Haotian Liao, Wen Chen, Yunlu Dai, Joseph J. Richardson, Junling Guo, Kefei Yuan, Yong Zeng, Kunlin Xie
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Significance of PD‑L1 clones and C‑MET expression in hepatocellular carcinoma
    Hyung‑Wook Chun, Ran Hong
    Oncology Letters.2019;[Epub]     CrossRef
  • Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade
    Hong Jae Chon, Won Suk Lee, Hannah Yang, So Jung Kong, Na Keum Lee, Eun Sang Moon, Jiwon Choi, Eun Chun Han, Joo Hoon Kim, Joong Bae Ahn, Joo Hang Kim, Chan Kim
    Clinical Cancer Research.2019; 25(5): 1612.     CrossRef
  • Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database
    Neil Mehta, Jennifer L. Dodge, John P. Roberts, Francis Y. Yao
    American Journal of Transplantation.2018; 18(5): 1206.     CrossRef
  • Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers
    Belinda Lee, Ryan Hutchinson, Hui-Li Wong, Jeanne Tie, Tracy Putoczki, Ben Tran, Peter Gibbs, Michael Christie
    Seminars in Cancer Biology.2018; 52: 241.     CrossRef
  • PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma
    Dagmar Kollmann, Desislava Ignatova, Julia Jedamzik, Yun-Tsan Chang, Gerd Jomrich, Andreas Baierl, Dmitry Kazakov, Michal Michal, Lars E. French, Wolfram Hoetzenecker, Tobias Schatton, Reza Asari, Matthias Preusser, Michael Gnant, Emmanuella Guenova, Seba
    OncoImmunology.2018;[Epub]     CrossRef
  • PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
    Bingxin Zheng, Tingting Ren, Yi Huang, Kunkun Sun, Shidong Wang, Xing Bao, Kuisheng Liu, Wei Guo
    Journal of Hematology & Oncology.2018;[Epub]     CrossRef
  • Immunotherapy for pulmonary squamous cell carcinoma and colon carcinoma with pembrolizumab
    Yoshihiro Nozawa, Yuka Oka, Jun Oosugi, Shinichi Takemura
    Medicine.2018; 97(19): e0718.     CrossRef
  • Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
    Ioannis Zerdes, Alexios Matikas, Jonas Bergh, George Z. Rassidakis, Theodoros Foukakis
    Oncogene.2018; 37(34): 4639.     CrossRef
  • Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
    Jing-Hua Li, Wei-Jie Ma, Gang-Gang Wang, Xiang Jiang, Xi Chen, Long Wu, Zhi-Su Liu, Xian-Tao Zeng, Fu-Ling Zhou, Yu-Feng Yuan
    Frontiers in Immunology.2018;[Epub]     CrossRef
  • MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity
    Alisa B. Lee-Sherick, Kristen M. Jacobsen, Curtis J. Henry, Madeline G. Huey, Rebecca E. Parker, Lauren S. Page, Amanda A. Hill, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Craig T. Jordan, Deborah DeRyckere, Douglas K. Graham
    JCI Insight.2018;[Epub]     CrossRef
  • Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
    Jaafar Jaafar, Eugenio Fernandez, Heba Alwan, Jacques Philippe
    Endocrine Connections.2018; 7(5): R196.     CrossRef
  • Prognostic value of PD -L1 expression in patients with primary solid tumors
    Xiao Xiang, Peng-Cheng Yu, Di Long, Xiao-Li Liao, Sen Zhang, Xue-Mei You, Jian-Hong Zhong, Le-Qun Li
    Oncotarget.2018; 9(4): 5058.     CrossRef
  • CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia
    Alexander Semaan, Dimo Dietrich, Dominik Bergheim, Jörn Dietrich, Jörg C. Kalff, Vittorio Branchi, Hanno Matthaei, Glen Kristiansen, Hans-Peter Fischer, Diane Goltz
    Virchows Archiv.2017; 470(2): 185.     CrossRef
  • Soluble PD-L1 and prognosis of patients with hepatocellular carcinoma
    Cheng-Piao Luo, Han-Yue Mo, Ling-Ling Wu, Yun Ma, Ning-Fu Peng
    European Journal of Cancer.2017; 71: 117.     CrossRef
  • Immune checkpoints and their inhibition in cancer and infectious diseases
    Lydia Dyck, Kingston H.G. Mills
    European Journal of Immunology.2017; 47(5): 765.     CrossRef
  • Expression and prognostic significance of programmed death protein 1 and programmed death ligand‐1, and cytotoxic T lymphocyte‐associated molecule‐4 in hepatocellular carcinoma
    Hyeyoon Chang, Wonkyung Jung, Aeree Kim, Han Kyeom Kim, Wan Bae Kim, Ji Hoon Kim, Baek‐hui Kim
    APMIS.2017; 125(8): 690.     CrossRef
  • PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
    Junyu Long, Jianzhen Lin, Anqiang Wang, Liangcai Wu, Yongchang Zheng, Xiaobo Yang, Xueshuai Wan, Haifeng Xu, Shuguang Chen, Haitao Zhao
    Journal of Hematology & Oncology.2017;[Epub]     CrossRef
  • PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer
    Dagmar Kollmann, Thomas Schweiger, Stefan Schwarz, Desislava Ignatova, Yun-Tsan Chang, Gerrit Lewik, Sebastian F. Schoppmann, Wolfram Hoetzenecker, Walter Klepetko, Emmanuella Guenova, Konrad Hoetzenecker
    OncoImmunology.2017; 6(9): e1331194.     CrossRef
  • PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer
    Yanhua Wu, Donghui Cao, Limei Qu, Xueyuan Cao, Zhifang Jia, Tiancheng Zhao, Quan Wang, Jing Jiang
    Oncotarget.2017; 8(38): 64066.     CrossRef
  • 16,810 View
  • 741 Download
  • 158 Web of Science
  • 148 Crossref
Close layer
Meta-Analysises
Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
Yo-Han Cho, So Young Yoon, Soo-Nyung Kim
Cancer Res Treat. 2017;49(1):255-262.   Published online May 18, 2016
DOI: https://doi.org/10.4143/crt.2015.452
AbstractAbstract PDFPubReaderePub
Purpose
A meta-analysis was conducted to examine the question of whether combination regimens are more effective than monotherapy as a second-line chemotherapy in advanced gastric cancer.
Materials and Methods
The MEDLINE and the EMBASE databases and the Cochrane Central Register for Controlled Trials were searched using appropriate keywords. Only randomized controlled trials were eligible.
Results
Taxane-based study is rare; thus, four irinotecan-based studies were finally included in the meta-analysis. Out of 661 patients, 331 patients were assigned to combination therapy and 330 to monotherapy. Cisplatin or fluoropyrimidine (S-1 or 5-fluorouracil) was used as a combination partner to irinotecan. The pooled hazard ratio (HR) for overall survival (OS) and for progression-free survival (PFS) was 0.938 (95% confidence interval [CI], 0.796 to 1.104; p=0.442) and 0.815 (95% CI, 0.693 to 0.958; p=0.013). In subgroup analysis according to previous exposure to a partner agent, the PFS benefit of combination was observed only in the partially exposed group (HR, 0.784; 95% CI, 0.628 to 0.980; p=0.032).
Conclusion
Second-line irinotecan-based combination was not associated with increased OS, but with PFS benefit, which seemed particularly significant for patients receiving combination with a new agent.

Citations

Citations to this article as recorded by  
  • Camptothecin and Its Derivatives from Traditional Chinese Medicine in Combination with Anticancer Therapy Regimens: A Systematic Review and Meta-Analysis
    Paul O. Odeniran, Paradise Madlala, Nompumelelo P. Mkhwanazi, Mahmoud E. S. Soliman
    Cancers.2024; 16(22): 3802.     CrossRef
  • Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
    N. S. Besova, T. A. Titova, D. L. Stroyakovsky, E. V. Perminova, S. G. Bagrova, E. S. Obarevich, V. A. Gorbunova, E. V. Artamonova, I. S. Stilidi
    Medical Council.2019; (10): 100.     CrossRef
  • Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study
    Maria Di Bartolomeo, Monica Niger, Giuseppe Tirino, Angelica Petrillo, Rosa Berenato, Maria Maddalena Laterza, Filippo Pietrantonio, Federica Morano, Maria Antista, Sara Lonardi, Lorenzo Fornaro, Stefano Tamberi, Elisa Giommoni, Alberto Zaniboni, Lorenza
    Targeted Oncology.2018; 13(2): 227.     CrossRef
  • Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver
    Iera Hernandez-Unzueta, Aitor Benedicto, Elvira Olaso, Eduardo Sanz, Cristina Viera, Beatriz Arteta, Joana Márquez
    Oncology Letters.2017; 13(6): 4002.     CrossRef
  • 11,096 View
  • 216 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Adjuvant Chemotherapy for Advanced Gastric Cancer in Elderly and Non-elderly Patients: Meta-Analysis of Randomized Controlled Trials
Seong-Hwan Chang, Soo-Nyung Kim, Hye Jung Choi, Misuk Park, Rock Bum Kim, Se-Il Go, Won Sup Lee
Cancer Res Treat. 2017;49(1):263-273.   Published online July 5, 2016
DOI: https://doi.org/10.4143/crt.2016.054
AbstractAbstract PDFPubReaderePub
Purpose
This study evaluated the benefits of adjuvant chemotherapy on elderly patients with advanced gastric cancer (AGC) using meta-analysis of well-designed randomized controlled clinical studies.
Materials and Methods
PubMed, Embase, and Cochrane were searched to retrieve clinical studies evaluating the benefits of adjuvant chemotherapy in the elderly with AGC. Hazards ratios (HRs) with 95% confidence intervals (CIs) were pooled across studies using a fixed-effects model.
Results
Two studies were included in this meta-analysis to estimate HR for the overall survival (OS), and relapse-free survival (RFS) between adjuvant chemotherapy and surgery in elderly and non-elderly patients. HR for OS in the elderly and non-elderly was 0.745 (95% CI, 0.552 to 1.006, p=0.055) and 0.636 (95% CI, 0.522 to 0.776; p < 0.001), respectively, which showed no heterogeneity regarding HR between the two groups (pinteraction=0.389). HR for RFS in the elderly and non-elderly was 0.613 (95% CI, 0.466 to 0.806; p < 0.001) and 0.633 (95% CI, 0.533 to 0.753; p < 0.001), respectively (pinteraction=0.846).
Conclusion
Meta-analysis suggests that the benefit of adjuvant chemotherapy to the elderly is not big enough to reach statistical significance while the HR for OS is less than 1 (0.745) and no heterogeneity are observed regarding the HR between the elderly and non-elderly patients.

Citations

Citations to this article as recorded by  
  • State of the scientific evidence and recommendations for the management of older patients with gastric cancer
    Irene Paredero-Pérez, Paula Jimenez-Fonseca, Juana María Cano, Virginia Arrazubi, Alberto Carmona-Bayonas, Marta Covela-Rúa, Ana Fernández-Montes, Marta Martín-Richard, Regina Gironés-Sarrió
    Journal of Geriatric Oncology.2024; 15(3): 101657.     CrossRef
  • Surgical options and survival prognosis in geriatric patients beyond average lifespan with locally advanced gastric cancer: a propensity score-matched analysis
    Zhen Tian, Mingyu Xia, Yifan Cheng, Jiajie Zhou, Ruiqi Li, Shuai Zhao, Qiannan Sun, Daorong Wang
    Surgical Endoscopy.2024; 38(5): 2756.     CrossRef
  • Prognostic factors and the necessity of chemotherapy for stage II gastric cancer: a model based on multicenter retrospective study
    Jiaming Fang, Feiyang Zhang, Jun Lu, Zijian Deng, Xianzhe Li, Xijie Chen, Changming Huang, Yingbo Chen, Lei Lian, Junsheng Peng, Shi Chen
    Discover Oncology.2023;[Epub]     CrossRef
  • Adjuvant Chemotherapy in Older Patients with Gastric Cancer: A Population-Based Cohort Study
    Wing-Lok Chan, Xiaodong Liu, Carlos King-Ho Wong, Michael Siu-Nam Wong, Ian Yu-Hong Wong, Ka-On Lam, Bryan Ho-Kwan Yun, Emina Edith Cheung, Rosa Pui-Ying Tse, Fion Chan, Simon Law, Dora Kwong
    Cancers.2023; 15(15): 3768.     CrossRef
  • The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study
    Yu-Hsuan Shih, Hsin-Chen Lin, Po-Wei Liao, Cheng-Wei Chou, Cheng-Hsien Lin, Chiann-Yi Hsu, Chieh-Lin Jerry Teng, Feng-Hsu Wu, Shao-Ciao Luo, Shao-Hsuan Kao
    BMC Cancer.2023;[Epub]     CrossRef
  • Age dependent benefit of neoadjuvant treatment in adenocarcinoma of the esophagus and gastroesophageal junction – a multicenter retrospective observational study of young versus old patients
    Ingmar F. Rompen, Nerma Crnovrsanin, Henrik Nienhüser, Kerstin Neuschütz, Lana Fourie, Leila Sisic, Beat P. Müller-Stich, Adrian T. Billeter
    International Journal of Surgery.2023;[Epub]     CrossRef
  • Long-Term Survival Outcomes of Elderly Patients Treated With S-1 or Capecitabine Plus Oxaliplatin for Stage II or III Gastric Cancer: A Multicenter Cohort Study
    Seohee Choi, Jae-Seok Min, Sang-Ho Jeong, Moon-Won Yoo, Young-Gil Son, Sung Jin Oh, Jong-Han Kim, Joong-Min Park, Hoon Hur, Ye Seob Jee, Sun-Hwi Hwang, Sung-Ho Jin, Sang Eok Lee, Young-Joon Lee, Kyung Won Seo, Sungsoo Park, Chang Min Lee, Chang Hyun Kim,
    Journal of Gastric Cancer.2022; 22(1): 67.     CrossRef
  • Considerations and Challenges in the Management of the Older Patients with Gastric Cancer
    Sotiris Loizides, Demetris Papamichael
    Cancers.2022; 14(6): 1587.     CrossRef
  • Surgical Oncology and Geriatric Patients
    Michael E. Johnston, Jeffrey J. Sussman, Sameer H. Patel
    Clinics in Geriatric Medicine.2019; 35(1): 53.     CrossRef
  • Optimal treatment for elderly patients with resectable proximal gastric carcinoma: a real world study based on National Cancer Database
    Xuefei Wang, Junjie Zhao, Mark Fairweather, Tingsong Yang, Yihong Sun, Jiping Wang
    BMC Cancer.2019;[Epub]     CrossRef
  • Thalidomide combined with chemotherapy in treating elderly patients with advanced gastric cancer
    Ya Li, Yanjun Chu, Ruifeng Song, Feng Xu
    Aging Clinical and Experimental Research.2018; 30(5): 499.     CrossRef
  • Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study
    Deng-Feng Ren, Fang-Chao Zheng, Jun-Hui Zhao, Guo-Shuang Shen, Raees Ahmad, Shui-Sheng Zhang, Yu Zhang, Jie Kan, Li Dong, Zi-Yi Wang, Fu-Xing Zhao, Jiu-Da Zhao
    World Journal of Clinical Cases.2018; 6(10): 373.     CrossRef
  • Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy
    Yuhree Kim, Malcolm H. Squires, George A. Poultsides, Ryan C. Fields, Sharon M. Weber, Konstantinos I. Votanopoulos, David A. Kooby, David J. Worhunsky, Linda X. Jin, William G. Hawkins, Alexandra W. Acher, Clifford S. Cho, Neil Saunders, Edward A. Levine
    Surgery.2017; 162(2): 285.     CrossRef
  • 10,768 View
  • 259 Download
  • 14 Web of Science
  • 13 Crossref
Close layer
Case Reports
Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone
Junghoon Shin, Jeong-Ok Lee, Ji-Young Choe, Soo-Mee Bang, Jong-Seok Lee
Cancer Res Treat. 2017;49(1):274-278.   Published online June 10, 2016
DOI: https://doi.org/10.4143/crt.2016.076
AbstractAbstract PDFPubReaderePub
Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin’s lymphoma arising from a B-cell lineage characterized by the formation of malignant effusion in body cavities without evidence of a detectable tumor. The effusion contains tumor cells universally infected with human herpesvirus 8 (HHV8), which is the critical factor differentiating PEL from HHV8-unrelated PEL-like lymphoma (PEL-LL). This report describes a 77-year-old male patient with pleural effusion and ascites, containing lymphoma cells expressing a B-cell phenotype, but without markers of HHV8 in immunocytochemical analysis. The patient was diagnosed with PEL-LL and treated with six cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), which resulted in a complete remission. The patient is currently disease-free 15 months post-treatment. To the best of our knowledge, this is the first report on administration of R-CHOP in a PEL-LL patient in South Korea.

Citations

Citations to this article as recorded by  
  • Primary Effusion Lymphoma-like Lymphoma Mimicking Tuberculous Pleural Effusion: Three Case Reports and a Literature Review
    Kenta Hayashino, Yusuke Meguri, Ryouya Yukawa, Aya Komura, Makoto Nakamura, Chikamasa Yoshida, Kazuhiko Yamamoto, Wakako Oda, Kenji Imajo
    Internal Medicine.2023; 62(17): 2531.     CrossRef
  • A rare case of fluid overload-associated large B-cell lymphoma and antigen loss at relapse
    Xue Yan, Bin Chen, Hongxia Jing, Zhinan Yang, Ting Zhang, Yani Lin, Jinning Shi
    Journal of Hematopathology.2023; 16(4): 235.     CrossRef
  • Primary Effusion Lymphoma: A Timely Review on the Association with HIV, HHV8, and EBV
    Chih-Yi Liu, Bo-Jung Chen, Shih-Sung Chuang
    Diagnostics.2022; 12(3): 713.     CrossRef
  • Targeting VEGF with bevacizumab inhibits malignant effusion formation of primary human herpesvirus 8‐unrelated effusion large B‐cell lymphoma in vivo
    Fumiya Ogasawara, Tomonori Higuchi, Tomohiro Nishimori, Yumiko Hashida, Kensuke Kojima, Masanori Daibata
    Journal of Cellular and Molecular Medicine.2022; 26(22): 5580.     CrossRef
  • Diagnostic significance of adenosine deaminase in pleural effusate for primary effusion lymphoma–like lymphoma
    Soichiro Nakako, Mitsushige Nishimura, Yoshiro Murakami, Atsuko Mugitani
    Clinical Case Reports.2020; 8(12): 3215.     CrossRef
  • Body Cavity–Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma
    Junghoon Shin, Young Hyeh Ko, Sung Yong Oh, Dok Hyun Yoon, Jeong-Ok Lee, Jin Seok Kim, Yong Park, Ho Jin Shin, Seok Jin Kim, Jong Ho Won, Sung-Soo Yoon, Won Seog Kim, Youngil Koh
    Cancer Research and Treatment.2019; 51(4): 1302.     CrossRef
  • Age and CD20 Expression Are Significant Prognostic Factors in Human Herpes Virus-8-negative Effusion-based Lymphoma
    Tomomi Kubota, Yosuke Sasaki, Eisuke Shiozawa, Masafumi Takimoto, Tsunekazu Hishima, Ja-Mun Chong
    American Journal of Surgical Pathology.2018; 42(12): 1607.     CrossRef
  • A Case of Diffuse Large B-Cell Lymphoma Mimicking Primary Effusion Lymphoma-Like Lymphoma
    Daisuke Usuda, Masahisa Arahata, Kento Takeshima, Ryusho Sangen, Akiteru Takamura, Yasuhiro Kawai, Yuji Kasamaki, Yoshitsugu Iinuma, Tsugiyasu Kanda
    Case Reports in Oncology.2017; 10(3): 1013.     CrossRef
  • 8,824 View
  • 198 Download
  • 8 Web of Science
  • 8 Crossref
Close layer
Treatment of Pulmonary Tumor Embolism from Choriocarcinoma: Extracorporeal Membrane Oxygenation as a Bridge through Chemotherapy
Jae Heun Chung, Hye Ju Yeo, Hyun Myung Cho, Jin Ook Jang, Byung Min Ye, Gun Yoon, Dong Hoon Shin, Dohyung Kim, Woo Hyun Cho
Cancer Res Treat. 2017;49(1):279-282.   Published online June 24, 2016
DOI: https://doi.org/10.4143/crt.2016.125
AbstractAbstract PDFPubReaderePub
A 22-year-old woman with a 1-month history of shortness of breath that was treated as a case of tuberculosis and pulmonary embolism was referred to the authors’ hospital. Because of the hemodynamic instability in this patient, venoarterial extracorporeal membrane oxygenation (ECMO) was administered in the intensive care unit. She underwent a pulmonary embolectomy for the treatment of progressive circulatory collapse secondary to a pulmonary embolism. The histopathologic result was consistent with a metastatic choriocarcinoma. Despite the surgical management, persistent refractory cardiogenic shock occurred. Subsequently, the patient was treated with chemotherapy in the presence of ECMO and responded well to chemotherapy. She was discharged after 3 months. This case suggests that metastatic choriocarcinoma should be considered as a differential diagnosis in women of childbearing age presenting with a pulmonary embolism, and ECMO may be beneficial in patients with pulmonary embolism for bridging to surgical embolectomy and chemotherapy.

Citations

Citations to this article as recorded by  
  • Isolated pulmonary artery choriocarcinoma masquerading as pulmonary embolism diagnosed by endovascular biopsy
    Simon Doran, Ronan Kernan, Niall McEniff
    Radiology Case Reports.2024; 19(8): 3525.     CrossRef
  • Extracorporeal membrane oxygenation in critically ill patients with active hematologic and non-hematologic malignancy: a literature review
    Roberto Rabello Filho, Daniel Joelsons, Bruno de Arruda Bravim
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Acute pulmonary tumour embolism and right systolic dysfunction in a hidden intrahepatic cholangiocarcinoma: case report
    Alejandra Portillo-Romero, Eric Cuevas-Medina, Maria Jose Santa Ana-Bayona, Santiago Saenz-Ancira, Costantino Mancusi, Megha Agarwal, A Shaheer Ahmed, Federico B Blasi, Polyvios Demetriades, Jonathan Senior
    European Heart Journal - Case Reports.2023;[Epub]     CrossRef
  • Advances in the use of ECMO in oncology patient
    Xiangnan Teng, Jiali Wu, Jing Liao, Shanling Xu
    Cancer Medicine.2023; 12(15): 16243.     CrossRef
  • A rare case of pulmonary artery embolism with choriocarcinoma: A case report and literature review
    Pengcheng Wang, Dunqiang Ren, Caihong Guo, Xiaoqian Ding, Yiwei Cao, Peige Zhao, Qiang Wang, Wenjuan Xu
    Oncology Letters.2023;[Epub]     CrossRef
  • Extracorporeal Membrane Oxygenator Failure in a Patient With Gestational Trophoblastic Neoplasm: Possible Mechanisms and Considerations in Critical Care
    Nathan J. Smith, Beth A. Nance, Lucian A. Durham, Lindsey A. McAlarnen, Erin A. Bishop, M. Tracy Zundel
    Journal of Cardiothoracic and Vascular Anesthesia.2022; 36(8): 2583.     CrossRef
  • Extracorporeal membrane oxygenation for lung cancer-related life-threatening hypoxia: A case report
    Seung Soo Yoo, Shin Yup Lee, Sun Ha Choi
    World Journal of Clinical Cases.2022; 10(25): 8974.     CrossRef
  • Extracorporeal Membrane Oxygenation to Facilitate Chemotherapy—Moving the Goalposts!
    Emad A Chishti, Thomas Marsden, Aaron Harris, Zhonglin Hao, Suresh Keshavamurthy
    Cureus.2022;[Epub]     CrossRef
  • Dyspnoea unmasked with point of care ultrasound. A Case Report
    Priya Ramachandran, Varghese Louis, Uma Devaraj, Kavitha Venkatanarayana, Uma Maheshwari Krishnaswamy
    SN Comprehensive Clinical Medicine.2021; 3(5): 1203.     CrossRef
  • Outcomes of extracorporeal membrane oxygenation in adults with active hematologic and nonhematologic malignancy
    Chul Park, Ui Won Ko, Ryoung‐Eun Ko, Soo Jin Na, Jeong Hoon Yang, Kyeongman Jeon, Gee Young Suh, Kiick Sung, Yang Hyun Cho
    Artificial Organs.2021;[Epub]     CrossRef
  • Acute cardiopulmonary failure in a young woman with high-risk gestational trophoblastic neoplasia: A case of induction chemotherapy during extracorporeal membrane oxygenation
    Lindsey A. McAlarnen, Nathan J. Smith, Beth A. Nance, M. Tracy Zundel, Erin A. Bishop
    Gynecologic Oncology Reports.2021; 37: 100849.     CrossRef
  • Pulmonary tumor embolism from breast cancer diagnosed by selective aspiration cytology using a Swan-Ganz catheter
    Ryohei Aoki, Toyoshi Yanagihara, Hiroshi Mannoji, Syunya Sunami, Nobuhiro Tsuruta, Reiko Yoneda, Makoto Usui
    Respiratory Medicine Case Reports.2021; 34: 101527.     CrossRef
  • The Utility of Extracorporeal Membrane Oxygenation in Patients With Hematologic Malignancies: A Literature Review
    Praveena Tathineni, Mauna Pandya, Bassem Chaar
    Cureus.2020;[Epub]     CrossRef
  • Lessons from a patient with cardiac arrest due to massive pulmonary embolism as the initial presentation of Wilms tumor: a case report and literature review
    Atsuna Fukuda, Takeshi Isoda, Naoya Sakamoto, Keisuke Nakajima, Tetsuya Ohta
    BMC Pediatrics.2019;[Epub]     CrossRef
  • Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium
    Belinda Rivera-Lebron, Michael McDaniel, Kamran Ahrar, Abdulah Alrifai, David M. Dudzinski, Christina Fanola, Danielle Blais, David Janicke, Roman Melamed, Kerry Mohrien, Elizabeth Rozycki, Charles B. Ross, Andrew J. Klein, Parth Rali, Nicholas R. Teman,
    Clinical and Applied Thrombosis/Hemostasis.2019;[Epub]     CrossRef
  • Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
    Sheng Wang, Dexi Zhou, Zhenyu Xu, Jing Song, Xueyi Qian, Xiongwen Lv, Jiajie Luan
    Current Drug Targets.2019; 20(11): 1180.     CrossRef
  • Pulmonary micro‐tumor emboli resulting in paradoxical emboli: a case report
    Louis‐Vincent Morin‐Thibault, Daniel Wiseman, Michelle Fortin, Christian Couture, Steeve Provencher
    Pulmonary Circulation.2018; 8(2): 1.     CrossRef
  • Possibility of venoarterial extracorporeal membranous oxygenator being a bridging therapy for hemodynamic deterioration of pulmonary tumor thrombotic microangiopathy prior to initiating chemotherapy
    Yoshiaki Iwashita, Takuya Hiramoto, Kei Suzuki, Ryotaro Hashizume, Kazuo Maruyama, Hiroshi Imai
    Medicine.2018; 97(37): e12169.     CrossRef
  • Role of chemotherapy and thrombolysis in treatment of choriocarcinoma accompanied with pulmonary embolism
    Mei Yang, Li Peng
    Medicine.2017; 96(36): e7866.     CrossRef
  • Antineoplastics

    Reactions Weekly.2017; 1643(1): 32.     CrossRef
  • 9,249 View
  • 190 Download
  • 18 Web of Science
  • 20 Crossref
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP